 CeNeS PharmaCeutiCalS PlC
Annual Report and Accounts 2007
index_CEN_ar07_cover.indd   2 06/05/2008   11:10:45 CeNeS Pharmaceuticals plc (LSE: CEN) identifies and develops novel 
drugs that are designed to improve patient outcomes in the therapeutic 
areas of pain, anaesthesia and neurology. Each CeNeS programme 
addresses a clinically validated target, has a well understood clinical 
development pathway and offers an attractive market opportunity.
CeNeS aims to build a profitable, European, specialty pharmaceutical 
company by developing, partnering and marketing a portfolio of new 
pharmaceutical products which offer significant improvements over the 
existing ‘gold standard’ treatments.
CeNeS has considerable experience in developing Central Nervous System 
(“CNS”) and pain products up to clinical proof of concept and beyond.
 01 HigHligHts 02 ChairmaN’S StatEmENt 
 04 ChiEf ExECutivE’S rEviEw 
 13 fiNaNCiaL rEviEw 
 15 bOARD OF DiRectORs 
 15 seNiOR MANA geMeNt 16 scieNtiFic ADVisORY bOARD
 18 DirECtorS’ rEPort 
 22 ReMuNeRA tiON RepORt 
 27 iNDEPENDENt auDitorS’ rEPort 
 29 cONsOliDA teD iNcOMe st AteMeNt 30 cONsOliDA teD bAlANce sHeet 
 31 cONsOliDA teD st AteMeNt OF cHANges iN eQuitY
 32 CoNSoLiD atED CaSh fL ow StatEmENt
 33 NOtes tO tHe FiNANciAl st AteMeNts 53 iNDEPENDENt auDitorS’ rEPort 
 55 cOMp ANY bAlANce sHeet 56 NOtes tO tHe cOMp ANY FiNANciAl st AteMeNts iBC DirECtorS, aD viSorS aND CoNtaCtS
index_CEN_ar07_cover.indd   3 06/05/2008   11:10:45 01 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
CliNiCal PiPeliNe
M6G – post ‑operative pain 	 	 Successful	major	Phase	III	study	results	announced	showing	clear	benefits	over	morphine
	 	 Investigational	New	Drug	Application	(“IND”)	approved	by	the	F ood	and	Drug	Administration	(“FD A ”)	in	April	2007
	 Strengthened	M6G	intellectual	property	(“IP ”)	position
	 Actively	pursuing	M6G	partnering	deals
Cns 5161 – CanCer pain and neuropathiC pain 	 Revenue	sharing	and	co‑development	agreement	with	ERGOMED
	 Acquisition	of	transdermal	patch	formulation	IP
	 Phase	IIa	cancer	pain	trial	underway	and	results	are	expected	later	in	2008
Pre‑CliNiCal/diSCovery PiPeliNe
Cns 7056 – short aCtinG sedation/anaesthesia
	 	 Licensing	agreement	with	Ono	Pharmaceutical	Co	Ltd	in	August	2007	for	Japanese	rights	to	CNS	7056
	 Japanese,	Hong	K ong	and	European	patents	granted	for	short	acting	sedative
	 Pre‑clinical	studies	including	pivotal	toxicology	completed	successfully
CoMt inhibitors – p arkinson’s disease
	 Pre‑clinical	development	candidate	for	P arkinson’s	disease	in	the	lead	identification	phase
BuSiNeSS develoPmeNt
	 M6G	partnering	process	is	ongoing.	Phase	III	clinical	data	clarifies	the	value	of	the	opportunity
	 Japanese	rights	to	CNS	7056	out ‑licensed	to	Ono	Pharmaceuticals
	 Licensing	discussions	ongoing	in	relation	to	earlier	portfolio	programmes
FiNaNCial aNd CorPorate
	 F und	raising	of	£5.7	million,	net	of	expenses,	through	placing	of	new	shares	in	August	2007
	 	 Decreased	net	loss	after	tax	of	£6.6	million	(2006:	£8.6	million)	mainly	due	to	the	cost	of	the	M6G	Phase	III	
trial	completed	in	2006
	 Cash	at	year	end	of	£4.3	million	(2006:	£6.3	million)
	 First	time	adoption	of	International	Financial	Reporting	Standards	(“IFRS”)	
	 	 On	10	April	2008,	it	was	announced	by	P aion	AG	that	it	proposes	to	acquire	all	of	the	issued	and	to	be	issued	
share	capital	of	CeNeS	by	a	court	sanctioned	scheme	of	arrangement	under	P art	26	of	the	Companies	Act	2006
highlights _0_CEN_ar07_front.indd   1 06/05/2008   11:11:50 02
ChAiRMAN’s st AtEMENt 
CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
overvieW
CeNeS	has	continued	to	make	significant	progress	with	its	product	
pipeline 	 in 	 2007. 	 In 	 F ebruary 	 2007 	 the 	 Company 	 announced 	 good	
Phase	III	data	from	the	largest	ever	Phase	III	trial	of	its	lead	drug	M6G	
and	in	August	announced	the	out ‑licensing	agreement	with	Ono	for	
Japanese	rights	to	the	short	acting	sedative/anaesthetic	CNS	7056.	
This	deal	alone	underpins	the	current	valuation	of	the	Company .
Also 	 in 	 August 	 we 	 completed 	 an 	 institutional 	 placing 	 of 	 shares 	 raising 	
a 	 t o t a l 	 o f 	 £ 5 . 7 5 	 m i l l i o n 	 ( n e t 	 o f 	 e x p e n s e s ) ; 	 t h i s 	 s e c u r e d 	 t h e 	 fi n a n c i a l	
position	of	the	Company	through	2008.	
I n 	 F e b r u a r y 	 2 0 0 8 , 	 C e N e S 	 c o n fi r m e d 	 t h a t 	 i t 	 w a s 	 i n 	 d i s c u s s i o n s 	 w h i c h	
m a y 	 o r 	 m a y 	 n o t 	 l e a d 	 t o 	 a n 	 o f f e r 	 f o r 	 t h e 	 C o m p a n y . 	 O n 	 1 0 	 A p r i l 	 2 0 0 8 ,	
it	was	announced	by	P aion	AG	that	it	proposes	to	acquire	all	of	the	
i s s u e d 	 a n d 	 t o 	 b e 	 i s s u e d 	 s h a r e 	 c a p i t a l 	 o f 	 C e N e S 	 b y 	 a 	 c o u r t 	 s a n c t i o n e d	
s c h e m e 	 o f 	 a r r a n g e m e n t 	 u n d e r 	 P a r t 	 2 6 	 o f 	 t h e 	 C o m p a n i e s 	 A c t 	 2 0 0 6 .	
F urther 	 details 	 are 	 set 	 out 	 in 	 a 	 separate 	 announcement 	 published 	 today .	
A 	 copy 	 of 	 this 	 announcement 	 will 	 be 	 sent 	 to 	 shareholders 	 shortly .
In 	 the 	 event 	 that 	 the 	 acquisition 	 of 	 CeNeS 	 by 	 P aion 	 AG 	 is 	 not	
c o m p l e t e d , 	 t h e 	 C o m p a n y 	 w i l l 	 n e e d 	 t o 	 r a i s e 	 a d d i t i o n a l 	 f u n d i n g	
through 	 one 	 or 	 a 	 combination 	 of 	 equity 	 fund 	 raising, 	 partnering	
o r 	 c o l l a b o r a t i o n 	 o p p o r t u n i t i e s , 	 o r 	 m e r g e r 	 a n d 	 a c q u i s i t i o n 	 a c t i v i t y	
in 	 order 	 to 	 continue 	 as 	 a 	 going 	 concern.	
CliNiCal ProGrammeS
M6G – Post‑oPerative P ain The 	 partnering 	 process 	 for 	 M6G 	 is 	 progressing 	 well 	 and 	 the	
Company 	 remains 	 confident 	 that 	 it 	 can 	 secure 	 a 	 partnering 	 deal 	
i n 	 t h e 	 n e a r 	 f u t u r e . 	 T h e 	 d e p t h 	 o f 	 e v i d e n c e 	 o b t a i n e d 	 f r o m 	 t h e 	 c o m p l e t e d	
P h a s e 	 I I I 	 s t u d y 	 M 6 G 0 2 2 , 	 s u p p o r t s 	 t h e 	 p r o d u c t 	 p r o fi l e 	 f o r 	 M 6 G	
of 	 a 	 novel 	 analgesic 	 with 	 a 	 better 	 side 	 effect 	 profile 	 than 	 morphine.
CeNeS	has	met	with	the	FD A	to	clarify	the	clinical	trials	programme	
required	for	the	development	of	M6G	in	the	US.	T wo	Phase	III	studies	
will	be	required:
1)		 A	comparison	of	the	analgesic	efficacy	and	safety	of	three	dose	
levels	of	M6G,	morphine	and	placebo	in	patients	with	acute	pain	
following 	 bunionectomy 	 – 	 CeNeS 	 has 	 completed 	 the 	 draft 	 protocol	
for	this	study .
2)		 T h e 	 s e c o n d 	 s t u d y 	 d e s i g n 	 h a s 	 n o t 	 y e t 	 b e e n 	 fi n a l i s e d 	 b u t 	 i s 	 e x p e c t e d	
t o 	 c o m p a r e 	 t h e 	 s a f e t y 	 a n d 	 a n a l g e s i c 	 e f fi c a c y 	 o f 	 M 6 G 	 v e r s u s 	 a n	
a l t e r n a t i v e 	 a n a l g e s i c 	 ( m o r p h i n e ) 	 a n d 	 p o s s i b l y 	 p l a c e b o 	 i n 	 t h e	
treatment 	 of 	 acute, 	 moderate 	 to 	 severe 	 post ‑operative 	 pain	
i n 	 patients	undergoing	major	surge ry .
Three	further	Phase	I	safety	studies	are	now	completed:
	 	 M6G023,	a	ma ss	balance	study 	designed	to	show	the	metabolic	
rate	of	an	IV	injection	of	M6G	in	healthy	volunteers;
	 	 M6G024,	a	ph armacokinetic	stu dy	in	mild	and	moderate	renally	
impaired	patients;	and
	 M6G029,	the	U S	IND	opening	study	in	volunteers.
CeNeS	currently	anticipates	that	MAA	and	ND A	( “ Marketing	
Authorisation	Approval	and	New	Drug	Application ” )	submissions	
for 	 M6G 	 could 	 be 	 made 	 in 	 2011 	 although 	 this 	 is 	 dependent	
o n 	 the	signing	of	p artnership	deals	 to	enable	the	partners	
to	fund	the	required	additional	Phase	III	trials.
CNS 5161 – NeuroP athiC P aiN
CeNes	second	clinical	candidate	is	CNS	5161	for	the	treatment	
of	neuropathic	pain,	a	poorly	treated	condition	with	an	estimated	
26	million	patients	worldwide.	Phase	II	studies	completed	to	date	
have	demonstrated	efficacy	and	an	acceptable	side	effect	profile	
i n 	 n e u r o p a t h i c 	 p a i n 	 p a t i e n t s . 	 U n d e r 	 t h e 	 c o ‑ d e v e l o p m e n t 	 p a r t n e r s h i p	
w i t h 	 E r g o m e d , 	 a n 	 e x p e r i e n c e d 	 c l i n i c a l 	 d e v e l o p m e n t 	 c o m p a n y	
specialising	in	neurology	and	oncology ,	CeNeS	has	planned	two	
further	Phase	II	studies	in	cancer	pain	and	neuropathic	pain	as	
the	first	stage	of	a	comprehensive	Phase	II	data	package.	
The	first	study	in	opioid	refractory	cancer	pain	started	recruitment	
in	2007	and	is	proceeding	to	plan.	It	is	a	Phase	II	dose	escalation	
study	in	36	patients	to	establish	the	optimal	schedule	for	infusion	
of	CNS	5 1 6 1 	 i n 	 t h e 	 m a n a g e m e n t 	 o f 	 c a n c e r 	 p a i n . 	 I t 	 w i l l 	 a s s e s s 	 t h e	
s a f e t y , 	 e f fi c a c y 	 a n d 	 p h a r m a c o k i n e t i c 	 p r o fi l e 	 o f 	 C N S 	 5 1 6 1 	 a d m i n i s t e r e d	
i n t r a v e n o u s l y 	 a t 	 v a r i o u s 	 d o s e s 	 o v e r 	 2 4 	 h o u r s 	 w h e n 	 a d d e d 	 t o 	 o p i o i d s	
for	the	treatment	of	cancer	pain	with	a	neuropathic	component.
The 	 second 	 study 	 is 	 planned 	 to 	 be 	 a 	 Phase 	 II 	 double 	 blind,	
t h r e e ‑ w a y 	 c r o s s 	 o v e r , 	 a c u t e 	 s t u d y 	 t o 	 c o m p a r e 	 t h e 	 e f fi c a c y 	 a n d	
safety 	 of 	 two 	 doses 	 of 	 CNS 	 5161 	 HC1 	 (250µg 	 and 	 500µg) 	 and	
p l a c e b o 	 i n 	approximately	75	patien ts	with	chronic,	intractable	
neuropathic	pain.
In	addition	CeNeS	has	started	development	of	a	transdermal	patch	
formulation 	 of 	 CNS 	 5161 	 for 	 the 	 management 	 of 	 chronic 	 neuropathic	
p a i n . 	 P r e l i m i n a r y 	 d a t a 	 p r o d u c e d 	 h a s 	 a l r e a d y 	 d e m o n s t r a t e d 	 t h e	
feasibility	for	a	transdermal	patch	formulation.	A	patch	formulation	
for	neuropathic	pain	is	planned	to	deliver	an	easy	to	use	premium	
product	to	treat	this	difficult	condition.	
_0_CEN_ar07_front.indd   2 06/05/2008   11:11:50 03 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
Pre ‑CliNiCal ProGrammeS
Cns 7056 – short aCtinG sedative and anaesthetiC
C N S 	 7 0 5 6 	 i s 	 a 	 s h o r t 	 a c t i n g 	 s e d a t i v e / a n a e s t h e t i c 	 w h i c h 	 w a s 	 a c q u i r e d	
f r o m 	 G l a x o S m i t h K l i n e 	 ( G S K ) 	 i n 	 2 0 0 3 . 	 T h e r e 	 i s 	 a 	 s t r o n g 	 t r e n d 	 w i t h i n 	 t h e	
h e a l t h c a r e 	 s y s t e m 	 t o w a r d s 	 d a y ‑ c a s e 	 p r o c e d u r e s 	 w h i c h 	 r e q u i r e 	 s e d a t i v e	
a g e n t s 	 t h a t 	 p e r m i t 	 r a p i d 	 r e c o v e r y 	 a n d 	 e a r l y 	 d i s c h a r g e 	 f r o m 	 h o s p i t a l .	
O n 	 6 	 A u g u s t 	 2 0 0 7 	 t h e 	 C o m p a n y 	 a n n o u n c e d 	 a 	 s i g n i fi c a n t	
o u t ‑ l i c e n s i n g 	 d e a l 	 w i t h 	 O n o 	 f o r 	 t h e 	 J a p a n e s e 	 r i g h t s 	 t o 	 C N S 	 7 0 5 6 	 f o r	
t h e 	 i n d i c a t i o n 	 o f 	 a n a e s t h e s i a . 	 O n o 	 i s 	 a 	 h i g h l y 	 r e g a r d e d 	 J a p a n e s e	
pharmaceutical	company	which	has	reviewed	CNS	7056	in	detail.	
W e 	 believe 	 this 	 deal 	 has 	 demonstrated 	 both 	 the 	 quality 	 of 	 the	
C N S 	 7 0 5 6 	 p r o g r a m m e 	 a n d 	 o u r 	 a b i l i t y 	 t o 	 n e g o t i a t e 	 a n d 	 c o m p l e t e	
out ‑licensing 	 deals 	 with 	 excellent 	 partners.
C e N e S 	 p l a n s 	 t o 	 fi l e 	 a n 	 I N D 	 a n d 	 t o 	 c o m p l e t e 	 a 	 p r o o f 	 o f 	 c o n c e p t	
P h a s e 	 I 	 s t u d y 	 i n 	 t h e 	 U S 	 i n 	 2 0 0 8 . 	 T h e 	 p i v o t a l 	 t o x i c o l o g y 	 w o r k 	 h a s	
b e e n 	 completed	in	early	2008.	The	onset	and	offset	of	sedation	for	
CNS	7 0 5 6 	 w i l l 	 b e 	 e x a m i n e d 	 a n d 	 c o m p a r e d 	 w i t h 	 t h a t 	 o f 	 m i d a z o l a m ,	
a	water ‑soluble	benzodiazepine	which	suffers	from	relatively	
long	and	variable	durations	of	action.	
Comt iNhiBitor – ParkiNSoN’S diSeaSe
P arkinson’s 	 disease, 	 the 	 second 	 most 	 common 	 neurodegenerative	
d i s e a s e 	 a f t e r 	 A l z h e i m e r ’ s 	 d i s e a s e , 	 r e s u l t s 	 f r o m 	 a 	 l o s s 	 o f 	 t h e	
neurotransmitter	dopamine	in	the	brain.	The	current	main	treatment	
is 	 replacement 	 therapy 	 using 	 L ‑DOP A , 	 the 	 precursor 	 of 	 dopamine.	
However 	 the 	 enzyme 	 COMT 	 causes 	 significant 	 depletion 	 of 	 L ‑DOP A 	
i n 	 t h e 	 b r a i n 	 a n d 	 t h e 	 p e r i p h e r y 	 w h i c h 	 l i m i t s 	 t h e 	 e f fi c a c y 	 o f 	 t h i s 	 t r e a t m e n t .	
C O M T 	 i n h i b i t o r s 	 h a v e 	 b e e n 	 s h o w n 	 t o 	 p r o v i d e 	 a 	 l o n g e r 	 “ o n ” 	 o r 	 f u n c t i o n a l	
t i m e 	 e a c h 	 d a y . 	 C u r r e n t l y 	 m a r k e t e d 	 C O M T 	 i n h i b i t o r s 	 h o w e v e r 	 h a v e	
l i m i t a t i o n s 	 w h i c h 	 a r e 	 t h o u g h t 	 t o 	 b e 	 a s s o c i a t e d 	 w i t h 	 t h e 	 p r e s e n c e	
of 	 the 	 nitrocatechol 	 chemical 	 group.
CeNeS	has	identified	a	novel	series	of	COMT	inhibitors	that	do	
not	contain	the	nitrocatechol	group.	The	programme	is	currently	
optimising	leads	with	the	aim	of	selecting	a	compound	that	fits	
the	target	product	profile.
C O M T 	 i n h i b i t o r s 	 a r e 	 c u r r e n t l y 	 e s t i m a t e d 	 t o 	 h a v e 	 a 	 1 0 % 	 s h a r e 	 o f 	 t h e	
P arkinson’s 	 disease 	 market 	 by 	 value 	 and 	 their 	 usage 	 is 	 growing.	
The	Company	estimates	that	peak	sales	of	COMT	inhibitors	could	
reach	£200	million	pa.
In 	 addition 	 to 	 P arkinson’s 	 disease, 	 a 	 number 	 of 	 recent 	 academic	
publications	point	to	the	potential	use	of	a	COMT	inhibitor	that	acts	
in	t h e 	 b r a i n 	 t o 	 i m p r o v e 	 t h e 	 p r o f o u n d 	 c o g n i t i v e 	 d e f e c t s 	 o f 	 s c h i z o p h r e n i a .	
Cognitive	disturbances	are	poorly	addressed	by	existing	therapies.
outlook
On 	 10 	 April 	 2008, 	 it 	 was 	 announced 	 by 	 P aion 	 AG 	 that 	 it 	 proposes 	
to 	 acquire 	 all 	 of 	 the 	 issued 	 and 	 to 	 be 	 issued 	 share 	 capital 	 of 	 CeNeS	
b y 	 a 	 c o u r t 	 s a n c t i o n e d 	 s c h e m e 	 o f 	 a r r a n g e m e n t 	 u n d e r 	 P a r t 	 2 6 	 o f 	 t h e	
Companies 	 Act 	 2006. 	 If 	 the 	 proposed 	 acquisition 	 is 	 completed,	
CeNeS 	 will 	 have 	 a 	 considerably 	 strengthened 	 financial 	 position 	
by	being	part	of	the	P aion	group,	which	will	assist	with	partnering	
and	clinical	development	decisions.	
I f 	 t h e 	 a c q u i s i t i o n 	 i s 	 c o m p l e t e d , 	 C e N e S , 	 a s 	 p a r t 	 o f 	 t h e 	 e n l a r g e d 	 g r o u p ,	
w i l l 	 c o n t i n u e 	 t o 	 m a i n t a i n 	 i t s 	 f o c u s 	 o n 	 a d v a n c i n g 	 e a c h 	 o f 	 i t s 	 p r o g r a m m e s ,	
with	a	number	of	key	milestones	and	deliverables	expected	in	2008.	
T h e 	 r e s u l t s 	 o f 	 t h e 	 fi r s t 	 o f 	 t w o 	 p l a n n e d 	 P h a s e 	 I I 	 s t u d i e s 	 f o r 	 C N S 	 5 1 6 1 	 w i l l	
report	results	mid‑2008.	An	IND	( “ Investigational	New	Drug ” )	filing	
i n 	 t h e 	 U S 	 a n d 	 p r o o f 	 o f 	 c o n c e p t 	 P h a s e 	 I 	 s t u d y 	 f o r 	 C N S 	 7 0 5 6 	 i n 	 s e d a t i o n	
is	p l a n n e d 	 f o r 	 H 2 	 2 0 0 8 . 	 T h e 	 B o a r d 	 b e l i e v e 	 t h a t 	 a 	 s u c c e s s f u l 	 o u t c o m e	
from	this	trial	will	transform	the	value	of	this	asset.	CeNes	partner	
O n o 	 i s 	 p l a n n i n g 	 a 	 P h a s e 	 I 	 s t u d y 	 i n 	 a n a e s t h e s i a 	 i n 	 J a p a n 	 i n 	 H 2 	 2 0 0 8 .	
Based	on	the	structure	of	the	enlarged	group	and	the	broadened	
p i p e l i n e 	 t h e 	 d i r e c t o r s 	 o f 	 C e N e S 	 b e l i e v e 	 t h e 	 e n l a r g e d 	 g r o u p 	 w i l l 	 b e 	 a b l e	
to 	 achieve 	 significant 	 pre‑clinical, 	 clinical 	 and 	 commercial 	 milestones.
In	the	event	that	the	acquisition	is	not	completed,	the	Company	will	
need to raise additional funding through one or a combination of 
equity 	 fund 	 raising, 	 partnering 	 or 	 collaboration 	 opportunities 	 activity 	 in	
o r d e r 	 t o 	 c o n t i n u e 	 a s 	 a 	 g o i n g 	 c o n c e r n . 	 T h e 	 D i r e c t o r s 	 h a v e 	 a 	 r e a s o n a b l e	
e x p e c t a t i o n 	 t h a t 	 t h e 	 C o m p a n y 	 c a n 	 r a i s e 	 s u c h 	 a d d i t i o n a l 	 c a s h 	 r e s o u r c e s .	
Therefore,	the	Directors	consider	that	it	is	appropriate	to	prepare	the	
fi n a n c i a l 	 s t a t e m e n t s 	 o n 	 a 	 g o i n g 	 c o n c e r n 	 b a s i s . 	 I f 	 t h e 	 C o m p a n y 	 w a s	
unable	to	continue	in	operational	existence	in	the	foreseeable	future,	
a d j u s t m e n t s 	 w o u l d 	 h a v e 	 t o 	 b e 	 m a d e 	 t o 	 r e v i s e 	 t h e 	 b a l a n c e 	 s h e e t 	 v a l u e s	
o f 	 a s s e t s 	 t o 	 t h e i r 	 r e c o v e r a b l e 	 a m o u n t s , 	 t o 	 p r o v i d e 	 f o r 	 f u r t h e r 	 l i a b i l i t i e s	
that 	 might 	 arise 	 and 	 to 	 reclassify 	 fixed 	 assets 	 as 	 current 	 assets.
alaN GoodmaN
ChairMan 10 aPril 2008 
_0_CEN_ar07_front.indd   3 06/05/2008   11:11:50 04 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
m6G for the treatment of post‑operative pain
ChiEF EXECUtiVE’s REViEW
PoSt‑oPerative P aiN
P ost ‑operative 	 pain 	 is 	 an 	 acute 	 condition 	 directly 	 resulting 	 from	
a 	 s u r g i c a l 	 p r o c e d u r e . 	 T h e 	 p a i n 	 t y p i c a l l y 	 l a s t s 	 f o r 	 a 	 f e w 	 d a y s 	 a n d 	 c a n	
r a n g e 	 i n 	 i n t e n s i t y 	 f r o m 	 m i l d 	 t o 	 s e v e r e 	 d e p e n d i n g 	 o n 	 t h e 	 t y p e 	 a n d	
duration 	 of 	 the 	 operation. 	 There 	 are 	 over 	 90 	 million 	 operations 	 in 	 the	
US	and	Europe	each	year	and	patients	are	treated	with	a	variety	
of	drugs	to	manage	post ‑operative	pain.	
T h e 	 m o s t 	 p o t e n t 	 c l a s s 	 o f 	 k n o w n 	 a n a l g e s i c 	 ( p a i n ‑ r e l i e v i n g ) 	 d r u g s 	 a r e 	 t h e	
o p i a t e s , 	 d e r i v e d 	 f r o m 	 t h e 	 o p i u m 	 p o p p y . 	 O p i a t e s 	 a c t 	 i n 	 t h e 	 b r a i n 	 w h e r e	
t h e y 	 ‘ s w i t c h 	 o f f ’ 	 t h e 	 s e n s a t i o n 	 o f 	 p a i n . 	 M o r p h i n e 	 i s 	 a n 	 o p i a t e 	 a n d	
remains	 t h e 	 ‘ g o l d 	 s t a n d a r d ’ 	 f o r 	 t h e 	 m a n a g e m e n t 	 o f 	 m o d e r a t e ‑ t o ‑ s e v e r e	
pain.	However ,	like	many	drugs	it	can	be	associated	with	undesirable	
s i d e 	 e f f e c t s . 	 T h e s e 	 s i d e 	 e f f e c t s 	 c a n 	 b e 	 d i s t r e s s i n g 	 f o r 	 p a t i e n t s , 	 m a y 	 l e a d	
t o 	 m e d i c a l 	 c o m p l i c a t i o n s 	 a n d 	 c a n 	 i m p o s e 	 a n 	 e c o n o m i c 	 b u r d e n	
o n 	 h e a l t h c a r e 	 p r o v i d e r s .	
N a u s e a 	 a n d 	 v o m i t i n g 	 a r e 	 a m o n g s t 	 t h e 	 m o s t 	 c o m m o n 	 s i d e 	 e f f e c t s	
o f 	 m o r p h i n e 	 a n d 	 u p 	 t o 	 5 0 % 	 o f 	 p a t i e n t s 	 r e c e i v i n g 	 m o r p h i n e 	 e x p e r i e n c e	
such 	 side 	 effects. 	 The 	 degree 	 of 	 discomfort 	 due 	 to 	 post ‑operative	
nausea 	 and 	 vomiting 	 ( “ PONV ” ) 	 i s 	 s u c h 	 t h a t 	 p a t i e n t s 	 h a v e 	 b e e n 	 r e p o r t e d	
t o 	 b e 	 w i l l i n g 	 t o 	 s u f f e r 	 a 	 d e g r e e 	 o f 	 p a i n 	 r a t h e r 	 t h a n 	 e x p e r i e n c e 	 P O N V .	
“ Acute 	 post ‑operative 	 pain 	 and 	 PONV 	 are 	 the 	 negative 	 outcomes	
commonly	associated	with	surgery	that	patients	are	most	anxious	
t o 	 a v o i d ” 	 ( M a c a r i o , 	 A 	 a n d 	 P e r g o l i z z i , 	 J 	 P a i n 	 a n d 	 N a u s e a 	 M a n a g e m e n t	
after 	 Surgery , 	 The 	 International 	 Journal 	 of 	 P ain 	 Medicine 	 and 	 P alliative	
Care 	 vol3 	 no3 	 2004).
S e d a t i o n 	 i s 	 a n o t h e r 	 c o m m o n 	 s i d e 	 e f f e c t 	 o f 	 m o r p h i n e 	 t r e a t m e n t 	 a n d	
in 	 the 	 post ‑operative 	 period 	 it 	 is 	 complicated 	 by 	 the 	 sleepiness 	 caused	
b y 	 t h e 	 a n a e s t h e t i c . 	 I f 	 p a t i e n t s 	 a r e 	 e x c e s s i v e l y 	 s e d a t e d , 	 i t 	 m a y 	 b e 	 d i f fi c u l t	
for	doctors	to	accurately	assess	their	well‑being.	Excessive	sedation	
i s 	 a l s o 	 linked	to	respiratory	depression	(a	reduction	in	breathing	rate).	
R e s p i r a t o r y 	 d e p r e s s i o n 	 i s 	 a 	 r a r e r , 	 b u t 	 p o t e n t i a l l y 	 d a n g e r o u s 	 s i d e 	 e f f e c t ,	
o f 	 m o r p h i n e 	 t r e a t m e n t . 	 T h e 	 b o d y ’ s 	 n o r m a l 	 r e s p o n s e 	 t o 	 l a c k 	 o f 	 o x y g e n	
o r 	 t h e 	 b u i l d 	 u p 	 o f 	 e x c e s s i v e 	 c a r b o n 	 d i o x i d e 	 i s 	 t o 	 i n c r e a s e 	 t h e 	 b r e a t h i n g	
r a t e 	 t o 	 c o m p e n s a t e . 	 T h i s 	 r e s p o n s e 	 i s 	 i n h i b i t e d 	 b y 	 m o r p h i n e . 	 T h i s 	 c a n	
b e 	 p a r t i c u l a r l y 	 d a n g e r o u s 	 i n 	 t h e 	 p o s t ‑ o p e r a t i v e 	 p e r i o d 	 s i n c e 	 a n a e s t h e t i c	
drugs 	 often 	 reduce 	 the 	 patient’s 	 breathing 	 rate.
morPhiNe metaB oliSm 
When	morphine	is	taken	into	the	body	it	is	broken	down	in	the	liver	
to	two	main	metabolites,	M6G	and	morphine‑3‑glucuronide	(“M3G”).	
M6G	is	a	potent	active	metabolite	of	morphine	and	is	an	effective	
analgesic,	whereas	M3G	is	ineffective.
m6G CliNiCal develoPmeNt 
C e N e S 	 i s 	 d e v e l o p i n g 	 M 6 G 	 f o r 	 t h e 	 m a n a g e m e n t 	 o f 	 m o d e r a t e 	 t o 	 s e v e r e	
post ‑operative	pain	and	has	reached	the	advanced	stages	of	clinical	
development	(Phase	III).	
PhaSe iii StudieS 
CoMPleted Phase iii study (M6G015)
T h e 	 fi r s t 	 P h a s e 	 I I I 	 t r i a l 	 o f 	 M 6 G 	 w a s 	 c o m p l e t e d 	 i n 	 2 0 0 5 . 	 T h i s 	 i n i t i a l	
P h a s e 	 I I I 	 t r i a l 	 ( d e s i g n a t e d 	 M 6 G 	 S t u d y 	 M 6 G 0 1 5 ) 	 w a s 	 c a r r i e d 	 o u t 	 i n 	 t h r e e	
European 	 countries, 	 recruiting 	 168 	 hospitalised 	 patients 	 suffering 	 from	
post ‑operative	pain	following	knee	replacement	surgery	carried	out	
under 	 spinal 	 anaesthesia. 	 The 	 prime 	 objective 	 of 	 the 	 study 	 was 	 to	
compare	the	analgesic	efficacy	and	duration	of	action	of	a	range	of	
d o s e s 	 o f 	 M 6 G 	 c o m p a r e d 	 w i t h 	 p l a c e b o . 	 M 6 G 0 1 5 	 c o n fi r m e d 	 t h a t 	 a 	 s i n g l e	
dose	of	M6G	administered	intravenously	at	30mg/70kg	body	weight	
provides	effective	analgesia	for	the	treatment	of	post ‑operative	pain.	
The	study	showed	a	clear	dose	response	relationship	with	a	greater	
effect	as	the	dose	of	M6G	increased.	The	study	results	also	showed	
that	M6G	is	safe	and	well	tolerated.
M 6 G 0 1 5 	 w a s 	 n o t 	 d e s i g n e d 	 t o 	 p r o d u c e 	 d e fi n i t i v e 	 e v i d e n c e 	 o n 	 t h e	
s i d e 	 e f f e c t 	 p r o fi l e 	 o f 	 M 6 G . 	 N e v e r t h e l e s s , 	 t h e 	 i n c i d e n c e 	 o f 	 n a u s e a	
and	vomiting	over	early	time	periods	after	M6G	was	low	and	similar	
to 	 placebo, 	 indicating 	 that 	 a 	 single 	 dose 	 of 	 M6G 	 that 	 can 	 provide	
p a i n 	 r e l i e f 	 d o e s 	 n o t 	 a p p e a r 	 t o 	 i n d u c e 	 n a u s e a 	 o r 	 v o m i t i n g .	
CoMPleted Phase iii study (M6G022) 
T h e 	 s t u d y 	 i n v o l v e d 	 2 4 	 c e n t r e s 	 i n 	 s i x 	 E u r o p e a n 	 c o u n t r i e s 	 a n d	
r e c r u i t e d 	 5 1 7 	 p a t i e n t s . 	 T h e 	 s t u d y 	 w a s 	 d e s i g n e d 	 p r i m a r i l y 	 t o 	 p r o v i d e	
key	information	on	a	comparison	of	effective	IV	pain	management	
regimens	of	M6G	or	morphine	treatment	for	a	minimum	of	24	hours	
(and	up	to	48	hours)	following	major	abdominal	surgery .	Morphine	
is	generally	accepted	as	the	‘gold	standard’	drug	for	use	in	these	
c i r c u m s t a n c e s . 	 I n i t i a l 	 p a i n 	 m a n a g e m e n t 	 w a s 	 a c h i e v e d 	 b y 	 a d m i n i s t r a t i o n	
of	a	loading	dose	and	titration	of	either	M6G	or	morphine	to	achieve	
a c c e p t a b l y 	 l o w 	 l e v e l s 	 o f 	 p a i n 	 f o r 	 t h e 	 p a t i e n t 	 t o 	 g o 	 o n t o 	 t h e 	 w a r d .	
In	the	ward,	pain	management	was	achieved	by	patient	controlled	
a n a l g e s i a 	 ( “ P C A ” ) , 	 w h e r e b y 	 t h e 	 p a t i e n t 	 w a s 	 a l l o w e d 	 t o 	 s e l f 	 a d m i n i s t e r	
a 	 d o s e 	 o f 	 M 6 G 	 o r 	 m o r p h i n e 	 a s 	 r e q u i r e d 	 t o 	 c o n t r o l 	 t h e i r 	 p a i n .	
T h e 	 s t u d y 	 w a s 	 r a n d o m i s e d 	 a n d 	 d o u b l e 	 b l i n d 	 s o 	 t h a t 	 n e i t h e r 	 p a t i e n t	
nor	carer	was	aware	of	which	treatment	was	being	administered.	
The 	 main 	 purpose 	 of 	 the 	 study 	 was 	 to 	 demonstrate 	 statistically 	 that:
	 	 treatment	with	either	M6G	or	mo rphine,	particularly	during	PCA ,	
results	in	similar	levels	of	pain	management;	and
_0_CEN_ar07_front.indd   4 06/05/2008   11:11:50 05 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
PhaSe iii StudieS CoNtiNued
CoMPleted Phase iii study (M6G022) Continued 	 	 effective	analgesic	treatment	during	PCA	results	in	lower	levels	
of	nausea	and	vomiting	in	patients	receiving	M6G	compared	
to	those	receiving	morphine.	
In	addition,	other	important	side	effects,	efficacy	and	safety	features	
were	determined	throughout	the	study .	The	key	outcomes	of	the	
study	are	summarised	below .
1.	M6G	MA T CHES	MORPHINE	FOR	ANALGESIC	EFFECT
I m p o r t a n t l y 	 f o r 	 a 	 n o v e l 	 p a i n 	 p r o d u c t , 	 t h e 	 t r i a l 	 r e s u l t s 	 u n e q u i v o c a l l y	
s h o w 	 t h a t 	 M 6 G 	 i s 	 a s 	 g o o d 	 a s 	 m o r p h i n e 	 i n 	 t e r m s 	 o f 	 a n a l g e s i a 	 a c h i e v e d	
i n 	 p a t i e n t s 	 u p 	 t o 	 4 8 	 h o u r s 	 p o s t ‑ o p e r a t i v e l y . 	 S u c c e s s f u l 	 a c h i e v e m e n t	
o f 	 t h i s 	 fi r s t 	 p r i m a r y 	 e n d p o i n t 	 s u p p o r t s 	 d a t a 	 f r o m 	 p r e v i o u s 	 c l i n i c a l 	 t r i a l s	
o f 	 M 6 G 	 a n d 	 i s 	 a n 	 e s s e n t i a l 	 c o m p o n e n t 	 i n 	 t h e 	 p r o d u c t 	 p r o fi l e 	 o f 	 M 6 G .	
2.	 M6G	 SHOWS	 SIGNIFICANT	 REDUCTION	 IN	 POST ‑OPERA TIVE	
NA USEA	AND	VOMITING	COMP ARED	TO	MORPHINE
T h e 	 t r i a l 	 r e s u l t s 	 c o n fi r m 	 t h e 	 e x c e l l e n t 	 p o t e n t i a l 	 o f 	 M 6 G 	 a s 	 a n	
a n a l g e s i c 	 w i t h 	 a 	 c l i n i c a l l y 	 s i g n i fi c a n t 	 i m p r o v e d 	 s i d e 	 e f f e c t 	 p r o fi l e	
c o m p a r e d 	 t o 	 m o r p h i n e . 	 T h e 	 s t u d y 	 r e s u l t s 	 s h o w 	 t h a t 	 p a t i e n t s	
r e c e i v i n g 	 M 6 G 	 e x p e r i e n c e d 	 a 	 2 8 % 	 r e d u c t i o n 	 i n 	 t h e 	 s e v e r i t y 	 o f 	 P O N V	
i n 	 t h e 	 k e y 	 6 – 2 4 	 h o u r s 	 a f t e r 	 t r e a t m e n t 	 ( s t a t i s t i c a l l y 	 s i g n i fi c a n t ,	
p=0.018).	In	addition,	the	incidence	of	dry	retching/vomiting	in	the	
M6G	arm	compared	to	the	morphine	arm	in	the	24	hour	period	after	
treatment 	 was 	 reduced 	 by 	 32% 	 (statistically 	 significant, 	 p=0.044). 	
The	incidence	and	severity	of	post ‑operative	nausea	in	the	M6G	arm	
was	27%	less	than	that	observed	in	the	morphine	arm	in	the	period	
6–24	hours	after	treatment.	This	was	the	second	primary	endpoint	
and	approached	statistical	significance	(p=0.052).
3. 	 P A TIENTS	RECEIVING	 M6G 	USED	LES S	ANTI ‑ EMETIC	DRUGS
In	addition	to	the	nausea	and	vomiting	reductions	of	over	25%,	
secondary	data	revealed	that	patients	receiving	M6G	required	
over	20%	less	anti‑emetic	medication	over	the	0–24	hour	period	
than	those	in	the	morphine	group.	This	shows	that	not	only	does	
M6G	induce	significantly	less	nausea	and	vomiting	than	morphine,	
but 	 also 	 that 	 the 	 post ‑operative 	 anti‑emetic 	 treatment 	 required	
is	considerably	reduced.	
The	potential	for	reduced	anti‑emetic	drug	costs	combined	with	
t h e 	 r e d u c t i o n 	 i n 	 m e d i c a l 	 a s s i s t a n c e 	 a n d 	 t h e 	 i m p r o v e d 	 p a t i e n t 	 c o m f o r t	
due	to	lower	PONV	supports	CeNeS	justification	of	a	substantial	
price	premium	for	M6G	compared	to	morphine.
4.	THE	DRUG	CONSUMPTION	PROFILE	OF	M6G	INDICA TES	
A	L ONG	DURA TION	OF	ACTION
It 	 has 	 been 	 shown 	 in 	 previous 	 studies 	 that 	 the 	 dose 	 of 	 M6G	
required	to	provide	analgesia	immediately	after	surgery	is	three	
t i m e s 	 t h a t 	 o f 	 m o r p h i n e . 	 I n 	 a c c o r d a n c e 	 w i t h 	 t h i s , 	 t h e 	 M 6 G 0 2 2	
t r i a l 	 w a s 	 d e s i g n e d 	 s u c h 	 t h a t 	 M 6 G 	 w a s 	 a v a i l a b l e 	 i n 	 a 	 3 : 1 	 r a t i o 	 t o	
morphine 	 during 	 the 	 titration 	 to 	 comfort 	 phase. 	 Thereafter 	 pain 	 relief	
w a s 	 p r o v i d e d 	 u s i n g 	 P C A 	 i n 	 a 	 d o s e 	 r a t i o 	 o f 	 2 : 1 	 ( M 6 G : 	 m o r p h i n e ) .	
In 	 the 	 initial 	 phase 	 after 	 surgery 	 the 	 dose 	 of 	 M6G 	 required 	 to 	 titrate	
patients 	 to 	 comfort 	 was 	 three 	 times 	 that 	 required 	 for 	 morphine 	 on	
a 	 w e i g h t 	 b a s i s . 	 H o w e v e r , 	 d u r i n g 	 t h e 	 p r o l o n g e d 	 P C A 	 p h a s e , 	 t h e 	 r a t i o	
w a s 	 l o w e r 	 ( 0 – 2 4 	 h o u r s 	 1 . 7 : 1 ; 	 2 4 – 4 8 	 h o u r s 	 1 . 3 : 1 ) . 	 T h i s 	 s h o w s 	 t h a t	
patients	in	the	M6G	group	made	less	demands	for	pain	relief	after	
titration 	 to 	 comfort, 	 as 	 assessed 	 by 	 presses 	 on 	 the 	 PCA 	 button.	
T h i s 	 d a t a 	 s u p p o r t s 	 t h e 	 h y p o t h e s i s 	 t h a t 	 M 6 G 	 h a s 	 a 	 l o n g e r 	 d u r a t i o n	
of 	 analgesic 	 action 	 than 	 morphine.	
5.	P A TIENTS	RECEIVING	M6G	WERE	LES S	SED A TED
T h e 	 M 6 G 0 2 2 	 d a t a 	 s h o w 	 t h a t 	 M 6 G 	 p a t i e n t s 	 e x p e r i e n c e 	 l o w e r 	 l e v e l s	
o f 	 s e d a t i o n 	 c o m p a r e d 	 t o 	 t h o s e 	 o n 	 m o r p h i n e . 	 T h i s 	 r e d u c t i o n	
is 	 particularly 	 noticeable 	 in 	 the 	 severe 	 sedation 	 scores 	 of 	 M6G	
patients	in	the	clinically	relevant	first	twelve	hours	after	surgery .
6.	SAFETy	PROFILE/AD VERSE	EVENTS
T h e 	 t r i a l 	 c o n fi r m e d 	 t h a t 	 M 6 G ’ s 	 s a f e t y 	 p r o fi l e 	 i s 	 s i m i l a r 	 t o 	 m o r p h i n e .	
Aside 	 from 	 reduced 	 nausea 	 and 	 vomiting, 	 the 	 adverse 	 events	
reported	were	at	levels	similar	to	those	experienced	by	patients	
receiving	morphine	in	a	post ‑operative	setting.
additioNal PhaSe i StudieS (m6G023, m6G024 
aNd m6G029)
T o	provide	the	relevant	Regulatory	Authorities	with	additional	clinical	
safety	information	for	a	Marketing	Authorisation	Application,	three	
further	small	studies	have	been	carried	out:
	 	 M6G023	is	a	m ass	balance	stud y	and	is	designed	to	show	the	
metabolic	fate	of	an	IV	injection	of	M6G.	T o	carry	out	this	study ,	
low	doses	of	radio‑labelled	(14C)	M6G	have	been	administered	
t o 	 s i x 	 h e a l t h y 	 v o l u n t e e r s . 	 T h e 	 d i s a p p e a r a n c e 	 o f 	 r a d i o ‑ l a b e l l e d	
material	from	the	blood	and	its	appearance	in	urine	and	faeces	
w a s 	 d e t e r m i n e d . 	 T h e 	 d a t a 	 g e n e r a t e d 	 s u p p o r t s 	 t h e 	 a n t i c i p a t e d	
differentiation	of	M6G	from	morphine,	i.e.	little	or	no	metabolism	
and	excretion	as	unmodified	M6G	by	the	kidneys.
_0_CEN_ar07_front.indd   5 06/05/2008   11:11:50 06 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
ChiEF EXECUtiVE’s REViEW CoNtiNUEd m6G for the treatment of post‑operative pain continued
additioNal PhaSe i StudieS (m6G023, m6G024 
aNd m6G029) CoNtiNued
	 	 M6G029	is	the 	US	IND ‑opening	study .	It	was	a	pharmacokinetic	
s t u d y 	 e x a m i n i n g 	 d o s e 	 p r o p o r t i o n a l i t y 	 a n d 	 a c c u m u l a t i o n 	 o f 	 M 6 G	
i n 	 v o l u n t e e r s . 	 T h e 	 a n t i c i p a t e d 	 f a v o u r a b l e 	 p r o fi l e 	 o f 	 l i n e a r	
pharmacokinetics	with	minimal	drug	accumulation	on	repeat	
dosing	was	observed.
	 	 M6G024	is	a	p harmacokinetic	s tudy	in	mild	and	moderate	renally	
impaired	patients.	M6G	is	excreted	from	the	body	by	the	kidney .	
D e t e r i o r a t i o n 	 o f 	 k i d n e y 	 f u n c t i o n , 	 t h e r e f o r e , 	 m a y 	 c a u s e 	 a c c u m u l a t i o n	
o f 	 M 6 G . 	 V o l u n t e e r s 	 w i t h 	 n o r m a l , 	 m i l d 	 o r 	 m o d e r a t e 	 r e n a l 	 i m p a i r m e n t	
received	an	IV	injection	of	M6G	and	the	relative	plasma	and	urine	
levels	of	M6G	were	determined	and	compared	between	these	
groups.	This	study	has	very	recently	completed	and	the	report	
is	being	prepared.
the marketS For m6G
The	global	market	for	opiate	use	in	managing	post ‑operative	pain	
w a s 	 e s t i m a t e d 	 a t 	 $ 1 	 b i l l i o n 	 i n 	 2 0 0 0 	 a n d 	 g r o w i n g 	 a t 	 a 	 r a t e 	 o f 	 6 – 7 % . 	 M 6 G	
r e p r e s e n t s 	 a n 	 a t t r a c t i v e 	 a l t e r n a t i v e 	 f o r 	 p a t i e n t s 	 a n d 	 h e a l t h c a r e 	 p r o v i d e r s	
with 	 potentially 	 significant 	 pharmaco‑economic 	 benefits 	 including 	
a 	 r e d u c t i o n 	 i n 	 t h e 	 u s e 	 o f 	 a n t i ‑ e m e t i c s , 	 n u r s i n g 	 t i m e 	 a n d 	 l e n g t h 	 o f 	 h o s p i t a l	
s t a y . 	 C e N e S 	 h a s 	 c o m m i s s i o n e d 	 t w o 	 i n d e p e n d e n t 	 s t u d i e s 	 r e s e a r c h i n g	
t h e 	 m a r k e t 	 f o r 	 M 6 G 	 i n 	 E u r o p e 	 a n d 	 t h e 	 U S . 	 T h e s e 	 s t u d i e s 	 h a v e 	 c o n fi r m e d	
C e N e S 	 u n d e r s t a n d i n g 	 t h a t 	 t h e r e 	 i s 	 a 	 s i g n i fi c a n t 	 g l o b a l 	 m a r k e t 	 f o r 	 M 6 G	
o f 	 a r o u n d 	 £ 2 0 0 	 m i l l i o n 	 a n d 	 t h a t 	 t h e 	 p l a n n e d 	 p r i c e 	 p r e m i u m 	 i s 	 l i k e l y 	 t o	
b e 	 a c c e p t a b l e 	 t o 	 p h y s i c i a n s 	 a n d 	 p h a r m a c i s t s 	 i n 	 h o s p i t a l s 	 a n d 	 a l s o 	 t h e	
v a r i o u s 	 G o v e r n m e n t 	 r e i m b u r s e m e n t 	 a u t h o r i t i e s . 	 T h e s e 	 a s s u m p t i o n s 	 a r e	
based 	 on 	 the 	 successful 	 delivery 	 of 	 M6G’s 	 potential 	 clinical 	 and 	 health	
e c o n o m i c 	 b e n e fi t s .	
PartNeriNG StrateG y
CeNeS 	 has 	 appointed 	 Rodman 	 & 	 Renshaw , 	 the 	 US 	 based 	 healthcare	
specialist 	 investment 	 bank, 	 to 	 assist 	 in 	 the 	 partnering 	 of 	 M6G.	
The	appointment	of	Rodman	&	Renshaw	strengthens	CeNes	ability	
to	m a n a g e 	 t h e 	 i n t e r n a t i o n a l 	 p a r t n e r i n g 	 p r o c e s s 	 a n d 	 i s 	 i n 	 k e e p i n g 	 w i t h	
t h e 	 o u t s o u r c i n g 	 b u s i n e s s 	 m o d e l . 	 T h e 	 q u a l i t y 	 o f 	 t h e 	 r e c e n t l y 	 a n n o u n c e d	
P h a s e 	 I I I 	 d a t a 	 o n 	 M 6 G 	 m e a n s 	 t h a t 	 t h e r e 	 i s 	 a 	 c o m p r e h e n s i v e 	 d a t a	
p a c k a g e 	 f o r 	 p o t e n t i a l 	 p a r t n e r s 	 t o 	 r e v i e w .	
T h e r e 	 i s 	 a 	 c l e a r 	 n e e d 	 f o r 	 n e w 	 d r u g s 	 t h a t 	 c a n 	 i m p r o v e 	 t h e 	 q u a l i t y	
o f 	 p a i n 	 m a n a g e m e n t 	 c u r r e n t l y 	 g i v e n 	 t o 	 p a t i e n t s 	 b y 	 s t a n d a r d 	 m o r p h i n e	
r e g i m e n s 	 a c r o s s 	 t h e 	 w o r l d 	 a n d 	 M 6 G 	 i s 	 w e l l 	 p o s i t i o n e d 	 t o 	 a d d r e s s 	 t h a t	
market.	CeNeS	is	confident	that	agreements	can	be	finalised	with	
p a r t n e r ( s ) 	 b a s e d 	 o n 	 t h e 	 e x i s t i n g 	 s e t 	 o f 	 c l i n i c a l 	 t r i a l 	 d a t a . 	 C o n c l u d i n g	
these 	 deals 	 will 	 generate 	 short 	 term 	 income 	 and 	 recurring 	 revenue	
streams 	 from 	 a 	 successful 	 product 	 launch 	 in 	 the 	 future.
reGulatory StrateG y
CeNeS	is	working	towards	compiling	the	efficacy	and	safety	data	
that 	 are 	 required 	 by 	 the 	 Regulatory 	 Authorities 	 for 	 Market 	 Authorisation	
Application	in	Europe.	CeNeS	has	also	successfully	completed	the	
a d d i t i o n a l 	 p r e ‑ c l i n i c a l 	 w o r k 	 t h a t 	 w a s 	 r e q u i r e d 	 b y 	 t h e 	 F D A 	 f o r 	 t h e	
US	m a r k e t 	 a n d 	 h a d 	 a n 	 I N D 	 a p p l i c a t i o n 	 a c c e p t e d 	 b y 	 t h e 	 F D A 	 i n 	 A p r i l 	 2 0 0 7 .	
This	filing	is	a	key	milestone	in	CeNes	history	and	represents	a 	 m a j o r	
step	forward	in	the	clinical	development	of	M6G.	The	opening	trial	
under	this	IND	was	the	Phase	I	pharmacokinetic	study	in	volunteers	
(M6G029).	W ith	the	successful	conclusion	of	this	study ,	CeNeS	has	
completed	the	studies	requested	by	the	FD A	to	support	a	Phase	III	
programme	in	the	USA .
CeNes	preferred	strategy	is	for	a	partner	to	be	involved	in	the	key	
decisions	regarding	regulatory	filing	strategies	both	in	Europe	and	
in	the	US.	The	strong	data	obtained	from	the	most	recent	Phase	III	
study	supports	the	proposed	product	profile	of	M6G	and	strengthens	
CeNes	position	with	potential	North	American	partners.	Registration	
could	be	achieved	in	the	US	in	2010	after	conducting	two	Phase	III	
studies	to	the	requirements	of	the	FD A .	It	is	important	to	note	that	the	
quality	and	robustness	of	the	clinical	data	produced	by	the	M6G022	
study	significantly	reduces	the	risk	for	the	development	of	M6G	by	
enabling	optimal	trial	design	and	the	selection	of	endpoints	in	the	
remaining	Phase	III	studies.	
In	Europe	the	narrow	failure	to	achieve	statistical	significance	with	the	
second	chosen	primary	endpoint	of	incidence	and	severity	of	nausea	
(p=0.052	not	p<0.050)	offers	three	options:
	 	 pursue	a	filing	application	in	cer tain	European	countries	with	the	
comprehensive 	 clinical 	 data 	 package 	 that 	 CeNeS 	 has 	 assembled;	
	 	 further	strengthen	the	European	package	by	conducting	an	
additional	European	Phase	III	study;	and
	 	 use	the	US	Phase	III	trials	to	sup port	the	European	application,	
potentially	with	a	global	partner .	
_0_CEN_ar07_front.indd   6 06/05/2008   11:11:50 07 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
iNtelleCtual ProPerty (“iP”)
CeNeS	has	established	a	significant	IP	portfolio	comprising	patents	
covering	novel	synthetic	routes	for	the	manufacture	of	M6G,	as	well	
as	key	intermediates,	novel	salts	and	know‑how .	The	Company	has	
two 	 cGMP 	 compliant 	 manufacturing 	 contractors 	 in 	 place 	 and 	 the	
p r i m a r y 	 m a n u f a c t u r e r 	 h a s 	 p r o d u c e d 	 v a l i d a t i o n 	 b a t c h e s 	 o f 	 M 6 G	
at 	 the 	 multi‑kilogram 	 scale. 	 The 	 synthetic 	 process 	 currently 	 used	
by 	 CeNeS 	 is 	 expected 	 to 	 be 	 the 	 least ‑cost 	 manufacturing 	 route 	 for	
M 6 G . 	 I n 	 a d d i t i o n , 	 C e N e S 	 a c q u i r e d 	 r i g h t s 	 t o 	 a n o t h e r 	 p r o p r i e t a r y	
synthetic 	 method 	 for 	 the 	 manufacture 	 of 	 M6G 	 from 	 Innovata 	 plc	
i n 	 M a r c h 	 2 0 0 6 . 	 T h i s 	 a g r e e m e n t 	 f u r t h e r 	 s t r e n g t h e n e d 	 C e N e S 	 I P	
p o s i t i o n 	 a r o u n d 	 M 6 G .	
C e N e S 	 a l s o 	 e x p e c t s 	 t o 	 b e n e fi t 	 f r o m 	 d a t a 	 a n d 	 m a r k e t i n g 	 e x c l u s i v i t y	
p r o v i s i o n s 	 a c c o r d e d 	 t o 	 c o m p a n i e s 	 t h a t 	 u n d e r t a k e 	 c l i n i c a l 	 t r i a l s ,	
r e p r e s e n t i n g 	 a 	 p e r i o d 	 o f 	 t e n 	 y e a r s 	 f o l l o w i n g 	 fi r s t 	 a p p r o v a l 	 i n 	 E u r o p e ,	
and	at	least	five	years	following	approval	in	the	US.	
In 	 2006, 	 CeNeS 	 was 	 granted 	 a 	 new 	 composition 	 of 	 matter 	 patent 	 o n	
a 	 n o v e l 	 s a l t 	 f o r m 	 o f 	 M 6 G 	 b y 	 t h e 	 E u r o p e a n 	 P a t e n t 	 O f fi c e . 	 T h e 	 i n v e n t i o n	
r e l a t e s 	 t o 	 a 	 s a l t 	 o f 	 M 6 G 	 w i t h 	 i m p r o v e d 	 s t a b i l i t y 	 a n d 	 t o 	 t h e 	 t h e r a p e u t i c	
u s e 	 o f 	 t h e 	 s a l t . 	 T h e 	 g r a n t e d 	 p a t e n t 	 i s 	 r e g i s t e r e d 	 i n 	 2 1 	 E u r o p e a n	
countries. 	 The 	 new 	 patent 	 expires 	 in 	 2022 	 and 	 has 	 the 	 potential	
to	extend	and	strengthen	the	protection	provided	by	the	existing	
process	patents.	
additioNal FormulatioNS aNd marketS
I f 	 M 6 G 	 i s 	 s u c c e s s f u l 	 i n 	 t r e a t i n g 	 p o s t ‑ o p e r a t i v e 	 p a i n 	 u s i n g 	 t h e 	 c u r r e n t 	 I V	
f o r m u l a t i o n 	 t h e r e 	 w i l l 	 b e 	 p o t e n t i a l 	 f o r 	 u s e 	 i n 	 o t h e r 	 p a i n 	 i n d i c a t i o n s	
such 	 as 	 chronic 	 pain 	 and 	 also 	 by 	 other 	 routes 	 of 	 administration 	 such 	
a s 	 e p i d u r a l 	 a n d 	 o r a l 	 d e l i v e r y . 	 S u c h 	 e x p a n s i o n 	 w o u l d 	 s i g n i fi c a n t l y	
increase 	 the 	 potential 	 peak 	 market 	 sales 	 of 	 M6G. 	 An 	 oral 	 formulation	
c o u l d 	 p o t e n t i a l l y 	 b e 	 u s e d 	 t o 	 t r e a t 	 m a n y 	 o f 	 t h e 	 2 . 7 	 m i l l i o n 	 p a t i e n t s 	 w h o	
develop	cancer	each	year	in	the	US	and	Europe.	The	market	for	oral	
morphine	formulations	is	currently	estimated	at	£600	million	annually .
_0_CEN_ar07_front.indd   7 06/05/2008   11:11:50 08 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
CNS 5161 for the treatment of neuropathic pain
ChiEF EXECUtiVE’s REViEW CoNtiNUEd Neuropathic 	 pain 	 represents 	 a 	 significant 	 unmet 	 medical 	 need 	 and 	
a 	 l a r g e , 	 g r o w i n g 	 m a r k e t 	 o p p o r t u n i t y 	 c u r r e n t l y 	 w o r t h 	 o v e r 	 $ 2 	 b i l l i o n	
g l o b a l l y . 	 I t 	 a r i s e s 	 f r o m 	 a 	 r a n g e 	 o f 	 p r i m a r y 	 d i s e a s e s 	 o r 	 c o n d i t i o n s	
(including	cancer ,	diabetes,	shingles	and	HIV/AIDS)	that	can	result	
in	nerve	damage	and	subsequently	chronic	pain.	Neuropathic	pain	
is	 difficult 	 to 	 treat 	 and 	 current 	 analgesics 	 do 	 not 	 provide 	 adequate 	 relief 	
f o r 	 m a n y 	 p a t i e n t s . 	 S u c h 	 n e u r o p a t h i c 	 p a i n 	 c a n 	 b e 	 d e s c r i b e d 	 b y 	 p a t i e n t s	
as 	 burning, 	 stinging, 	 shooting, 	 aching 	 or 	 electric‑shock ‑like 	 sensations 	
which	can	last	for	many	months	or	years.	Common	features	of	these	
abnormal	conditions	include	increased	pain	in	response	to	repeated	
s t i m u l a t i o n 	 ( “ w i n d ‑ u p ” 	 p a i n ) , 	 h y p e r a l g e s i a 	 ( r e d u c e d 	 p a i n 	 t h r e s h o l d 	 a n d	
e x a g g e r a t e d 	 r e s p o n s e 	 t o 	 m i l d 	 n o x i o u s 	 s t i m u l i ) , 	 a n d 	 a l l o d y n i a 	 ( p a i n f u l	
r e s p o n s e 	 t o 	 s t i m u l i 	 t h a t 	 a r e 	 n o t 	 n o r m a l l y 	 p a i n f u l ) . 	 D r u g 	 t r e a t m e n t s 	 f o r	
n e u r o p a t h i c 	 p a i n 	 r e p r e s e n t 	 a 	 s i g n i fi c a n t 	 a r e a 	 o f 	 u n m e t 	 m e d i c a l 	 n e e d	
and 	 a 	 growing 	 market 	 opportunity .
O n e 	 o f 	 t h e 	 m o s t 	 c o m m o n 	 f o r m s 	 o f 	 n e u r o p a t h i c 	 p a i n 	 i s 	 a s s o c i a t e d	
with 	 diabetes. 	 It 	 is 	 estimated 	 that 	 there 	 are 	 over 	 13 	 million 	 patients	
in	the	US	and	Europe	with	diabetes	and	that	over	30%	of	these	
e x p e r i e n c e 	 n e u r o p a t h i c 	 p a i n , 	 w h i c h 	 c a n 	 l a s t 	 f o r 	 m a n y 	 y e a r s .	
In	addition,	herpes	z o s t e r 	 i n f e c t i o n s 	 c a n 	 l e a d 	 t o 	 s h i n g l e s 	 a n d 	 u p	
t o 	 2 0 % 	 o f 	 t h e 	 1 . 5 	 t o 	 2 . 0 	 m i l l i o n 	 p a t i e n t s 	 i n 	 t h e 	 U S 	 a n d 	 E u r o p e	
w i t h 	 s h i n g l e s 	 e x p e r i e n c e 	 n e u r o p a t h i c 	 p a i n , 	 w h i c h 	 i s 	 o f t e n 	 r e s i s t a n t	
t o 	 c u r r e n t 	 t r e a t m e n t s 	 a n d 	 c a n 	 l a s t 	 f o r 	 m a n y 	 m o n t h s .	
CurreNt druG treatmeNt oF NeuroP athiC P aiN
S o m e 	 p a t i e n t s 	 w i t h 	 m i l d 	 t o 	 m o d e r a t e 	 n e u r o p a t h i c 	 p a i n 	 m a y 	 r e s p o n d 	 t o	
s i m p l e 	 a n a l g e s i c s 	 o r 	 n o n ‑ s t e r o i d a l 	 a n t i ‑ i n fl a m m a t o r y 	 d r u g s 	 ( “ N S A I D s ” )	
but 	 most 	 patients 	 will 	 require 	 more 	 specialist 	 drug 	 therapy . 	 Due 	 to 	 the	
difficulty 	 in 	 treating 	 neuropathic 	 pain, 	 it 	 can 	 account 	 for 	 up 	 to 	 40% 	
o f 	 p a t i e n t s 	 r e f e r r e d 	 t o 	 s p e c i a l i s t 	 p a i n 	 c l i n i c s . 	 T h e 	 m o r e 	 c o m m o n	
t r e a t m e n t s 	 i n c l u d e 	 t r i c y c l i c 	 a n t i ‑ d e p r e s s a n t 	 d r u g s 	 a n d 	 a n t i ‑ c o n v u l s a n t	
d r u g s , 	 t h o u g h 	 t h e i r 	 s i d e 	 e f f e c t s 	 c a n 	 b e 	 p r o b l e m a t i c 	 a n d , 	 m a n y 	 o f 	 t h e s e	
drugs	are	not	licensed	for	the	treatment	of	neuropathic	pain.
The 	 anti‑convulsant 	 gabapentin 	 is 	 currently 	 the 	 only 	 oral 	 drug 	 licensed	
for 	 the 	 treatment 	 of 	 neuropathic 	 pain 	 in 	 the 	 UK 	 and 	 had 	 worldwide 	 sales	
o f 	 $ 2 . 7 	 b i l l i o n 	 i n 	 2 0 0 3 , 	 o f 	 w h i c h 	 a 	 s i g n i fi c a n t 	 p r o p o r t i o n 	 i s 	 b e l i e v e d 	 t o 	 b e	
for	neuropathic	pain.	Gabapentin	has	a	more	favourable	side	effect	
p r o fi l e 	 t h a n 	 s o m e 	 o t h e r 	 a n t i ‑ c o n v u l s a n t s 	 b u t 	 d o e s 	 n o t 	 w o r k 	 i n 	 t h e	
m a j o r i t y 	 o f 	 n e u r o p a t h i c 	 p a i n 	 p a t i e n t s . 	 C a p s a i c i n 	 c r e a m , 	 c o m m e r c i a l l y	
p r e p a r e d 	 f r o m 	 d r i e d 	 c h i l l i 	 p e p p e r s , 	 i s 	 a l s o 	 l i c e n s e d 	 f o r 	 s o m e 	 t y p e s 	 o f	
n e u r o p a t h i c 	 p a i n 	 a n d 	 m a y 	 b e 	 a p p l i e d 	 t o p i c a l l y . 	 H o w e v e r , 	 i t 	 c a n 	 c a u s e	
initial 	 stinging 	 that 	 deters 	 some 	 patients. 	 Local 	 anaesthetic 	 drugs 	 can	
a l s o 	 b e 	 u s e d 	 t o 	 p r o v i d e 	 s h o r t 	 t e r m 	 s o o t h i n g 	 r e l i e f 	 f r o m 	 n e u r o p a t h i c 	 p a i n .	
O p i o i d 	 a n a l g e s i c s 	 c a n 	 b e 	 e f f e c t i v e 	 f o r 	 s o m e 	 p a t i e n t s , 	 e s p e c i a l l y 	 w h e n	
c o m b i n e d 	 w i t h 	 o t h e r 	 d r u g s .	
In	extreme	cases	nerve	blocks,	nerve	ablation	and	spinal	analgesia	
may	be	required	to	ease	this	distressing	condition.	
There	remains	a	clear	need	for	an	effective	agent	with	a	favourable	
side	effect	profile	for	the	treatment	of	neuropathic	pain.
Glutamate aNd NeuroP athiC P aiN
Glutamate	is	a	major	excitatory	transmitter	in	the	brain	and	binds	
to	N‑methyl‑D ‑aspartate	(“NMD A ”)	receptors	on	nerves	in	the	spinal	
cord.	This	mechanism	has	been	implicated	in	the	sensitisation	of	
long	term	pain	responses.
D r u g s 	 t h a t 	 b l o c k 	 t h e 	 N M D A 	 r e c e p t o r 	 h a v e 	 b e e n 	 s h o w n 	 t o 	 b e 	 e f f e c t i v e	
i n 	 m o d e l s 	 o f 	 p e r s i s t e n t 	 p a i n 	 a n d 	 s o m e 	 o f 	 t h e 	 o l d e r 	 n o n ‑ s p e c i fi c 	 N M D A	
antagonists 	 have 	 shown 	 promise 	 in 	 the 	 treatment 	 of 	 neuropathic 	 pain.	
However , 	 they 	 are 	 often 	 associated 	 with 	 unacceptable 	 side 	 effects.
CNS 5161 
CNS 	 5161 	 is 	 a 	 novel 	 and 	 selective 	 non‑competitive 	 NMD A 	 receptor	
antagonist. 	 It 	 acts 	 by 	 binding 	 to 	 a 	 site 	 within 	 the 	 ion‑channel	
associated	with	the	NMD A	receptor ,	rather	than	competing	with	
glutamate	at	the	agonist	recognition	site.
erGomed aGreemeNt
CeNeS	has	a	revenue	sharing	and	co‑development	agreement	with	
E R G O M E D 	 ( s i g n e d 	 i n 	 J u l y 	 2 0 0 6 ) 	 u n d e r 	 w h i c h 	 a 	 c o m p r e h e n s i v e	
Phase	II	development	programme	for	CNS	5161	has	been	planned.
Under	the	agreement,	CeNeS	and	ERGOMED	are	working	together	
to	assemble	a	comprehensive	Phase	II	data	package	with	the	goal	
o f 	 d e m o n s t r a t i n g 	 t h a t 	 C N S 	 5 1 6 1 	 c a n 	 p r o v i d e 	 s u s t a i n e d 	 p a i n 	 r e l i e f 	 t o	
i m p r o v e 	 t r e a t m e n t 	 i n 	 c e r t a i n 	 p a i n 	 c o n d i t i o n s . 	 B o t h 	 p a r t i e s 	 a r e 	 i n v e s t i n g	
their	respective	expert	internal	resources	and	contribute	funding	into	
t h e 	 p r o g r a m m e 	 t o 	 c o v e r 	 t h e 	 e x t e r n a l 	 c l i n i c a l 	 t r i a l 	 c o s t s . 	 U n d e r 	 t h e 	 t e r m s	
of	the	agreement,	ERGOMED	is	entitled	to	a	share	of	commercial	
revenues 	 generated 	 from 	 CNS 	 5161 	 in 	 a 	 ratio 	 of 	 ERGOMED’s	
i n v e s t m e n t 	 c o m p a r e d 	 t o 	 t h e 	 t o t a l 	 d e v e l o p m e n t 	 c o s t s . 	 T h e i r 	 s h a r e 	 o f	
a n y 	 r e v e n u e s 	 g e n e r a t e d 	 c a n 	 b e 	 i n c r e a s e d 	 i n 	 t h e 	 f u t u r e 	 i f 	 E R G O M E D ,	
i n 	 a g r e e m e n t 	 w i t h 	 C e N e S , 	 t a k e s 	 r e s p o n s i b i l i t y 	 f o r 	 a 	 f u r t h e r 	 p e r c e n t a g e	
of 	 the 	 investment 	 required 	 in 	 the 	 planned 	 Phase 	 II 	 programme.
_0_CEN_ar07_front.indd   8 06/05/2008   11:11:51 09 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
CNS 5161 CliNiCal develoPmeNt 
F o l l o w i n g 	 a 	 s u c c e s s f u l 	 s m a l l 	 i n i t i a l 	 s t u d y 	 i n 	 p a t i e n t s 	 w i t h 	 n e u r o p a t h i c	
p a i n 	 ( C N S 	 5 1 6 1 	 0 0 3 ) , 	 C e N e S 	 c a r r i e d 	 o u t 	 a 	 f u r t h e r 	 s i m i l a r 	 p r o o f	
o f 	 c o n c e p t 	 s t u d y 	 ( C N S 	 5 1 6 1 	 0 0 3 A ) 	 w h i c h 	 r e p o r t e d 	 p o s i t i v e 	 r e s u l t s	
in	June	2005.	In	the	study ,	which	was	designed	to	establish	the	
therapeutic 	 window 	 of 	 CNS 	 5161, 	 the 	 product 	 was 	 associated 	 with	
a	clear	trend	to	improvement	in	pain	levels	and	was	well	tolerated	
with	no	instances	of	the	psychotomimetic	side	effects	associated	
w i t h 	 s o m e 	 N M D A 	 a n t a g o n i s t s . 	 T h i s 	 l a t t e r 	 fi n d i n g 	 c o n fi r m s 	 C e N e S	
understanding 	 that 	 CNS 	 5161 	 occupies 	 a 	 unique 	 position 	 in 	 its 	 class.
In	partnership	with	ERGOMED	CeNeS	plans	to	pursue	two	
development	routes	for	CNS	5161	in	parallel;	an	IV/subcutaneous	
infusion	presentation	for	the	treatment	of	refractory	pain	in	patients	
with	cancer	and	an	adhesive	patch	presentation	that	can	be	applied	
to	the	skin	and	so	provide	pain	relief	over	a	number	of	days.	Initial	
studies	have	confirmed	the	feasibility	of	administering	CNS	5161	
by	the	patch	route.	
The	first	study	has	started	and	is	a	Phase	II	dose‑escalation	study	
designed	to	establish	the	optimal	schedule	for	infusion	of	CNS	5161	
i n 	 t h e 	 m a n a g e m e n t 	 o f 	 c a n c e r 	 p a i n . 	 I t 	 i s 	 b e i n g 	 c a r r i e d 	 o u t 	 a t 	 a 	 s p e c i a l i s t	
oncology 	 unit 	 in 	 Europe 	 and 	 will 	 assess 	 the 	 safety , 	 efficacy 	 and 	
pharmacokinetic	profile	of	CNS	5161	administered	intravenously	at	
various	doses	over	24	hours	when	added	to	opioids	for	the	treatment	
of	cancer	pain	with	a	neuropathic	component.	
The	aim	of	the	study	is	to	identify	the	maximum	tolerated	dose	and	
analgesic	efficacy	of	CNS	5161	in	this	patient	population.	The	study	
w i l l 	 a l s o 	 a s s e s s 	 a n y 	 c o r r e l a t i o n 	 b e t w e e n 	 c h a n g e s 	 i n 	 p a i n 	 l e v e l 	 a n d	
t h e 	 p l a s m a 	 c o n c e n t r a t i o n s 	 o f 	 C N S 	 5 1 6 1 . 	 U p 	 t o 	 3 6 	 s u b j e c t s 	 w i l l 	 b e	
enrolled	sequentially	and	receive	intravenous	infusions	of	CNS	5161	
a d m i n i s t e r e d 	 a t 	 f o u r 	 h o u r 	 i n t e r v a l s 	 a t 	 i n c r e a s i n g 	 d o s e 	 l e v e l s . 	 T h e 	 r e s u l t s	
of	the	study	are	planned	to	be	available	in	2008.
P ain 	 is 	 an 	 inevitable 	 consequence 	 of 	 most 	 solid 	 cancers. 	 It 	 has 	 been	
e s t i m a t e d 	 t h a t 	 n e a r l y 	 t h r e e 	 m i l l i o n 	 p a t i e n t s 	 i n 	 t h e 	 s e v e n 	 m a j o r 	 m a r k e t s	
w i l l 	 r e q u i r e 	 t r e a t m e n t 	 f o r 	 c a n c e r 	 p a i n 	 a n n u a l l y 	 a n d 	 t h a t 	 m o r e 	 t h a n	
7 0 % 	 o f 	 l a t e 	 s t a g e 	 c a n c e r 	 p a t i e n t s 	 s u f f e r 	 f r o m 	 m o d e r a t e 	 t o 	 s e v e r e 	 p a i n	
( S o u r c e 	 A p e x 	 H e a l t h c a r e ) . 	 O p i o i d s 	 a r e 	 c o m m o n l y 	 u s e d 	 f o r 	 m a n a g i n g	
m o d e r a t e 	 t o 	 s e v e r e 	 c a n c e r 	 p a i n , 	 b u t 	 i t 	 h a s 	 b e e n 	 e s t i m a t e d 	 t h a t 	 a r o u n d	
20%	of	patients	will	experience	opioid‑refractory	pain	that	has	to	be	
treated 	 using 	 alternative 	 therapies.
the marketS For CNS 5161
C N S 	 5 1 6 1 	 i s 	 b e i n g 	 d e v e l o p e d 	 f o r 	 a 	 p o o r l y 	 t r e a t e d 	 p o p u l a t i o n 	 o f	
around 	 eight 	 million 	 patients 	 suffering 	 from 	 neuropathic 	 pain 	 in 	 the	
m a j o r 	 p h a r m a c e u t i c a l 	 m a r k e t s . 	 T h e 	 n e u r o p a t h i c 	 p a i n 	 m a r k e t 	 i s	
c u r r e n t l y 	 e s t i m a t e d 	 t o 	 e x c e e d 	 $ 2 	 b i l l i o n 	 w o r l d w i d e 	 b u t 	 e x i s t i n g 	 d r u g s	
are	believed	to	work	in	only	about	30%	of	patients	with	neuropathic	
p a i n . 	 T h e 	 t o t a l 	 a v a i l a b l e 	 m a r k e t 	 s h o u l d 	 t h e r e f o r e 	 b e 	 s i g n i fi c a n t l y 	 l a r g e r .	
I f 	 C e N e S 	 i s 	 a b l e 	 t o 	 c o n fi r m 	 t h e 	 e f fi c a c y 	 o f 	 C N S 	 5 1 6 1 	 i n 	 t h e 	 t r e a t m e n t	
o f 	 n e u r o p a t h i c 	 p a i n 	 a n d 	 i s 	 a b l e 	 t o 	 e s t a b l i s h 	 t h a t 	 i t 	 i s 	 w e l l 	 t o l e r a t e d 	 b y	
p a t i e n t s 	 t h i s 	 c o u l d 	 p r o v e 	 t o 	 b e 	 a 	 v a l u a b l e 	 c o m m e r c i a l 	 o p p o r t u n i t y .	
A l t h o u g h 	 n e u r o p a t h i c 	 p a i n 	 i s 	 t h e 	 l e a d 	 t h e r a p e u t i c 	 i n d i c a t i o n 	 f o r	
C N S 	 5 1 6 1 , 	 c l i n i c a l 	 o b s e r v a t i o n s 	 a n d 	 p r e ‑ c l i n i c a l 	 fi n d i n g s 	 w i t h 	 N M D A	
antagonists 	 suggest 	 that 	 this 	 drug 	 candidate 	 has 	 the 	 potential 	 to	
prevent	or	treat	a	wide	range	of	neurological	disorders	that	involve	
n e u r o n a l 	 d e g e n e r a t i o n , 	 a l t e r e d 	 n e u r o n a l 	 a c t i v i t y 	 o r 	 n e u r o ‑ i n fl a m m a t i o n .	
These	diseases	include	P arkinson’s	disease,	Huntington’s	disease,	
epilepsy , 	 addiction, 	 multiple 	 sclerosis, 	 AIDS, 	 dementia 	 and 	 the	
n e u r o l o g i c a l 	 c o m p l i c a t i o n s 	 o f 	 c e r t a i n 	 c e n t r a l 	 n e r v o u s 	 s y s t e m 	 i n j u r i e s	
and 	 infections.
 
_0_CEN_ar07_front.indd   9 06/05/2008   11:11:51 10 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
ChiEF EXECUtiVE’s REViEW CoNtiNUEd CNS 7056 a short acting sedative
SedatioN aNd aNaeStheSia
Sedation	is	required	for	a	wide	range	of	surgical	and	non‑surgical	
procedures. 	 The 	 high 	 cost 	 of 	 overnight 	 hospital 	 stays 	 means 	 that 	 there	
is 	 a 	 trend 	 towards 	 day ‑case 	 procedures. 	 This 	 creates 	 a 	 requirement 	 for	
I V 	 s e d a t i v e 	 a g e n t s 	 t h a t 	 p e r m i t 	 a 	 r a p i d 	 a n d 	 p r e d i c t a b l e 	 r e c o v e r y .	
C N S 	 7 0 5 6 	 h a s 	 t h e 	 p o t e n t i a l 	 t o 	 fi t 	 t h i s 	 p r o fi l e .	
C N S 	 7 0 5 6 	 w o r k s 	 v i a 	 a 	 c l i n i c a l l y 	 v a l i d a t e d 	 m e c h a n i s m 	 a s 	 a n 	 a g o n i s t 	 a t	
the 	 benzodiazepine 	 site 	 of 	 the 	 GABA
A
	 r e c e p t o r . 	 A g e n t s 	 w i t h 	 a 	 s i m i l a r	
mechanism	of	action	have	been	used	for	many	years	as	sedatives	
( e . g . 	 m i d a z o l a m ) 	 b u t 	 s u f f e r 	 f r o m 	 r e l a t i v e l y 	 l o n g 	 a n d 	 v a r i a b l e 	 d u r a t i o n s	
o f 	 a c t i o n , 	 p r i m a r i l y 	 d u e 	 t o 	 a c t i v e 	 m e t a b o l i t e s . 	 C N S 	 7 0 5 6 	 w a s 	 d e v e l o p e d	
by 	 GlaxoSmithKline 	 (“GSK”) 	 to 	 have 	 equivalent 	 sedative 	 effects 	 to	
a g e n t s 	 s u c h 	 a s 	 m i d a z o l a m 	 b u t , 	 u n i q u e l y , 	 t h e 	 c o m p o u n d 	 i s 	 d e s i g n e d	
t o 	 b e 	 r a p i d l y 	 b r o k e n 	 d o w n 	 i n 	 t h e 	 b o d y 	 t o 	 a n 	 i n a c t i v e 	 m e t a b o l i t e 	 a n d	
c o n s e q u e n t l y 	 t o 	 h a v e 	 a 	 v e r y 	 s h o r t 	 d u r a t i o n 	 o f 	 a c t i o n .	
C N S 	 7 0 5 6 	 i s 	 t h e 	 l e a d 	 c o m p o u n d 	 o f 	 a 	 s e r i e s 	 t h a t 	 w a s 	 a s s i g n e d	
t o 	 C e N e S 	 f r o m 	 G S K 	 i n 	 N o v e m b e r 	 2 0 0 3 . 	 T h e 	 c o m p o u n d 	 fi t s 	 v e r y	
well	with	the	CeNeS	focus	on	precedented	mechanisms	and	builds	
o n 	 t h e 	 e x p e r t i s e 	 e s t a b l i s h e d 	 i n 	 t h e 	 p e r i ‑ o p e r a t i v e 	 a r e a 	 w i t h 	 t h e	
development	of	M6G.	The	design	of	CNS	7056	was	based	on	the	
experience	gained	at	GSK	with	the	short	acting	opiate,	remifentanil.	
CNS	7056	is	an	ester ‑based	drug	that	is	rapidly	hydrolysed	in	the	
body	by	esterases	to	an	inactive	metabolite.	An	attractive	potential	
advantage	offered	by	this	mechanism	of	deactivation	is	a	predictable	
onset	and	offset	profile,	in	contrast	to	midazolam.	Pre‑clinical	studies	
r e v e a l 	 t h a t 	 t h i s 	 c o m p o u n d 	 h a s 	 a 	 s i g n i fi c a n t l y 	 s h o r t e r 	 d u r a t i o n 	 o f 	 a c t i o n	
than 	 midazolam. 	 The 	 lack 	 of 	 reliance 	 on 	 a 	 cytochrome 	 P450 	 for	
metabolism 	 means 	 less 	 scope 	 for 	 drug‑drug 	 interactions 	 compared	
t o 	 m i d a z o l a m 	 a n d 	 s h o u l d 	 p e r m i t 	 i t s 	 u s e 	 i n 	 p a t i e n t s 	 w i t h 	 r e d u c e d 	 l i v e r	
function.	This	is	frequently	important	in	the	intensive	care	setting.
 
SedatioN For NoN‑SurGiCal aNd SurGiCal 
ProCedureS
Sedation 	 is 	 important 	 in 	 a 	 number 	 of 	 settings, 	 both 	 non‑surgical 	 and 	
surgical. 	 Non‑surgical 	 procedures 	 where 	 sedation 	 is 	 required 	 include	
e n d o s c o p i e s , 	 b r o n c h o s c o p i e s , 	 m a n i p u l a t i o n s 	 ( s u c h 	 a s 	 t h e 	 r e ‑ s e t t i n g	
o f 	 d i s l o c a t e d 	 l i m b s ) 	 a n d 	 w o u n d 	 d r e s s i n g . 	 S u r g i c a l 	 p r o c e d u r e s 	 i n c l u d e	
those	performed	under	local	and	general	anaesthesia.	Long	term	
treatment	with	sedatives	is	also	employed	in	the	intensive	care	unit.	
Agents 	 acting 	 as 	 agonists 	 at 	 the 	 benzodiazepine 	 site 	 of 	 the 	 GABA
A
 
receptor	such	as	lorazepam,	diazepam	and	especially	midazolam	
are	the	most	commonly	used	sedative	agents.
CurreNt Short aCtiNG Sedative aGeNtS
A s 	 t h e 	 fi r s t 	 w a t e r ‑ s o l u b l e 	 b e n z o d i a z e p i n e , 	 m i d a z o l a m 	 w a s 	 s e e n	
as	a	major	breakthrough	when	introduced	to	the	market	in	the	early	
1980s.	As	with	other	benzodiazepines	and	unlike	anaesthetics	such	
a s 	 p r o p o f o l , 	 m i d a z o l a m 	 i n d u c e s 	 a 	 c o n t r o l l e d 	 s e d a t i o n 	 a n d 	 h a s	
amnesic	properties.	However ,	midazolam	has	a	number	of	notable	
drawbacks.	These	include	respiratory	depression	and	a	prolonged	
and	variable	duration	of	action.	The	latter	is	due	to	the	existence	of	
an 	 active 	 metabolite. 	 Prolonged 	 sedation 	 can 	 result 	 in 	 extended	
h o s p i t a l 	 c o n fi n e m e n t 	 w i t h 	 r e s u l t a n t 	 i n c r e a s e s 	 i n 	 c o s t s . 	 A n o t h e r	
drawback	of	midazolam	is	that	it	is	mainly	metabolised	in	the	liver	
by 	 a 	 major 	 drug‑metabolising 	 enzyme 	 (cytochrome 	 P450 	 3A4).	
T h i s 	 m e a n s 	 t h a t 	 d r u g ‑ d r u g 	 i n t e r a c t i o n s 	 c a n 	 b e 	 p r o b l e m a t i c 	 a s	
is	its	administration	to	patients	with	compromised	liver	function.	
_0_CEN_ar07_front.indd   10 06/05/2008   11:11:51 11 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
aNaeStheSia aS aN additioNal iNdiCatioN
O n 	 t h e 	 b a s i s 	 o f 	 v e r y 	 e n c o u r a g i n g 	 p r e ‑ c l i n i c a l 	 d a t a , 	 r e v e a l i n g 	 a 	 r a p i d	
onset 	 and 	 offset 	 of 	 sedative 	 action 	 and 	 rapid 	 metabolism 	 by 	 human 	 liver	
s a m p l e s , 	 C e N e S 	 i s 	 n o w 	 e v a l u a t i n g 	 t h e 	 p o t e n t i a l 	 o f 	 C N S 	 7 0 5 6 	 f o r 	 t h e	
additional 	 indications 	 of 	 the 	 induction 	 and 	 maintenance 	 of 	 anaesthesia.	
P r o p o f o l 	 i s 	 u s e d 	 w i d e l y 	 f o r 	 t h e 	 i n d u c t i o n 	 a n d 	 m a i n t e n a n c e 	 o f 	 a n a e s t h e s i a .	
W h i l s t 	 p r o p o f o l 	 i s 	 a n 	 e x t r e m e l y 	 s u c c e s s f u l 	 I V 	 a n a e s t h e t i c , 	 i t s 	 l i m i t a t i o n s	
include 	 pain 	 on 	 injection 	 and 	 cardiovascular 	 depression 	 (lowering 	 of 	 heart	
r a t e 	 a n d 	 b l o o d 	 p r e s s u r e ) . 	 T h e 	 p r e ‑ c l i n i c a l 	 p r o fi l e 	 o f 	 C N S 	 7 0 5 6 	 s u g g e s t s	
that 	 it 	 may 	 overcome 	 some 	 of 	 these 	 limitations 	 and 	 could 	 offer 	 a 	 new	
paradigm 	 for 	 IV 	 anaesthesia.
the marketS For CNS 7056
A 	 l a r g e 	 a n d 	 g r o w i n g 	 n u m b e r 	 o f 	 s u r g i c a l 	 a n d 	 n o n ‑ s u r g i c a l	
p r o c e d u r e s 	 a r e 	 c o n d u c t e d 	 i n 	 h o s p i t a l s 	 a n d 	 s u r g e r i e s 	 w o r l d w i d e .	
M a n y 	 o f 	 t h e s e 	 p r o c e d u r e s 	 a r e 	 c o n d u c t e d 	 u n d e r 	 s e d a t i o n 	 r a t h e r	
than	general	anaesthesia.	The	worldwide	sedative/hypnotic	market	
f o r 	 a n a e s t h e s i a 	 i s 	 e s t i m a t e d 	 t o 	 b e 	 $ 8 0 0 	 m i l l i o n 	 a n d 	 t h e 	 U S 	 h o l d s	
a 	 6 0 % 	 s h a r e 	 o f 	 t h e 	 v a l u e . 	 M i d a z o l a m 	 s a l e s 	 r e v e a l 	 t h a t 	 t h i s 	 a g e n t	
is 	 used 	 in 	 a 	 large 	 proportion 	 of 	 procedures. 	 Midazolam 	 became	
g e n e r i c 	 i n 	 m i d ‑ 2 0 0 0 	 ( U S ) . 	 P r i o r 	 t o 	 b e c o m i n g 	 g e n e r i c , 	 s a l e s 	 i n 	 1 9 9 9	
were 	 $450 	 million. 	 The 	 additional 	 use 	 of 	 CNS 	 7056 	 as 	 an 	 agent 	
for the induction and maintenance of anaesthesia could double 
the 	 potential 	 market 	 opportunity . 	 Propofol 	 is 	 used 	 widely 	 for 	 the	
induction	and	maintenance	of	anaesthesia	in	the	US,	Europe	and	
Japan,	and	its	sales	during	2002	were	approximately	$500	million.	
CNS 7056 develoPmeNt StatuS
The	IP	position	around	CNS	7056	was	recently	strengthened	when	
t h e 	 E u r o p e a n , 	 H o n g 	 K o n g 	 a n d 	 J a p a n e s e 	 P a t e n t 	 O f fi c e s 	 g r a n t e d 	 t h e	
p a t e n t 	 f o r 	 a 	 s e r i e s 	 o f 	 s e d a t i v e 	 c o m p o u n d s , 	 i n c l u d i n g 	 C N S 	 7 0 5 6 .	
CNS	7056	is	progressing	through	pre‑clinical	development.	CeNeS	
is 	 undertaking 	 the 	 pre‑clinical 	 development 	 work 	 with 	 the 	 intention 	 of	
filing 	 an 	 IND 	 in 	 the 	 US 	 within 	 the 	 next 	 few 	 months. 	 CeNeS 	 is 	 planning 	
to 	 conduct 	 the 	 first 	 proof 	 of 	 concept 	 Phase 	 I 	 study 	 in 	 the 	 US 	 because 	
the	Company	has	identified	the	US	as	a	major	potential	market	for	
short	acting	sedatives.	Unlike	many	CNS	indications,	it	is	planned	
t h a t 	 t h e 	 c l i n i c a l 	 p r o o f 	 o f 	 c o n c e p t 	 f o r 	 t h i s 	 c o m p o u n d 	 w i l l 	 b e 	 e v a l u a t e d	
in 	 the 	 Phase 	 I 	 trials, 	 where 	 the 	 onset 	 and 	 offset 	 of 	 sedation 	 for	
C N S 	 7 0 5 6 	 w i l l 	 b e 	 e x a m i n e d 	 a n d 	 c o m p a r e d 	 w i t h 	 t h a t 	 o f 	 m i d a z o l a m .	
Sedative 	 effects 	 can 	 readily 	 be 	 monitored 	 in 	 volunteers 	 by 	 measuring	
p a r a m e t e r s 	 s u c h 	 a s 	 r e d u c t i o n 	 o f 	 a w a r e n e s s 	 a n d 	 m o v e m e n t 	 o r 	 c h a n g e s	
i n	the	electrical	activity	of	the	brain.	
CNS 7056 JaPaNeSe P artNer
In	August	2007	CeNeS	out ‑licensed	Japanese	rights	to	CNS	7056	
t o 	 O n o 	 P h a r m a c e u t i c a l 	 C o 	 L i m i t e d 	 t o 	 d e v e l o p 	 t h e 	 c o m p o u n d 	 a s	
a	g e n e r a l 	 a n a e s t h e t i c 	 a n d 	 s h o r t ‑ a c t i n g 	 s e d a t i v e . 	 U n d e r 	 t h i s 	 a g r e e m e n t ,	
Ono	will	pay	to	CeNeS	upfront	and	milestone	payments	based	on	
development	stage	as	well	as	royalties	on	sales	of	CNS ‑7056.
_0_CEN_ar07_front.indd   11 06/05/2008   11:11:51 12 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
Comt inhibitors for Parkinson’s disease
ChiEF EXECUtiVE’s REViEW CoNtiNUEd ParkiNSoN’S diSeaSe
P a r k i n s o n ’ s 	 d i s e a s e 	 i s 	 a 	 n e u r o d e g e n e r a t i v e 	 d i s e a s e 	 a f f e c t i n g	
approximately 	 2% 	 of 	 the 	 population 	 over 	 the 	 age 	 of 	 65. 	 The	
symptoms	of	P arkinson’s	disease	such	as	tremor ,	rigidity	and	
s l o w n e s s 	 o f 	 m o v e m e n t 	 r e s u l t 	 f r o m 	 t h e 	 l o s s 	 o f 	 n e u r o n e s 	 c o n t a i n i n g	
the	neurotransmitter	dopamine	in	parts	of	the	brain	responsible	
for	controlling	movement.	
In	line	with	our	stated	lower	risk	approach,	CeNeS	has	examined	
the	continuing	use	of	L ‑DOP A	as	the	main	treatment	of	P arkinson’s	
disease	and	selected	a	discovery	opportunity	that	could	significantly	
enhance	its	effectiveness.
Replacement	therapy	using	the	precursor	of	dopamine,	L ‑DOP A	
combined	with	a	Dopa‑decarboxylase	(“DDC ”)	inhibitor	(carbidopa	
or	benserazide)	is	the	mainstay	of	therapy	in	P arkinson’s	disease.	
C a t e c h o l ‑ O ‑ m e t h y l t r a n s f e r a s e 	 ( “ C O M T ” ) 	 i s 	 a n 	 e n z y m e 	 t h a t 	 m e t a b o l i s e s	
c a t e c h o l a m i n e s 	 s u c h 	 a s 	 L ‑ D O P A 	 a n d 	 d o p a m i n e 	 a n d 	 c a u s e s 	 a 	 s i g n i fi c a n t	
depletion	of	L ‑DOP A	in	the	brain	and	periphery ,	limiting	its	efficacy .	
C O M T 	 i n h i b i t o r s 	 e s s e n t i a l l y 	 s m o o t h 	 o u t 	 t h e 	 p h a r m a c o k i n e t i c s 	 o f	
L ‑ D O P A , 	 g i v i n g 	 p a t i e n t s 	 a 	 l o n g e r 	 ‘ o n ’ 	 o r 	 f u n c t i o n a l 	 t i m e 	 e a c h 	 d a y .	
T h e y 	 a l s o 	 h a v e 	 a 	 s p a r i n g 	 e f f e c t 	 o n 	 t h e 	 d o s e 	 o f 	 L ‑ D O P A 	 r e q u i r e d 	 a n d	
thus 	 may 	 delay 	 the 	 development 	 of 	 motor 	 fluctuations 	 and 	 dyskinesias.
CurreNt Comt iNhiBitorS
I n 	 t h e 	 m i d ‑ t o ‑ l a t e 	 1 9 9 0 s 	 t w o 	 C O M T 	 i n h i b i t o r s 	 w e r e 	 i n t r o d u c e d 	 t o 	 t h e	
m a r k e t : 	 t o l c a p o n e 	 a n d 	 e n t a c a p o n e . 	 H o w e v e r , 	 t o l c a p o n e 	 w a s 	 w i t h d r a w n	
f r o m 	 t h e 	 E U 	 m a r k e t 	 i n 	 l a t e 	 1 9 9 8 	 d u e 	 t o 	 l i v e r 	 t o x i c i t y , 	 w h i c h 	 i s 	 u n r e l a t e d	
to 	 COMT 	 inhibition. 	 T olcapone 	 has 	 recently 	 been 	 re‑introduced 	 to 	 the	
m a r k e t 	 i n 	 E u r o p e 	 b u t , 	 a s 	 i n 	 t h e 	 U S , 	 i t s 	 u s e 	 i s 	 s e v e r e l y 	 r e s t r i c t e d .	
As	such,	entacapone	(co‑marketed	by	Orion	and	Novartis)	is	the	
o n l y 	 u n r e s t r i c t e d 	 C O M T 	 i n h i b i t o r 	 a v a i l a b l e 	 i n 	 t h e 	 m a j o r 	 m a r k e t s .	
However , 	 entacapone 	 has 	 a 	 number 	 of 	 drawbacks, 	 namely 	 a 	 short	
half ‑life,	low	oral	bioavailability	and	minimal	brain	penetration.	
Comt iNhiBitor diSCovery ProGramme
T olcapone	and	entacapone,	in	common	with	the	majority	of	known	
potent 	 COMT 	 inhibitors, 	 contain 	 the 	 undesirable 	 3‑nitrocatechol 	 unit	
that 	 is 	 associated 	 with 	 poor 	 oral 	 absorption, 	 short 	 plasma 	 half ‑life 	
and 	 extensive 	 metabolism 	 issues. 	 The 	 goal 	 of 	 breaking 	 away 	 from	
this	nitrocatechol	series	has	been	achieved	by	CeNeS	scientists	and	
a	number	of	discrete	chemical	series	without	the	nitrocatechol	group	
have	been	identified.	The	COMT	inhibitor	programme	was	carefully	
chosen	by	CeNeS	in	line	with	our	strategy	to	have	a	low‑risk	profile	
and 	 to 	 address 	 a 	 clear 	 commercial 	 opportunity . 	 A 	 number 	 of 	 potent	
compounds	are	now	being	evaluated	in	the	lead	optimisation	
process,	prior	to	selection	of	a	development	candidate.	
the PoteNtial uSe oF Comt iNhiBitorS iN 
SChizoPhreNia
In	addition	to	P arkinson’s	disease,	a	number	of	recent	academic	
publications	point	to	the	potential	use	of	a	COMT	inhibitor	that	acts	
i n 	 t h e 	 b r a i n 	 t o 	 i m p r o v e 	 t h e 	 p r o f o u n d 	 c o g n i t i v e 	 d e fi c i t s 	 o f 	 s c h i z o p h r e n i a .	
Cognitive	 disturba nces	 often	 prevent	 schizophrenics	 from	 readjusting	
t o 	 s o c i e t y 	 a n d 	 r e q u i r e 	 p a t i e n t s 	 t o 	 b e 	 u n d e r 	 m e d i c a l 	 c a r e 	 f o r 	 t h e i r 	 e n t i r e	
l i v e s . 	 D e s p i t e 	 t h e 	 a v a i l a b i l i t y 	 o f 	 a 	 v a r i e t y 	 o f 	 c u r r e n t 	 a n t i ‑ p s y c h o t i c 	 d r u g s ,	
c o g n i t i v e 	 d i s t u r b a n c e s 	 a r e 	 p o o r l y 	 a d d r e s s e d 	 b y 	 e x i s t i n g 	 t h e r a p i e s .	
C e N e s 	 n o v e l 	 C O M T 	 i n h i b i t o r s 	 h a v e 	 t h e 	 p o t e n t i a l 	 t o 	 a d d r e s s 	 t h i s	
significant	unmet	need.	The	worldwide	sales	of	drugs	used	to	treat	
schizophrenia	are	$12	billion.	
the market For Comt iNhiBitorS
T h e 	 g l o b a l 	 m a r k e t 	 o f 	 d r u g s 	 f o r 	 P a r k i n s o n ’ s 	 d i s e a s e 	 w a s 	 $ 1 . 7 	 b i l l i o n	
in	2003	and	is	predicted	to	grow	to	$3	billion	by	2012.	The	growth	
w i l l 	 a r i s e 	 l a r g e l y 	 d u e 	 t o 	 t h e 	 i n c r e a s e d 	 p r e v a l e n c e 	 o f 	 t h e 	 d i s e a s e ,	
a s 	 a 	 r e s u l t 	 o f 	 t h e 	 a g e i n g 	 p o p u l a t i o n . 	 T h e 	 u s e 	 o f 	 C O M T 	 i n h i b i t o r s	
is 	 currently 	 growing 	 rapidly . 	 COMT 	 inhibitors 	 currently 	 have 	 more	
than	a	10%	share	of	the	P arkinson’s	disease	market.
Neil Clark
Chief exeCutive 10 aPril 2008
_0_CEN_ar07_front.indd   12 06/05/2008   11:11:51 13 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
FiNANCiAl REViEW
reSultS oF oPeratioNS
W e 	 h a v e 	 c o m p a r e d 	 o u r 	 r e s u l t s 	 f o r 	 t h e 	 y e a r 	 w i t h 	 o u r 	 r e s u l t s 	 f o r 	 t h e	
year	ended	31	December	2006	as	restated	for	the	implementation	
of	IFRS.	
The	loss	for	the	year	ended	31	December	2007	was	£6.6	million	
( 2 0 0 6 : 	 £8.6 	 million). 	 The 	 reduced 	 loss 	 is 	 the 	 result 	 of 	 lower 	 r e s e a r c h	
and 	 development 	 expenditure, 	 mainly 	 as 	 a 	 result 	 of 	 the 	 l a r g e 	 P h a s e 	 I I I	
clinical 	 trial 	 for 	 M6G 	 which 	 completed 	 recruitment 	 in 	 December 	 2006.	
C a s h 	 a s 	 a t 	 3 1 	 D e c e m b e r 	 2 0 0 7 	 w a s 	 £ 4 . 3 	 m i l l i o n 	 ( 2 0 0 6 : 	 £ 6 . 3 	 m i l l i o n ) .	
R e v e n u e 	 f r o m 	 o u t ‑ l i c e n s i n g 	 a c t i v i t i e s 	 w a s 	 £ 0 . 5 	 m i l l i o n 	 i n 	 t h e 	 y e a r 	 e n d e d	
3 1 	 D e c e m b e r 	 2 0 0 7 	 ( 2 0 0 6 : 	 l e s s 	 t h a n 	 £ 0 . 1 	 m i l l i o n ) 	 a n d 	 i n c l u d e d 	 u p f r o n t	
payment 	 under 	 the 	 agreement 	 with 	 Ono 	 Pharmaceutical 	 Co 	 Ltd.
A s 	 e x p e c t e d , 	 r e s e a r c h 	 a n d 	 d e v e l o p m e n t 	 c o s t s 	 d e c r e a s e d 	 t o	
£ 5 . 9 	 m i l l i o n 	 ( 2 0 0 6 : 	 £ 7 . 2 	 m i l l i o n ) . 	 C o s t s 	 i n 	 2 0 0 6 	 w e r e 	 h i g h e r 	 d u e	
t o 	 t h e 	 M 6 G 0 2 2 	 P h a s e 	 I I I 	 s t u d y 	 w h i c h 	 c o m p l e t e d 	 r e c r u i t m e n t	
i n 	 D e c e m b e r 	 2 0 0 6 . 	 A d m i n i s t r a t i v e 	 e x p e n s e s 	 f o r 	 t h e 	 y e a r 	 t o	
31 	 December 	 2007 	 were 	 lower 	 at 	 £2.2 	 million 	 (2006: 	 £2.6 	 million).
T h e r e 	 w a s 	 n o 	 o t h e r 	 o p e r a t i n g 	 i n c o m e 	 f o r 	 t h e 	 y e a r 	 e n d e d	
31	December	2007	(2006:	£0.1	million).	Net	interest	receivable	
for	the	year	ended	31	December	2007	was	£0.2	million	
(2006:	£0.3	million).
iNtaNGiBle aSSetS
I n t a n g i b l e 	 a s s e t s 	 c o m p r i s e 	 g o o d w i l l 	 o f 	 £ 6 . 3 	 m i l l i o n 	 ( 2 0 0 6 : 	 £ 6 . 3 	 m i l l i o n )	
and	licenses	of	less	than	£0.1	million	(2006:	less	than	£0.1	million).	
T h e 	 g o o d w i l l 	 h a s 	 b e e n 	 r e v i e w e d 	 f o r 	 i m p a i r m e n t 	 b y 	 t h e 	 D i r e c t o r s 	 a n d	
no	impairment	has	been	made	(see	note	13).	Licenses	comprise	
p a t e n t s 	 a c q u i r e d 	 a n d 	 a r e 	 b e i n g 	 a m o r t i s e d 	 o v e r 	 1 5 	 y e a r s , 	 b e i n g 	 t h e	
life 	 of 	 the 	 patent.
t axatioN
The	Group	submits	a	claim	each	year	for	Research	and	Development	
T a x 	 C r e d i t s . 	 A 	 t a x 	 c r e d i t 	 o f 	 £ 0 . 8 	 m i l l i o n 	 ( 2 0 0 6 : 	 £ 0 . 8 	 m i l l i o n ) 	 h a s 	 b e e n	
e s t i m a t e d 	 f o r 	 t h e 	 y e a r 	 e n d e d 	 3 1 	 D e c e m b e r 	 2 0 0 7 . 	 T h e 	 c l a i m 	 f o r 	 t h e	
year	ended	31	December	2006	comprised	a	claim	of	£0.6	million	and	
£0.2	million	relating	to	an	under ‑provision	in	prior	years.	The	amount	
for	the	year	ended	31	December	2007	has	yet	to	be	agreed	with	the	
HMRC.	The	claim	submitted	for	2006	of	£0.6	million	was	agreed	by	
HMRC	and	payment	was	received	in	August	2007.
reCeivaBleS aNd P ayaBleS 
T o t a l 	 r e c e i v a b l e s 	 a s 	 a t 	 3 1 	 D e c e m b e r 	 2 0 0 7 	 a r e 	 £ 1 . 3 	 m i l l i o n	
(2006:	£1.2	million),	including	amounts	due	from	HMRC	in	respect	
of	Research	and	Development	T ax	Credits	at	31	December	2007	
of	£0.8	million	(2006:	£0.6	million).	
Payables 	 due 	 within 	 one 	 year 	 were 	 lower 	 at 	 £1.8 	 million	
( 2 0 0 6 : 	 £ 3 . 0 	 m i l l i o n ) 	 a s 	 a 	 r e s u l t 	 o f 	 l o w e r 	 i n v o i c e d 	 c o s t s 	 a n d	
a c c r u a l s 	 i n 	 r e s p e c t 	 o f 	 t h e 	 M 6 G 	 0 2 2 	 P h a s e 	 I I I 	 c l i n i c a l 	 t r i a l .	
The	Company	has	reviewed	and	recalculated	the	onerous	lease	
provision	of	£1.0	million	(2006:	less	than	£1.0	million)	which	reflects	
the	expected	liability	relating	to	the	leases	of	premises	in	Scotland	
that	are	no	longer	required	by	the	Group.
CaSh reSourCeS
C a s h 	 a t 	 b a n k 	 a n d 	 i n 	 h a n d 	 a s 	 a t 	 3 1 	 D e c e m b e r 	 2 0 0 7 	 w a s	
£ 4 . 3 	 m i l l i o n 	 ( 2 0 0 6 : 	 £ 6 . 3 	 m i l l i o n ) . 	 N e t 	 f u n d s 	 d e c r e a s e d 	 b y	
£ 2 . 0 	 m i l l i o n 	 ( 2 0 0 6 : 	 £ 2 . 1 	 m i l l i o n ) 	 i n 	 2 0 0 7 , 	 a f t e r 	 r a i s i n g 	 £ 5 . 7 	 m i l l i o n	
net 	 of 	 expenses 	 through 	 a 	 placing 	 of 	 new 	 shares 	 in 	 August 	 2007.
On	10	April	2008,	it	was	announced	by	P aion	AG	that	it	proposes	
to	acquire	all	of	the	issued	and	to	be	issued	share	capital	of	CeNeS	
by	a	court	sanctioned	scheme	of	arrangement	under	P art	26	of	the	
C o m p a n i e s 	 A c t 	 2 0 0 6 . 	 I f 	 t h e 	 p r o p o s e d 	 a c q u i s i t i o n 	 i s 	 c o m p l e t e d ,	
CeNeS	will	have	a	considerably	strengthened	financial	position	by	
being	part	of	the	P aion	group,	which	will	assist	with	partnering	and	
clinical	development	decisions.	
If 	 the 	 acquisition 	 is 	 completed, 	 CeNeS, 	 as 	 part 	 of 	 the 	 enlarged 	 group,	
w i l l 	 c o n t i n u e 	 t o 	 m a i n t a i n 	 i t s 	 f o c u s 	 o n 	 a d v a n c i n g 	 e a c h 	 o f 	 i t s 	 p r o g r a m m e s ,	
with	a	number	of	key	milestones	and	deliverables	expected	in	2008.	
T h e 	 r e s u l t s 	 o f 	 t h e 	 fi r s t 	 o f 	 t w o 	 p l a n n e d 	 P h a s e 	 I I 	 s t u d i e s 	 f o r 	 C N S 	 5 1 6 1 	 w i l l	
report 	 results 	 mid‑2008. 	 An 	 IND 	 (Investigational 	 New 	 Drug) 	 filing 	 in 	 the 	
US	and	proof	of	concept	Phase	I	study	for	CNS	7056	in	sedation	is	
planned	for	H2	2008.	The	Board	believe	that	a	successful	outcome	
f r o m 	 t h i s 	 t r i a l 	 w i l l 	 t r a n s f o r m 	 t h e 	 v a l u e 	 o f 	 t h i s 	 a s s e t . 	 C e N e s 	 p a r t n e r 	 O n o	
i s 	 p l a n n i n g 	 a 	 P h a s e 	 I 	 s t u d y 	 i n 	 a n a e s t h e s i a 	 i n 	 J a p a n 	 i n 	 H 2 	 2 0 0 8 .	
_0_CEN_ar07_front.indd   13 06/05/2008   11:11:51 14 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
FiNANCiAl REViEW CoNtiNUEd CaSh reSourCeS CoNtiNued
Based	on	the	structure	of	the	enlarged	group	and	the	broadened	
p i p e l i n e 	 t h e 	 D i r e c t o r s 	 o f 	 C e N e S 	 b e l i e v e 	 t h e 	 e n l a r g e d 	 g r o u p 	 w i l l 	 b e 	 a b l e	
t o 	 a c h i e v e 	 s i g n i fi c a n t 	 p r e ‑ c l i n i c a l , 	 c l i n i c a l 	 a n d 	 c o m m e r c i a l 	 m i l e s t o n e s .	
In	the	event	that	the	acquisition	is	not	completed,	the	Company	
will need to raise additional funding through one or a combination 
of 	 equity 	 fund 	 raising, 	 partnering 	 or 	 collaboration 	 opportunities	
activity	in	order	to	continue	as	a	going	concern.	The	Directors	have	
a 	 r e a s o n a b l e 	 e x p e c t a t i o n 	 t h a t 	 t h e 	 C o m p a n y 	 c a n 	 r a i s e 	 s u c h 	 a d d i t i o n a l	
cash 	 resources. 	 Therefore, 	 the 	 Directors 	 consider 	 that 	 it 	 is 	 appropriate	
to	prepare	the	financial	statements	on	a	going	concern	basis.	If	the	
C o m p a n y 	 w a s 	 u n a b l e 	 t o 	 c o n t i n u e 	 i n 	 o p e r a t i o n a l 	 e x i s t e n c e 	 i n 	 t h e	
foreseeable	future,	adjustments	would	have	to	be	made	to	revise	
the	balance	sheet	values	of	assets	to	their	recoverable	amounts,	
to	provide	for	further	liabilities	that	might	arise	and	to	reclassify	
fixed	assets	as	current	assets.
CaPital reorGaNiSatioN
O n 	 1 0 	 J u l y 	 2 0 0 7 	 t h e 	 S c o t t i s h 	 C o u r t 	 a p p r o v e d 	 a n 	 o r d e r 	 f o r 	 t h e	
c a n c e l l a t i o n 	 o f 	 t h e 	 s h a r e 	 p r e m i u m 	 a c c o u n t 	 a n d 	 a 	 t r a n s f e r 	 t o 	 t h e 	 p r o fi t	
and	loss	account.	This	was	approved	by	shareholders	in	July	2005.
toNy oSB orNe
finanCe direCtor 10 aPril 2008 
_0_CEN_ar07_front.indd   14 06/05/2008   11:11:51 15 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
BoARd oF diRECtoRs alaN GoodmaN 
ChairMan (57) 
A l a n 	 G o o d m a n , 	 a 	 l e a d i n g 	 b i o t e c h 	 e n t r e p r e n e u r , 	 h a s 	 f o u n d e d 	 o r	
c o ‑ f o u n d e d 	 m a n y 	 b i o t e c h n o l o g y 	 a n d 	 h e a l t h c a r e 	 c o m p a n i e s , 	 i n c l u d i n g	
A g r i c u l t u r a l 	 G e n e t i c s 	 C o m p a n y 	 L t d , 	 M e d e v a 	 p l c , 	 C h i r o s c i e n c e 	 G r o u p 	 p l c ,	
A c a m b i s 	 p l c , 	 O x f o r d 	 B i o M e d i c a 	 p l c , 	 C e N e S 	 P h a r m a c e u t i c a l s 	 p l c 	 a n d	
C o r e 	 G r o u p 	 p l c . 	 H e 	 w a s 	 n o n ‑ e x e c u t i v e 	 c h a i r m a n 	 o f 	 O x f o r d 	 B i o M e d i c a 	 p l c ,	
chief 	 executive 	 of 	 Acambis 	 plc 	 and 	 a 	 director 	 of 	 Alizyme 	 plc.
Neil Clark 
Chief exeCutive (45) 
Neil	has	a	life	sciences	degree	and	is	a	Chartered	Accountant	with	
o v e r 	 t e n 	 y e a r s ’ 	 i n t e r n a t i o n a l 	 p r o f e s s i o n a l 	 e x p e r i e n c e 	 w o r k i n g 	 f o r	
C o o p e r s 	 & 	 L y b r a n d . 	 N e i l 	 j o i n e d 	 C e N e S 	 i n 	 1 9 9 7 	 a n d 	 w a s 	 m a d e	
F i n a n c e 	 D i r e c t o r 	 i n 	 J u l y 	 2 0 0 0 . 	 N e i l 	 b e c a m e 	 C h i e f 	 O p e r a t i n g 	 O f fi c e r	
in	October	2001	and	led	the	restructuring	of	CeNeS.	Neil	was	
promoted	to	Chief	Executive	in	January	2005.
toNy oSB orNe
finanCe direCtor and CoMP any seCretary (38)
T ony	has	14	years'	experience	working	for	biotechnology	companies,	
both 	 private 	 and 	 public 	 and 	 has 	 a 	 broad 	 experience 	 of 	 corporate	
and	licensing	financial	transactions.	After	qualifying	as	a	Chartered	
Accountant	in	1993	T ony	joined	Cobra	Therapeutics	Ltd	(formerly	
Therexsys	Ltd)	in	1994	as	financial	controller .	T ony	joined	CeNeS	
in	July	2000	and	was	appointed	Finance	Director	in	October	2007.
roNald irWiN 
non‑exeCutive direCtor (72) 
R o n a l d 	 h a s 	 h a d 	 a 	 n u m b e r 	 o f 	 p o s i t i o n s 	 w i t h 	 I C I 	 p l c , 	 W e l l c o m e 	 F o u n d a t i o n ,	
Sterling	W inthrop	Inc,	Marion	Merrell	Dow	Ltd	(chairman	and	managing	
d i r e c t o r ) 	 a n d 	 B r i t i s h 	 B i o t e c h n o l o g y 	 p l c . 	 H e 	 h a s 	 b e e n 	 a 	 n o n ‑ e x e c u t i v e	
d i r e c t o r 	 o f 	 X e n o v a 	 G r o u p 	 p l c , 	 T a n v e c 	 G r o u p 	 L t d 	 ( c h a i r m a n ) 	 a n d	
P h a r m o v a t i o n 	 L t d . 	 H e 	 i s 	 c u r r e n t l y 	 n o n ‑ e x e c u t i v e 	 c h a i r m a n	
o f 	 Echo	International	Health	Services	 Ltd.
dr Peter JohNSoN 
non‑exeCutive direCtor (72) 
P e t e r 	 h a s 	 e x t e n s i v e 	 R & D 	 a n d 	 m a n a g e m e n t 	 e x p e r i e n c e 	 w i t h 	 fi v e 	 m a j o r	
i n t e r n a t i o n a l 	 p h a r m a c e u t i c a l 	 c o m p a n i e s : 	 W e l l c o m e 	 p l c , 	 H o e c h s t 	 A G ,	
SmithKline	plc,	Fisons	plc	and	Astra	plc.	He	is	currently	chairman	
of 	 Oxford 	 BioMedica 	 plc. 	 In 	 the 	 last 	 five 	 years 	 he 	 has 	 also 	 been 	
n o n ‑ e x e c u t i v e 	 d i r e c t o r 	 o f 	 Q u a d r a n t 	 H e a l t h c a r e 	 p l c , 	 c h a i r m a n	
of 	 CBAMS 	 Ltd 	 and 	 executive 	 chairman 	 of 	 Sterix 	 Ltd.
alaN Smith 
non‑exeCutive direCtor (63) 
Alan	is	a	member	of	the	Chartered	Institute	of	P ublic	Finance	and	
Accountancy .	He	was	chairman	of	Acambis	plc	from	1999	until	2006	
and	prior	to	this	a	non‑executive	director	since	1995.	He	was	group	
managing	director	of	Anglian	W ater	plc	until	December	1997	and	
i s 	 c u r r e n t l y 	 c h a i r m a n 	 o f 	 A v l a r 	 B i o V e n t u r e s 	 L t d 	 a n d 	 c h a i r m a n	
of	Medical	Device	Innovations	Ltd.	
sENioR MANAgEMENt dr GaviN kilP atriCk 
Chief sCientifiC offiCer After	completing	his	PhD	in	pharmacology	at	the	Institute	of	P sychiatry ,	
U n i v e r s i t y 	 o f 	 L o n d o n , 	 i n 	 1 9 8 5 , 	 G a v i n 	 j o i n e d 	 G S K 	 a n d 	 w o r k e d 	 o n 	 t h e	
development 	 of 	 novel 	 drugs 	 for 	 CNS 	 and 	 gastrointestinal 	 disorders.	
In	1995,	he	moved	to	Roche	Ltd	as	Head	of	P sychiatry	Research.	In	1999	
Gavin	joined	CeNeS	as	Research	Director .	In	2002	Gavin	co‑founded	the	
d r u g 	 d i s c o v e r y 	 c o m p a n y , 	 T h e r a S c i 	 L t d . 	 T h e r a S c i 	 L t d 	 w a s 	 a c q u i r e d 	 b y	
CeNeS 	 in 	 2003. 	 He 	 is 	 an 	 author/co‑author 	 of 	 more 	 than 	 80 	 academic	
publications,	an	editor	of	the	journals	‘Neuropharmacology’	and	‘Current	
Opinion	in	Investigational	Drugs’	and	a	member	of	the	Scientific	Advisory	
Board	for	the	charity	‘Ataxia	UK’.
SimoN kerr 
CoMMerCial direCtor 
S i m o n 	 h a s 	 w o r k e d 	 i n 	 t h e 	 p h a r m a c e u t i c a l 	 a n d 	 b i o t e c h n o l o g y	
sectors	for	over	20	years	in	business	development,	marketing	and	
sales	roles.	H e 	 i n i t i a l l y 	 h e l d 	 a 	 n u m b e r 	 o f 	 c o m m e r c i a l 	 r o l e s 	 w i t h	
B e e c h a m 	 P h a r m a c e u t i c a l s 	 p l c , 	 W e l l c o m e 	 p l c 	 a n d 	 S c o t i a 	 P h a r m a c e u t i c a l s 	 plc,	
p r i o r 	 t o 	 m o v i n g 	 i n t o 	 t h e 	 b i o t e c h n o l o g y 	 s e c t o r 	 i n 	 1 9 9 6 . 	 H e 	 h a s 	 s u b s e q u e n t l y	
held	board‑level	positions	in	four	biotechnology	companies:	Gemini	
G e n o m i c s 	 (1996)	L td,	Cambridge	Genetics	(1998)	Ltd,	Circassia	Ltd	
(2001)	and	TheraSci	Ltd	(2002).	He	joined	CeNeS	in	November	2003	
upon	completion	of	the	acquisition	of	TheraSci	Ltd	by	CeNeS.
keith m Borkett BSC (hoNS)
develoPMent direCtor K e i t h 	 h a s 	 w o r k e d 	 i n 	 t h e 	 p h a r m a c e u t i c a l 	 i n d u s t r y 	 f o r 	 o v e r 	 2 0 	 y e a r s . 	 A f t e r	
s t a r t i n g 	 h i s 	 c l i n i c a l 	 r e s e a r c h 	 c a r e e r 	 w o r k i n g 	 i n 	 t h e 	 C l i n i c a l 	 P h a r m a c o l o g y	
U n i t 	 o f 	 G 	 D 	 S e a r l e 	 L t d 	 i n 	 H i g h 	 W y c o m b e , 	 U K , 	 h e 	 m o v e d 	 o n 	 t o 	 m a n a g i n g	
E u r o p e a n 	 P h a s e 	 I I 	 a n d 	 I I I 	 s t u d i e s 	 a s 	 a 	 C l i n i c a l 	 R e s e a r c h 	 A s s o c i a t e . 	 A f t e r	
s e v e n 	 years	with	Searle	Ltd,	he	moved	to	Schering	Plough	Corp	working	
i n 	 o n c o l o g y 	 a n d 	 r e s p i r a t o r y 	 d i s e a s e s . 	 K e i t h 	 t h e n 	 s p e n t 	 t w e l v e 	 y e a r s 	 a t	
A m g e n 	 I n c 	 a s 	 a 	 c l i n i c a l 	 p r o j e c t 	 m a n a g e r 	 r e s p o n s i b l e 	 f o r 	 t h e 	 E u r o p e a n	
C l i n i c a l 	 D e v e l o p m e n t 	 o f 	 c o m p o u n d s 	 i n 	 h a e m a t o l o g y / o n c o l o g y 	 f r o m 	 P h a s e 	 I	
through 	 to 	 licensing, 	 before 	 joining 	 Roche 	 Products 	 Ltd 	 as 	 Operations 	 Project	
Leader 	 responsible 	 for 	 the 	 global 	 clinical 	 operations 	 of 	 products 	 in 	 the 	 fields 	
of	haematology/oncology	and	rheumatoid	arthritis.	K eith	joined	CeNeS	
in 	 August 	 2005.
_0_CEN_ar07_front.indd   15 06/05/2008   11:11:51 16 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
The role of the SAB is to review and provide advice on the scientific work conducted in CeNeS. 
The SAB provides guidance to individual projects and also at a strategic (portfolio) level. 
The SAB meets annually and its members are detailed below. They have been selected on the 
basis of recognised expertise in CNS drug discovery and development and/or expertise in pain, 
anaesthesia and Parkinson’s disease. The SAB is chaired by Dr Ann Hayes. In 2007, the 
Company further strengthened the SAB by the appointment of Dr Terry Smith.
sCiENtiFiC AdVisoRY BoARd aNN hayeS Phd 
F or	22	years	Ann	Hayes	worked	for	GlaxoW ellcome	plc	specialising	
in	the	areas	of	CNS	and	pain.	She	was	a	director	in	drug	discovery ,	
with	particular	expertise	in	determining	long	term	discovery	strategy ,	
i n 	 p o r t f o l i o 	 m a n a g e m e n t 	 a n d 	 i n 	 d i s c o v e r y 	 p r o j e c t 	 m a n a g e m e n t .	
After	leaving	GSK	in	2001,	Ann	set	up	a	business	as	an	independent	
pharmaceutical	consultant.	In	this	capacity	she	has	co‑founded	two	
companies,	Ionix	Pharmaceuticals	Ltd,	and	TheraSci	Ltd,	which	has	
s i n c e 	 b e e n 	 a c q u i r e d 	 b y 	 C e N e S . 	 A n n 	 i s 	 a 	 n o n ‑ e x e c u t i v e 	 d i r e c t o r 	 o f	
Plethora	Solutions	plc	and	Curidium	plc,	a	director	of	Theradeas	Ltd,	
a	member	of	the	Scientific	Advisory	Boards	for	Lectus	and	Senexis	
and	has	also	been	non‑executive	director	at	TheraSci	Ltd,	Ionix	Ltd	
and	Sirus	Ltd.
david BrookS md dSC FrCP Fmed SCi 
David	Brooks	is	Hartnett	Professor	of	Neurology	in	the	division	of	
Neuroscience, 	 F aculty 	 of 	 Medicine, 	 Imperial 	 College, 	 London. 	 He 	 is 	 also	
Head 	 of 	 the 	 Neurology 	 Group 	 at 	 the 	 Medical 	 Research 	 Council 	 Clinical	
S c i e n c e s 	 C e n t r e , 	 H a m m e r s m i t h 	 H o s p i t a l , 	 L o n d o n . 	 A d d i t i o n a l l y , 	 h e 	 i s	
H e a d 	 o f 	 N e u r o l o g y , 	 M e d i c a l 	 D i a g n o s t i c s , 	 G E 	 H e a l t h c a r e 	 P L C . 	 D a v i d 	 i s	
a 	 m e m b e r 	 o f 	 U K 	 P a r k i n s o n ’ s 	 D i s e a s e 	 S o c i e t y 	 R e s e a r c h 	 A d v i s o r y 	 P a n e l	
a n d 	 w a s 	 a 	 m e m b e r 	 o f 	 t h e 	 M e d i c a l 	 R e s e a r c h 	 C o u n c i l 	 N e u r o s c i e n c e 	 a n d	
M e n t a l 	 H e a l t h 	 b o a r d 	 2 0 0 5 – 2 0 0 8 , 	 a n d 	 t h e 	 R e s e a r c h 	 A d v i s o r y 	 B o a r d	
o f 	 t h e 	 M i c h a e l 	 J 	 F o x 	 F o u n d a t i o n 	 2 0 0 2 – 2 0 0 6 . 	 H e 	 h a s 	 a l s o 	 s a t 	 o n 	 t h e	
G e r m a n 	 B M B F 	 D e m e n t i a 	 N e t w o r k 	 a n d 	 P a r k i n s o n 	 N e t w o r k 	 A d v i s o r y	
P a n e l s . 	 D a v i d 	 i s 	 o n 	 t h e 	 e d i t o r i a l 	 b o a r d s 	 o f 	 s e v e r a l 	 j o u r n a l s 	 i n c l u d i n g	
B r a i n . 	 I n 	 2 0 0 1 	 h e 	 w a s 	 e l e c t e d 	 a 	 F e l l o w 	 o f 	 t h e 	 A c a d e m y 	 o f 	 M e d i c a l	
Science,	UK .	His	research	involves	the	use	of	positron	emission	
tomography	and	magnetic	resonance	imaging	to	study	cerebral	
control	of	movement	and	performance	of	therapeutic	trials	in	
P a r k i n s o n ’ s , 	 H u n t i n g t o n ’ s , 	 a n d 	 A l z h e i m e r ’ s 	 d i s e a s e . 	 T o 	 d a t e , 	 h e 	 h a s	
published 	 over 	 250 	 reports 	 in 	 peer 	 reviewed 	 journals, 	 including 	 Nature.
miCk SerPell , mB ChB, FSChP , eCFmG, FrCa , FFPrCa 
Mick 	 Serpell 	 graduated 	 from 	 medical 	 school 	 at 	 the 	 University 	 of	
D u n d e e 	 i n 	 1 9 8 3 . 	 H e 	 c o m p l e t e d 	 h i s 	 t r a i n i n g 	 i n 	 a n a e s t h e s i a 	 a n d	
p a i n 	 m a n a g e m e n t 	 i n 	 D u n d e e , 	 O r e b r o 	 i n 	 S w e d e n 	 a n d 	 D a r t m o u t h	
Hitchcock	Medical	Centre	in	New	Hampshire,	US.	He	took	up	his	
consultant	post	in	Glasgow	in	1993	and	became	senior	lecturer	at	
the	University	Department	of	Anaesthesia,	Glasgow	in	1999.	His	
research	interests	include	pharmacological	and	regional	analgesia	
management	of	acute	and	chronic	pain.	He	is	particularly	interested	
i n 	 t h e 	 d i a g n o s i s 	 a n d 	 e a r l y 	 t r e a t m e n t 	 o f 	 n e u r o p a t h i c 	 p a i n . 	 H e 	 l e a d s 	 t h e	
Clinical	T rials	Unit	at	the	P ain	Clinic	in	Gartnavel.	He	has	undertaken	
over 	 30 	 commercial 	 studies 	 over 	 the 	 past 	 eight 	 years. 	 He 	 is 	 chairman	
o f 	 t h e 	 R e s e a r c h 	 a n d 	 P r i o r i t y 	 P r o g r a m m e 	 f o r 	 P a i n 	 & 	 A c u t e 	 M e d i c i n e 	 f o r	
the 	 Glasgow 	 Acute 	 Hospital 	 T rusts. 	 Mick 	 is 	 an 	 Executive 	 Member 	 of	
t h e 	 M a n a g e d 	 C l i n i c a l 	 N e t w o r k 	 i n 	 P a i n 	 f o r 	 G r e a t e r 	 G l a s g o w 	 & 	 C l y d e	
NHS. 	 He 	 is 	 Chairman 	 of 	 the 	 Local 	 Arrangements 	 Committee 	 for 	 the	
W o r l d 	 C o n g r e s s 	 o f 	 P a i n , 	 t o 	 b e 	 h e l d 	 i n 	 G l a s g o w , 	 i n 	 A u g u s t 	 2 0 0 8 .	
H e 	 i s 	 a l s o 	 C h a i r m a n 	 o f 	 t h e 	 N e u r o p a t h i c 	 P a i n 	 S I G 	 ( B r i t i s h 	 P a i n 	 S o c i e t y )	
and 	 is 	 an 	 Examiner 	 for 	 the 	 Royal 	 College 	 of 	 Anaesthetists.
david BroWN Phd , FrSC 
David	Brown	has	over	30	years’	experience	in	the	pharmaceutical/
b i o t e c h n o l o g y 	 i n d u s t r y 	 b o t h 	 i n 	 r e s e a r c h 	 a n d 	 i n 	 s e n i o r 	 e x e c u t i v e 	 r o l e s .	
F r o m 	 1 9 7 4 	 t o 	 2 0 0 2 	 h e 	 s e r v e d 	 w i t h 	 A s t r a 	 Z e n e c a 	 p l c , 	 P fi z e r 	 p l c ,	
G l a x o 	 p l c , 	 a n d 	 m o s t 	 r e c e n t l y 	 w i t h 	 F 	 H o f f m a n 	 L a ‑ R o c h e 	 L t d 	 a s 	 G l o b a l	
H e a d 	 o f 	 D r u g 	 D i s c o v e r y . 	 I n 	 t h i s 	 r o l e 	 h e 	 h a d 	 r e s p o n s i b i l i t y 	 f o r 	 t h e	
o u t p u t 	 o f 	 c l i n i c a l 	 c a n d i d a t e 	 d r u g s 	 f r o m 	 a p p r o x i m a t e l y 	 2 0 0 0 	 s c i e n t i s t s	
across	Roche’s	five	research	sites.	F rom	2002	to	2004	David	was	
p r e s i d e n t 	 a n d 	 C E O 	 o f 	 C e l l z o m e 	 A G , 	 a 	 B i o t e c h n o l o g y 	 c o m p a n y	
h e a d q u a r t e r e d 	 i n 	 H e i d e l b e r g 	 G e r m a n y . 	 D a v i d 	 h a s 	 e x t e n s i v e 	 e x p e r i e n c e	
of 	 pharmaceutical 	 R&D . 	 Whilst 	 at 	 Pfizer 	 he 	 was 	 named 	 co‑inventor 	
on	the	patent	for	Viagra,	a	treatment	for	male	impotence,	and	led	the	
team 	 that 	 developed 	 Viagra 	 through 	 to 	 proof 	 of 	 clinical 	 efficacy 	 in 	 man. 	
He 	 also 	 played 	 a 	 key 	 role 	 in 	 the 	 discovery 	 of 	 Relpax, 	 a 	 treatment	
for	migraine.	
_0_CEN_ar07_front.indd   16 06/05/2008   11:11:51 17 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
J roBert SNeyd ma mB md FrCa
Robert	Sneyd	is	Professor	of	Anaesthesia	and	Vice	Dean	of	the	
P eninsula	College	of	Medicine	and	Dentistry ,	Plymouth,	UK .	After	
graduating 	 from 	 Cambridge 	 he 	 continued 	 his 	 training 	 at 	 St 	 Thomas’	
H o s p i t a l 	 L o n d o n 	 a n d 	 l a t e r 	 a t 	 S t 	 G e o r g e ’ s 	 t h e n 	 M a n c h e s t e r 	 a n d	
Ann 	 Arbor , 	 Michigan, 	 USA . 	 His 	 research 	 interests 	 include 	 drug	
development	and	clinical	investigations	especially	in	intravenous	
a n a e s t h e s i a 	 a n d 	 a n a l g e s i a 	 w h e r e 	 h e 	 h a s 	 a c t e d 	 a s 	 P r i n c i p a l	
Investigator 	 for 	 the 	 first 	 human 	 administration 	 of 	 several 	 new 	
sedative‑hypnotic	agents.	Prof	Sneyd	has	previously	worked	as	
a 	 m e d i c a l 	 a d v i s o r 	 i n 	 t h e 	 P h a r m a c e u t i c a l 	 i n d u s t r y 	 w i t h 	 p a r t i c u l a r	
experience	in	Japan	and	he	has	significant	experience	in	working	
with	industry	to	ensure	that	clinical	development	programmes	are	
optimally	aligned	with	clinical	priorities	and	unmet	patient	needs.
PETER S.A. GLASS, MB, CHB
P eter	Glass	is	Professor	and	Chairman	of	Anesthesiology	at	the	
S t a t e 	 U n i v e r s i t y 	 o f 	 N e w 	 y o r k 	 a t 	 S t o n y 	 B r o o k , 	 w h e r e 	 h e 	 a l s o 	 i s 	 C h i e f	
of	Anesthesia	at	the	University	Hospital.	After	receiving	a	medical	
d e g r e e 	 f r o m 	 t h e 	 U n i v e r s i t y 	 o f 	 W i t w a t e r s r a n d 	 i n 	 J o h a n n e s b u r g ,	
Dr	Glass	trained	at	the	Johannesburg	Hospital	and	spent	15	years	
on	the	faculty	at	Duke	University	before	joining	the	faculty	at	Stony	
Brook.	His	research	interests	are	the	pharmacology	of	analgesics,	
anesthetics 	 and 	 muscle 	 relaxants, 	 ambulatory 	 anesthesia, 	 drug	
delivery	systems	and	post ‑operative	analgesia.	This	research	has	
b e e n 	 f u n d e d 	 b y 	 g r a n t s 	 f r o m 	 p r i v a t e 	 f u n d i n g 	 a g e n c i e s 	 a n d 	 t h e	
pharmaceutical	industry	and	Dr	Glass	has	served	as	a	consultant	
for	NIH	funded	grants.	
D r 	 G l a s s 	 h a s 	 p u b l i s h e d 	 o v e r 	 1 2 5 	 p e e r ‑ r e v i e w e d 	 m a n u s c r i p t s , 	 3 9 	 b o o k	
c h a p t e r s , 	 n u m e r o u s 	 e d i t o r i a l s 	 a n d 	 i n v i t e d 	 m o n o g r a p h s . 	 H e 	 i s 	 S e c t i o n	
Editor , 	 Ambulatory 	 Anesthesia 	 for 	 Anesthesia 	 & 	 Analgesia 	 and 	 is 	
a 	 r e v i e w e r 	 f o r 	 s e v e r a l 	 p h a r m a c o l o g y 	 a n d 	 a n e s t h e s i o l o g y 	 j o u r n a l s .	
H e 	 h a s 	 b e e n 	 C h a i r m a n 	 o f 	 t h e 	 V A 	 M e r i t 	 R e v i e w 	 S u b c o m m i t t e e 	 f o r	
A l c o h o l i s m , 	 D r u g 	 D e p e n d e n c e , 	 A n e s t h e s i a , 	 a n d 	 C l i n i c a l 	 P h a r m a c o l o g y .	
D r . 	 G l a s s 	 h a s 	 s e r v e d 	 a s 	 t h e 	 p r e s i d e n t 	 o f 	 t h e 	 I n t e r n a t i o n a l 	 S o c i e t y	
o f 	 A n e s t h e t i c 	 P h a r m a c o l o g y 	 ( f o r m a l l y 	 S I V A ) , 	 s e r v e s 	 o n 	 t h e 	 B o a r d 	 o f	
D i r e c t o r s 	 o f 	 t h e 	 S o c i e t y 	 o f 	 A m b u l a t o r y 	 A n e s t h e s i a , 	 l i s t s 	 m e m b e r s h i p	
in	several	professional	organisations,	and	has	served	on	several	
committees 	 of 	 the 	 American 	 Society 	 of 	 Anesthesiology 	 and 	 Association	
o f 	 U n i v e r s i t y 	 A n e s t h e s i o l o g i s t s . 	 H e 	 i s 	 a l s o 	 a 	 f r e q u e n t l y 	 i n v i t e d 	 n a t i o n a l	
a n d 	 i n t e r n a t i o n a l 	 l e c t u r e r .	
terry Smith Phd
T erry	trained	as	a	pharmacologist	at	the	University	of	London	
followed	by	a	postdoctoral	position	at	the	Unit	for	Research	on	
Addictive	Drugs,	University	of	Aberdeen.	This	has	been	followed	by	
over	25	years'	experience	in	research,	development	and	commercial	
positions	within	the	pharmaceutical	industry ,	including	W ellcome	
Research	Laboratories,	British	T echnology	Group	plc	and	CeNeS.	
The	majority	of	this	experience	has	been	within	the	neuroscience	
area,	with	a	particular	emphasis	on	pain	and	analgesia.
_0_CEN_ar07_front.indd   17 06/05/2008   11:11:51 18 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
Directors’ report 
for the year ended 30 September 2007
The Directors present their Annual Report on the affairs of CeNeS Pharmaceuticals plc (“the Company”) together with the Consolidated 
Financial Statements of the Company and its subsidiaries (“the Group”) for the year ended 31 December 2007.
PriNCiP al aCtivity 
The principal activity of the Group is the discovery and development of drug products for the treatment of disorders of the central nervous system (“CNS”) 
including the treatment of pain and sedation.
BuSiNeSS review
Review and futuRe developments The Group has continued to follow its strategy of progressing its pipeline of pharmaceutical products towards commercialisation with 
the aim of building a profitable, European specialty pharmaceutical company. A full review of the business and future prospects is given 
in the Chief Executive’s review on pages 4 to 12 and the Financial Review on pages 13 and 14.
Results Revenue for the year was £0.5 million (2006: less than £0.1 million) and comprises revenues from licence fees. The loss of the Group 
for the year after taxation was £6.6 million (2006: £8.6 million).
pRincipal Risks and unceRtainties CeNeS faces risks and uncertainties that are common to other companies developing novel pharmaceutical products. 
CliNiCAl
A drug may fail at any stage of its clinical development as a result of insufficient efficacy or safety issues. Clinical programmes may also 
encounter delays as a result of the performance of clinical research organisations and other third parties, failure to obtain the necessary 
regulatory and ethical approvals or an inability to recruit patients.
REgulA toRy
The regulatory environment differs around the world and is subject to change. Changes to the regulatory environment may result in delays 
and additional costs. Ethical, regulatory or marketing approvals may be delayed or withheld or may carry unacceptable conditions.
Safety or efficacy issues may come to light once a product has been approved which may result in the withdrawal or a restriction of use of the product.
MAnuFACtuRing
CeNeS uses contract manufacturers who could cease supply at short notice. This may result in delays to clinical programmes and 
increased costs.
the development of a manufacturing process may also encounter delays and additional costs due to technical problems, for example in the 
scale‑up of a process so that larger quantities of the product can be produced.
intEllECtu Al pRopERty And CoMpEtition
the group may not be able to secure and maintain intellectual property for its products. there is no guarantee that the group’s current 
or future patent applications will be successful or that challenges will not be made against them. the group’s intellectual property may 
become invalid or expire before its products are successfully launched.
Competitor companies may develop equivalent or better technologies or products which may limit the potential commercial success of the 
group’s products.
FiNANCiAl
in the longer term the group plans to generate cash flows from the successful development and commercialisation of its products. until then 
the Group will be dependent upon funding through the completion of licensing deals or through the injection of capital. 
KEy pERSonnEl
The Group is reliant on being able to attract and retain people with the right skills.
reSearCh aNd develoPmeNt
The Group is involved with an active programme of research and development of CNS and pain products. The costs of research and 
development are expensed to the profit and loss account as incurred.
Research and development costs have decreased to £5.9 million (2006: £7.2 million). The spend in 2006 was higher mainly as a result of the 
500 patient M6G Phase iii study which completed recruitment at the end of 2006.
divideNdS
The Directors do not recommend the payment of a dividend (2006: nil). 
_0_CEN_ar07_back.indd   18 06/05/2008   11:17:29 19 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
direCtorS
The present membership of the Board is set out on page 15 together with brief biographies.
The Directors who served during the year were:
Mr Alan G Goodman Chairman  
Mr neil R Clark    Chief Executive  
Mr tony osborne    Finance director (appointed 1 october 2007) 
Mr t Ronald irwin     non‑executive director  
dr peter Johnson     non‑executive director  
Mr Alan Smith    non‑executive director 
Mr Clark, Mr osborne, Mr irwin and dr Johnson will retire at the next Annual general Meeting and offer themselves for re‑election.
direCtorS’ ShareholdiNgS aNd ServiCe CoNtraCtS
details of the directors’ contracts and their beneficial interests in the shares of the Company are shown in the Remuneration Report  
on pages 22 to 26. 
PoliCy oN P aymeNt of CreditorS
t he g roup seeks the best possible terms from suppliers consistent with consideration of quality, delivery price and discounts. in many cases 
these are agreed with the supplier as part of the process of placing an order. provided that the supplier has met its contractual obligations, 
then the Group endeavours to ensure that payment is made on these terms. This policy is known to all staff who handle payments to suppliers.
The average number of creditor days of the Company at 31 December 2007 was 36 days (2006: 35 days).
Key PerformaNCe iNdiCatorS (“KPi s”)
t he directors consider that cash and spending on R&d to be the g roup’s Kpis. t hese factors are discussed in the Financial Review on pages 
13 and 14.
emPloymeNt PoliCy
The Group is aware of its obligations to disabled persons and makes every effort to ensure they receive equal opportunities and are not 
discriminated against on the grounds of their disability. The Group will make every effort to assist any individual who becomes disabled during 
the course of their employment.
All employees are kept informed about the group’s progress and objectives through regular meetings. the directors believe that it is 
important that the group’s employees’ interests are closely aligned with the group.
to this end all employees either already hold, or are eligible to receive options under the current and/or any new share option schemes.
goiNg CoNCerN 
the group is engaged in the development of biopharmaceutical products and expects those activities to absorb liquid resources until such 
products begin to be commercialised. 
 on 10 April 2008, it was announced by p aion Ag that it proposes to acquire all of the issued and to be issued share capital of CeneS by 
a court sanctioned scheme of arrangement under part 26 of the Companies Act 2006. if the proposed acquisition is completed, CeneS will 
have a considerably strengthened financial position by being part of the paion group, which will assist with partnering and clinical 
development decisions. 
if the acquisition is completed, Cen eS, as part of the enlarged group, will continue to maintain its focus on advancing each of its programmes, 
with a number of key milestones and deliverables expected in 2008. t he results of the first of two planned phase ii studies for Cn S 5161 will 
report results mid‑2008. An ind (“investigational new drug”) filing in the uS and proof of concept phase i study for CnS 7056 in sedation 
is planned for H2 2008. t he Board believe that a successful outcome from this trial will transform the value of this asset. Cen eS partner o no 
is planning a phase i study in anaesthesia in Japan in H2 2008. 
Based on the structure of the enlarged group and the broadened pipeline the directors of CeNeS believe the enlarged group will be able 
to achieve significant pre‑clinical, clinical and commercial milestones.
in the event that the acquisition is not completed, the Company will need to raise additional funding through one or a combination of equity 
fund raising, partnering or collaboration opportunities activity in order to continue as a going concern. t he directors have a reasonable 
expectation that the Company can raise such additional cash resources. therefore, the directors consider that it is appropriate to prepare 
the financial statements on a going concern basis. if the Company was unable to continue in operational existence in the foreseeable future, 
adjustments would have to be made to revise the balance sheet values of assets to their recoverable amounts, to provide for further liabilities 
that might arise and to reclassify fixed assets as current assets.
_0_CEN_ar07_back.indd   19 06/05/2008   11:17:29 20 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
Directors’ report continueD
for the year ended 30 September 2007
StatemeNt of direCtorS’ reSPoNSiBilitieS iN reSPeCt of the aNNual rePort aNd the fiNaNCial StatemeNtS
the directors are responsible for preparing the Annual Report, the directors’ Remuneration Report and the group and the parent company 
financial statements in accordance with applicable law and regulations. 
Company law requires the directors to prepare financial statements for each financial year. u nder that law the directors have prepared 
the group financial statements in accordance with international Financial Reporting Standards (“iFRS”) as adopted by the European union, 
and the parent company financial statements and the directors’ Remuneration Report in accordance with applicable law and u nited Kingdom 
Accounting Standards (u nited Kingdom g enerally Accepted Accounting practice). t he g roup and parent company financial statements 
are required by law to give a true and fair view of the state of affairs of the Company and the g roup and of the profit or loss of the g roup 
for that period.
in preparing those financial statements, the directors are required to:
 select suitable accounting policies and then apply them consistently;
 make judgements and estimates that are reasonable and prudent;
    state that the group financial statements comply with iFRS as adopted by the European union, and with regard to the parent company 
financial statements that applicable uK Accounting Standards have been followed, subject to any material departures disclosed and 
explained in the financial statements
    prepare the group and parent company financial statements on the going concern basis unless it is inappropriate to presume that the 
group will continue in business, in which case there should be supporting assumptions or qualifications as necessary. 
the directors confirm that they have complied with the above requirements in preparing the financial statements.
t he directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position 
of the Company and the group and to enable them to ensure that the group financial statements comply with the Companies Act 1985 and 
Article 4 of the iAS Regulation and the parent company financial statements and the d irectors’ Remuneration Report comply with the 
Companies Act 1985. they are also responsible for safeguarding the assets of the Company and the group and hence for taking reasonable 
steps for the prevention and detection of fraud and other irregularities.
the directors are responsible for the maintenance and integrity of the Company’s website. legislation in the united Kingdom governing 
the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 
diSCloSure of iNformatioN to auditorS
in accordance with Section 234ZA of the Companies Act, in the case of each of the persons who are directors at the time the report is approved, 
the following applies:
  so far as the directors are aware, there is no relevant audit information of which the Company’s auditors are unaware; and
  they have taken all the steps that they ought to have taken as Directors in order to make themselves aware of any audit information and 
to establish that the Company’s auditors are aware of that information.
fiNaNCial riSK maNagemeNt
the group’s operations expose it to a variety of financial risks that include price risk, credit risk, liquidity risk and interest rate risk. the group 
has in place a risk management programme that seeks to limit the adverse effects on the financial performance of the group by monitoring 
levels of debt finance and the related finance costs. the group does not use derivative financial instruments to manage financial risks and 
as such, no hedge accounting is applied.
given the size of the group, the directors have not delegated the responsibility of monitoring financial risk management to a sub‑committee 
of the Board, although risk management is reviewed by the Audit Committee. the policies set by the Board of directors are implemented by 
the group’s finance department. the department has policies and procedures in place that set out guidelines to manage price risk, liquidity 
risk, interest rate risk, credit risk, and the circumstances where it would be appropriate to use financial instruments to manage these.
a) pRice Risk the group is exposed to price risk as a result of its operations. However, given the size of the group’s operations, the costs of managing 
exposure to the price risk exceed any potential benefits. t he directors will revisit the appropriateness of this policy should the g roup’s operations 
change in size or nature. the group has no material exposure to equity securities price risk. the group has one equity investment in an unlisted  
company, Xention limited, which has been written down to £1 in the financial statements.
b) cRedit Risk Where debt finance is utilised, this is subject to pre‑approval by the Board of directors. t he amount of exposure to any individual counterparty 
is subject to a limit, which is reassessed annually by the Board. the group had no exposure to credit concentration risk at year end as it had 
no trade receivables apart from loan note disclosed in note 15. Also, the group has no material debt finance.
_0_CEN_ar07_back.indd   20 06/05/2008   11:17:29 21 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
fiNaNCial riSK maNagemeNt CoNtiNued
c) liquidity Risk the group does not currently have any material short or long term debt finance other than trade creditors which arise under the normal 
course of business.
d) inteRest Rate cash flow Risk the group has interest bearing assets. interest bearing assets include only short term deposits, which earn interest at fixed rates, and cash 
balances, which earn interest at floating rates. the directors will revisit the appropriateness of this policy should the operations of the group 
change in size or nature.
SuBStaNtial ShareholdiNgS
As at 9 April 2008, under Section 198 of the Companies Act 1985, the Company had been notified of the following interests amounting to 
3% or more of the ordinary share capital of the Company.
Name     Number % holding
gartmore *          3,986,016  18.2%
Avlar Bioventures Fund ii          2,436,449  11.1%
Barclays Stockbrokers limited          1,538,632  7.0%
uSS          1,081,162  4.9%
* includes 982,620 shares held by the Strathclyde pension Fund, which is managed by gartmore.
auditorS
in accordance with Section 384 of the Companies Act 1985, a resolution for the reappointment of pricewaterhouseCoopers llp as auditors 
of the Company is to be proposed at the forthcoming Annual General Meeting.
aNNual geNeral meetiNg
the date for the 2008 Annual general Meeting has not yet been set.
t he notice of the Annual g eneral Meeting, together with explanatory information concerning the resolutions to be proposed at the 
Annual General Meeting will be sent to shareholders in due course.
By order of the Board
toNy oSB orNe
company secRetaRy 10 apRil 2008 
_0_CEN_ar07_back.indd   21 06/05/2008   11:17:29 22 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
reMunerA tion report As a Company listed on AiM, CeneS pharmaceuticals plc is not required to present a directors’ Remuneration Report, however, some voluntary  
disclosures have been made. 
the principal function of the Remuneration Committee is to determine, on behalf of the Board, the remuneration and other benefits of the 
Executive directors, including pension contributions, share options, bonus payments and service contracts. the fees paid to non‑executive 
directors are determined by the Board as a whole. non‑executive directors do not receive bonuses or pension contributions.
The Committee gives full consideration to the provisions set out in Schedule B of the Combined Code in determining appropriate 
remuneration packages.
the remuNeratioN P aCKage 
The Remuneration Committee is aware that it must attract and retain individuals of the highest calibre by continuing to offer packages that are 
fair and reasonable for the responsibilities involved. the Committee endeavours to ensure that such packages are sufficiently dependent on 
achievement to motivate individuals to continue to contribute to the success of the Company. The Remuneration Committee is sensitive to the 
pay and employment conditions elsewhere in the Company when considering executive pay and annual salary increases. the Remuneration 
Committee comprises dr peter Johnson (Chairman) and Mr Ronald irwin. Mr Alan goodman is an ex‑officio member who exempts himself 
from meetings where his own remuneration is considered.
There were three meetings in 2007 and all members were present. 
Basic salary – the basic salary of each executive director is determined by the Remuneration Committee, taking into account the individual’s 
performance, the achievement of personal objectives and basic salaries in companies whose activities and size are comparable to those of 
CeNeS Pharmaceuticals plc.
Bonus arrangements – directors’ bonuses are discretionary and are approved by the Remuneration Committee. the bonuses are linked 
to performance against specific targets for the group. the maximum achievable bonus is not normally to be above 50% of basic salary. 
details of bonuses awarded for 2007 are shown in the table on page 24.
pension contributions – the g roup makes defined contributions to personal pension arrangements on behalf of the Executive directors 
at a defined percentage of 10% of salary, excluding bonus, car allowance or other forms of remuneration.
Share options – all Executive directors are entitled to participate in the Company’s share option schemes. the performance criteria for the 
share option schemes are disclosed on page 25. Any options granted thereunder are approved by the Remuneration Committee.
ServiCe CoNtraCtS
Each of the directors has a service agreement or letter of appointment with the Company. details of the terms of employment (including salary)  
are set out below:
alan GilbeRt Goodman
Alan Gilbert Goodman has a service contract with the Company dated 17 November 1999. Mr Goodman is currently Chairman of the 
Company and his salary in 2007 was £118,968. t he agreement provides that Mr g oodman spends two days per week working on the 
group’s business. the agreement is for an initial term of twelve months and thereafter may be terminated by either party on twelve months’ 
notice. Mr goodman is also entitled to a pension contribution equal of 10% of his salary, permanent health insurance, life insurance cover, 
private medical insurance and a company car. There are no provisions in the service agreement for compensation upon early termination 
of Mr goodman’s contract. 
neil RobeRt claRk neil Robert Clark has a service contract with the Company dated 14 August 2000. Mr Clark is currently Chief Executive of the Company 
and his salary in 2007 was £190,858. the agreement is for an initial term of twelve months and thereafter may be terminated by either party 
on twelve months’ notice. Mr Clark is also entitled to a pension contribution equal to 10% of his salary, permanent health insurance, 
life insurance cover, private medical insurance and a car allowance of £5,000. there are no provisions in the service agreement  
for compensation upon early termination of Mr Clark’s contract. 
antony eRic osboRne Antony Eric osborne has a service contract with the Company dated 1 october 2007. Mr osborne was appointed as Finance director of the 
Company with effect from 1 o ctober 2007 and his annual salary from the date of his appointment was £105,000. t he agreement is for an 
initial term of six months and thereafter may be terminated by either party on six months’ notice. Mr o sborne is also entitled to a pension 
contribution equal to 10% of his salary, permanent health insurance, life insurance cover, private medical insurance and a car allowance 
of £5,000. there are no provisions in the service agreement for compensation upon early termination of Mr osborne’s contract.
_0_CEN_ar07_back.indd   22 06/05/2008   11:17:29 23 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
ServiCe CoNtraCtS CoNtiNued
t Ronald iRwin t Ronald irwin was appointed a non‑executive director of the Company by a letter of appointment with effect from 13 december 1999. 
Mr irwin’s total fees in 2007 were £32,525, including fees for his roles as Chairman of the Audit Committee and as a member of the 
Remuneration Committee. the appointment as a non‑executive director may be terminated by either party on three months’ notice.
dR peteR Johnson
dr peter Johnson was appointed a non‑executive director of the Company by a letter of appointment with effect from 16 october 2003.  
dr Johnson’s total fees in 2007 were £32,525, including fees for his roles as Chairman of the Remuneration Committee and as a member 
of the Audit Committee. the appointment as a non‑executive director may be terminated by either party on three months’ notice.
alan smith Alan Smith was appointed a non‑executive director of the Company by a letter of appointment with effect from 8 January 2004. Mr Smith’s 
total fees in 2007 were £24,255. the appointment may be terminated by either party on three months’ notice.
Each non‑executive director is also entitled to reimbursement of out of pocket expenses.
total Shareholder returN
t he graph below shows the total Shareholder Return performance of the Company in comparison to the Ft SE All Share and the Ft SE AiM 
indices over the past five years.
the F tSE All Share is chosen an appropriate index because it is used to measure the Company’s performance in assessing the exercising 
of share options under the Company schemes. CeNeS is quoted on the Alternative investment Market (“AiM”).
direCtorS’ ShareholdiNgS
the directors’ beneficial interests in the shares of the Company are shown below. none of the directors has any other beneficial interest 
in the shares of any other Group companies.
300
250
200
150
100
50
0
Share Price (pence)
2002 2003 2004 2005 2006 2007
CeNeS
FTSE All Share
FTSE AIM
_0_CEN_ar07_back.indd   23 06/05/2008   11:17:29 24 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
reMunerA tion report continueD
     interest in  interest in 
     ordinary of  ordinary of 
     shares shares 
     30 pence 30 pence 
     each each 
     31 december 31 December 
     2007 2006 
    Notes Number Number
Mr T R irwin     20,645  15,886
Mr N R Clark     24,020  19,150
Mr A E osborne        3  4,500 —
Mr A g goodman        1,2  559,031  549,508
Dr P Johnson     4,444  4,444
Mr A Smith    2 4,760 —
Notes:
(1)    154,605 of these ordinary shares are held by AtM investments ltd, a company limited by shares with Mr goodman as a director. 58,047 of these ordinary 
shares are held by Avlar Bioventures ltd, a company controlled by Alan goodman and 33,333 of these ordinary shares are held by the Avlar p ension plan 
of which Mr Goodman is a trustee.
(2)    Mr g oodman, the Chairman of Cen eS, is also a d irector of Avlar Bioventures l imited and a l imited partner in the funds it manages. Mr Smith, 
a non‑executive director of CeneS, is also Chairman of Avlar Bioventures limited. one of the funds managed by Avlar Bioventures limited has an interest 
in 2,436,449 ordinary shares in CeneS.
(3)    Mr osborne had  an interest in 4,500 shares at 1 october 2007, his date of appointment as a director .
direCtorS’ remuNeratioN
The remuneration paid in respect of Directors who served during the year was as follows:
        taxable          pension  
    Basic    benefits  Subtotal Pension t otal Subtotal contributions T otal 
 Fees salary Bonus note (3) 2007 contributions 2007 2006 2006 2006 
Director £ £ £ £ £ £ £ £ £ £
executive         
Mr n R Clark  —  190,858  57,330  7,239  255,427  19,116 274,543  247,692  18,194  265,886
Mr A g goodman (note 5)  —  118,968  35,692  —   154,660  11,892 166,552  150,133  11,331  161,464
Mr A E osborne
(note 4)  —  26,250  21,000  1,529  48,779  2,625 51,404 — — —
Non‑executive           
Mr t R irwin (note 1)  32,525  —  —  —  32,525  — 32,525  30,975  —  30,975
dr p Johnson (note 2)  32,525  —  —  —  32,525  — 32,525  30,975  —  30,975
Mr A Smith  24,255  —  —  —  24,255  — 24,255  23,100  —  23,100
total  89,305  336,076  114,022  8,768  548,171  33,633 581,804  482,875  29,525  512,400
Notes:
(1)  these amounts represent fees payable to irwin Associates international on  behalf of Mr t R irwin’s services.
(2)  these amounts represent fees payable to Johnson p artners on behalf of dr p Johnson’s services.
(3)  non‑pensionable taxable benefits include car allowance and medical insurance.
(4)  these amounts represent emoluments from the date of appointment of Mr o sborne as a director of the Company.
(5)  A g goodman waived the right to receive a car allowance and medical insurance benefits. 
The Group operates a discretionary bonus scheme which is decided by the Remuneration Committee based on performance amongst other factors.
_0_CEN_ar07_back.indd   24 06/05/2008   11:17:29 25 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
iNtereStS iN Share oPtioNS
      (restated)*  granted  Exercised  lapsed  As at      
      As at  during  during the  during  31 december    Earliest  
      1 January  the year  the year  the year  2007  Exercise  exercise  
directors’ options  notes  2007  number  number  number  number  price  date  Expiry date
Mr n R Clark  2,5  3,365  —  —  —  3,365  £1 in aggregate  30 Jun 03  03 Jul 10
    2,5  39,218  —  —  —  39,218  £1 in aggregate  31 dec 04  31 dec 11
    2,5  54,916  —  —  —  54,916  £1 in aggregate  01 Aug 06  01 Aug 13
    2,5  50,000  —  —  —  50,000  £1 in aggregate  20 Apr 07  20 Apr 14
    3,6  2,439  —  —  (2,439)  —  —  —  —
    1  507  —  —  —  507  148p  note1  02 Mar 11
    3,6  39,066  —  —  —  39,066  233p  22 dec 07  22 dec 11
    3,6  66,666  —  —  —  66,666  210p  02 Feb 09  02 Feb 13
    3,6  —  33,333  —  —  33,333  184p  30 Mar 10  30 Mar 17
      256,177  33,333  —  (2,439)  287,071
Mr A g goodman  1  67,462  —  —  —  67,462  147p  note 1  14 Jan 09
    2,5  4,230  —  —  —  4,230  £1 in aggregate  19 Jun 03  30 Jun 10
    2,5  30,937  —  —  —  30,937  £1 in aggregate  31 dec 04  31 dec 11
    2,5  43,312  —  —  —  43,312  £1 in aggregate  01 Aug 06  01 Aug 13
    2,5  26,666  —  —  —  26,666  £1 in aggregate  20 Apr 07  20 Apr 14
    3,6  15,877  —  —  —  15,877  233p  22 dec 07  22 dec 11
    3,6  33,333  —  —  —  33,333  210p  02 Feb 09  02 Feb 13
    3,6  —  33,332  —  —  33,332  184p  30 Mar 10  30 Mar 17
      221,817  33,332  —  —  255,149
Mr A E osborne  3,6  818  —  —  (818)  —  —  —  —
(appointed  3,6  17,187  —  —  —  17,187  240p  01 Jan 05  01 Jan 09
1 oct 2007)  3,6  30,000  —  —  —  30,000  120p  01 Aug 06  01 Aug 10
    3,6  25,666  —  —  —  25,666  311p  20 Apr 07  20 Apr 11
    3,6  14,955  —  —  —  14,955  232p  22 dec 07  22 dec 11
    3,6  28,333  —  —  —  28,333  206p  02 Feb 09  02 Feb 13
    3,6  26,666  —  —  —  26,666  184p  30 Mar 10  30 Mar 14
*All options initially granted for 1 pence shares have been converted into 30 pence shares and their original number divided by 30 as from 22 August 2007. 
_0_CEN_ar07_back.indd   25 06/05/2008   11:17:29 26 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
reMunerA tion report continueD
Notes:
(1)    Mr A g goodman and Mr A g goodman’s spouse, Mrs E goodman and Mr Clark have entered into option agreements with CeneS limited pursuant 
to which they have a right to subscribe at par for a number of shares in Cen eS l imited. in the event that the option is exercised (the end date for exercising 
being seven years from the date of grant of the option) the option holder will be under an obligation to transfer his ordinary shares in CeNeS l imited 
to CeneS pharmaceuticals plc in return for approximately 0.68, 30 pence ordinary shares for each CeneS limited ordinary share.
(2)    these options have been granted under the CeneS pharmaceuticals plc Executive Share option plan and have a performance target linked to the 
FtSE All‑Share 900 companies’ performance over a period of three years (see note 5).
(3)  options granted  under the CeneS pharmaceuticals plc unapproved Share option Scheme (see note 21).
(4)    Subject to the rules of the relevant option scheme and the agreement of the Remuneration Committee, directors and employees may have the right 
to exercise their options awarded under the relevant schemes within a six month period following the termination of their employment contracts.
(5)    performance condition schedule for the Cen eS pharmaceuticals plc Executive Share o ption plan – t he performance target is that the growth in the Company’s 
share price over a three year period (starting with the date of grant of the option) must exceed the growth in total shareholder return (“tSR”) for the F tSE 
A All‑Share 900 companies (excluding investment companies) over that period. options may be exercised in full only if the growth of the Company’s share 
price over a three year period commencing on the date of grant would put the Company at the same level or above the Company which is ranked 225th of 
the FtSE A All‑Share 900 companies (excluding investment companies) ranked according to the growth in tSR over that period. options may be exercised 
over half the number of shares in the Company to which they relate if the growth in the Company’s share price over a fixed three year period commencing 
on the date of grant would put the Company at the same level or above the median company of the FtSE A All‑Share 900 companies (excluding investment  
companies) ranked according to growth in tSR over that period. if the p erformance target is not met over the fixed three year period, it shall be re‑tested 
over a four year period or a five year period (each period having the same start date). if the performance target is not met, the option will lapse.
(6)    performance condition schedule for the Cen eS pharmaceuticals plc Approved and u napproved Share o ption schemes – t he exercise of the option 
will be subject to the satisfaction of a performance target. the performance target is that the growth in the Company’s share price over a three year period 
(starting with the date of the grant of the option) must exceed the growth in tSR for the F tSE A All‑Share 900 (excluding investment companies) over that 
period. options may be exercisable in full only if the growth in the Company’s share price over a fixed three year period commencing on the date of grant 
would put the Company at the same level or above the median company of the FtSE All‑Share 900 Companies (excluding investment companies)  ranked 
according to the growth in t SR over that period. if the performance target is not met over the fixed three year period, it may be re‑tested over a four year 
period or a five year period (each period having the same start date). if the performance target is not met, the option will lapse.
(7)   options shown as at 1 January 2007 for Mr A osborne are the options held by Mr osborne at his date of appointment as a director on 1 october 2007.
the market price of the Company’s shares at 31 december 2007 was 41.25 pence.
the highest and lowest prices during the year were 258.9 pence and 39 pence respectively.
dr Peter JohNSoN
chaiRman of the RemuneRation committee 10 apRil 2008
_0_CEN_ar07_back.indd   26 06/05/2008   11:17:30 27 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
We have audited the group financial statements of CeneS pharmaceuticals plc for the year ended 31 december 2007 which comprise the 
Consolidated income Statement, the Consolidated Balance Sheet, the Consolidated Statement of Changes in Equity, the Consolidated Cash 
Flow Statement and the related notes. these group financial statements have been prepared under the accounting policies set out therein.
We have reported separately on the parent company financial statements of Cen eS pharmaceutical plc for the year ended 31 december 2007. 
that report is modified by the inclusion of an emphasis of matter.
reSPeCtive reSPoNSiBilitieS of direCtorS aNd auditorS
the directors’ responsibilities for preparing the Annual Report and the group financial statements in accordance with applicable law and 
international Financial Reporting Standards (“iFRS”) as adopted by the European union are set out in the Statement of directors’ Responsibilities.
our responsibility is to audit the group financial statements in accordance with relevant legal and regulatory requirements and international 
Standards on Auditing (uK and ireland). this report, including the opinion, has been prepared for and only for the Company’s members as 
a body in accordance with Section 235 of the Companies Act 1985 and for no other purpose. We do not, in giving this opinion, accept or 
assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save 
where expressly agreed by our prior consent in writing.
We report to you our opinion as to whether the group financial statements give a true and fair view and whether the group financial 
statements have been properly prepared in accordance with the Companies Act 1985. We also report to you whether in our opinion the 
information given in the directors’ Report is consistent with the group financial statements. the information given in the directors’ Report 
includes that specific information presented in the Chief Executive’s Review and the Financial Review that is cross referred from the Business 
Review section of the directors’ Report. 
in addition we report to you if, in our opinion, we have not received all the information and explanations we require for our audit, or if information 
specified by law regarding directors’ remuneration and other transactions is not disclosed.
We read other information contained in the Annual Report and consider whether it is consistent with the audited group financial statements. 
the other information comprises only: Key events since January 2007, the Chairman’s Statement, the Chief Executive’s Review, the Financial 
Review, Board of directors, Senior Management, Scientific Advisory Board, the directors’ Report, the directors’ Remuneration Report and the 
directors, Advisors and Contacts. We consider the implications for our report if we become aware of any apparent misstatements or material 
inconsistencies with the group financial statements. our responsibilities do not extend to any other information.
BaSiS of audit oPiNioN
We conducted our audit in accordance with international Standards on Auditing (uK and ireland) issued by the Auditing practices Board. An audit  
includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the group financial statements. it also includes an  
assessment of the significant estimates and judgements made by the directors in the preparation of the g roup financial statements, and of whether 
the accounting policies are appropriate to the group’s circumstances, consistently applied and adequately disclosed.
We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide 
us with sufficient evidence to give reasonable assurance that the group financial statements are free from material misstatement, whether  
caused by fraud or other irregularity or error. in forming our opinion we also evaluated the overall adequacy of the presentation of information 
in the group financial statements.
inDepenDent AuDitors’ report to tHe MeMBers oF cenes pHArMAceuticALs pLc _0_CEN_ar07_back.indd   27 06/05/2008   11:17:30 28 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
oPiNioN
in our opinion:
    the group financial statements  give a true and fair view, in accordance with iFRSs as adopted by the European union, of the state of the 
group’s affairs as at 31 december 2007 and of its loss and cash flows for the year then ended;
  the group financial statements  have been properly prepared in accordance with the Companies Act 1985; and
  the information given in the directors’ Report is consistent with the group financial statements.
emPhaSiS of matter – goiNg CoNCerN
in forming our opinion on the group financial statements, which is not qualified, we have considered the adequacy of the disclosures made in  
the group financial statements concerning the basis of preparation described in note 2. the group financial statements have been prepared on  
a going concern basis and the validity of this depends on the group’s parent company successfully obtaining future funding. this indicates the  
existence of a material uncertainty which may cast significant doubt on the g roup’s ability to continue as a going concern. t he g roup financial 
statements do not include any adjustments that would result from a failure to obtain such funds.
PriCewaterhouSeCooPerS llP
chaRteRed accountants and ReGisteRed a uditoRs cambRidGe 10 apRil 2008
Notes:
  The maintenance and integrity of the CeNeS Pharmaceuticals plc website is the responsibility of the Directors; the work carried out by the 
auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may 
have occurred to the financial statements since they were initially presented on the website.
    l egislation in the u nited Kingdom governing the preparation and dissemination of financial statements may differ from legislation 
in other jurisdictions.
inDepenDent AuDitors’ report to tHe MeMBers oF cenes pHArMAceuticALs pLc continueD
_0_CEN_ar07_back.indd   28 06/05/2008   11:17:30 29 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
consoLiDA teD incoMe st AteMent for the year ended 31 december 2007
     2007 2006 
    Notes £’000   £’000
revenue    5 541 53
Research and development expenditure          (5,850)  (7,200)
Administrative expenses          (2,273)  (2,602)
other operating income        7  —  26
operating loss     (7,582)  (9,723)
Finance income        8  188 267
loss before tax    6 (7,394)  (9,456)
income tax credit        11  837  815
loss for the year    22 (6,557)  (8,641)
loss per ordinary share
– basic and diluted    12 (36.0p) (62.5p)
the notes on pages 33 to 52 are an integral part of these consolidated financial statements.
_0_CEN_ar07_back.indd   29 06/05/2008   11:17:30 30 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
consoLiDA teD BALAnce sHeet aS at 31 december 2007
     2007 2006 
    Notes £’000   £’000
Non‑current assets
intangible assets    13 6,370  6,375
property, plant and equipment        14  20 26
Trade and other receivables    15 148  148
     6,538  6,549
Current assets
Trade and other receivables    16 272 366
income tax asset        11  836 650
Cash and cash equivalents      4,261  6,296
     5,369  7,312
Current liabilities
Trade and other payables    17 (1,756)  (2,993)
Provisions for liabilities and charges    19 (321) (321)
Net current assets     3,292  3,998
t otal assets less current liabilities     9,830  10,547
Non‑current liabilities
Provisions for liabilities and charges    19 (638)  (638)
Net assets     9,192  9,909
Capital and reserves
Share capital    20 6,576  4,839
Share capital to be issued    20 3,687  3,687
Share premium    20 4,010  116,866
Capital redemption reserve     15,697  15,697
other reserves          10,396  10,396
profit and loss account          (31,174)  (141,576)
t otal equity     9,192  9,909
the notes on pages 33 to 52 are an integral part of these consolidated financial statements.
the financial statements on pages 29 to 52 were approved by the Board of directors on 10 April 2008 and were signed on its behalf by:
Neil ClarK
chief executive 
_0_CEN_ar07_back.indd   30 06/05/2008   11:17:30 31 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
consoLiDA teD st AteMent oF cHAnGes in eQuitY
   Share  Capital    
    Share  capital to  Share  redemption  other  Retained  
  capital be issued premium reserve reserves loss T otal 
    £’000  £’000  £’000  £’000  £’000  £’000  £’000
as at 1 January 2006 4,098 3,899 113,080 15,697 10,396 (133,102) 14,068
Share‑based payments — — — — — 167 167
lapsed share options — (212) — — — — (212)
issue of share capital (net of expenses)  741  —  3,786  —  —  —  4,527
loss for the period   —  —  —  —  —  (8,641)  (8,641)
as at 31 december 2006  4,839 3,687 116,866 15,697 10,396 (141,576) 9,909
Share‑based payments — — — — — 93 93
Capital reorganisation  —  —  (116,866)  —  —  116,866  —
issue of share capital (net of expenses)  1,737  —  4,010  —  —  —  5,747
loss for the period — — — — —  (6,557)  (6,557)
as at 31 december 2007 6,576 3,687 4,010 15,697 10,396 (31,174) 9,192
included in other reserves as at 31 december 2007 is a merger reserve of £10,370,000 (2006: £10,370,000) and a share option reserve 
of £26,000 (2006: £26,000). 
The capital redemption reserve of £15.7 million arose as a result of a sub‑division of shares in August 2003.
Capital reorganisation relates to a write off of the share premium balance of £116,866,000, against the brought forward losses following 
a court order issued by the Scottish Court on 10 July 2007. The capital restructuring was approved by shareholders at the Annual General Meeting 
held on 5 July 2005.
_0_CEN_ar07_back.indd   31 06/05/2008   11:17:30 32 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
consoLiDA teD cAsH FL oW st AteMent for the year ended 31 december 2007
     2007 2006 
     £’000  £’000
operating loss          (7,582)  (9,723)
Depreciation     12 11
Amortisation     5 3
iFRS 2 share‑based payment      93 167
Decrease in trade and other receivables     98 121
increase/(decrease) in trade and other payables          (1,236)  1,478
operating activities
net cash outflow from operating activities           (8,610)  (7,943)
Research and development tax credit received          651  1,065
Net cash used in operating activities     (7,959)  (6,878)
investing activities
interest received     183 267
Purchases of plant and equipment     (6) —
Purchase of intangible assets     — (77)
Net cash generated from investing activities     177 190
financing activities
Proceeds from issue of shares      6,079  4,821
Transaction costs     (332)  (294)
Repayment of loans     — (7)
net cash generated from financing activities          5,747  4,520
Net decrease in cash and cash equivalents     (2,035)  (2,168)
Cash and cash equivalents at beginning of year     6,296  8,464
Cash and cash equivalents at end of year     4,261  6,296
_0_CEN_ar07_back.indd   32 06/05/2008   11:17:30 33 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents for the year ended 31 december 2007
1. geNeral iNformatioN
Cen eS pharmaceutical plc is a Company incorporated and domiciled in the u nited Kingdom. t he address of the registered office is given on the 
inside back cover. 
2. PriNCiP al aCCouNtiNg PoliCieS
the principal accounting policies adopted in the preparation of the group’s financial statements are set out below:
basis of pRepaRation these financial statements have been prepared in accordance with international Financial Reporting Standards (“iFRS”) as adopted for use 
by the Eu and endorsed by 31 december 2007 and international Financial Reporting interpretation Committee (“iFRiC”) interpretations and 
with those parts of the Companies Act 1985 applicable to companies reporting under iFRS. 
the financial statements have been prepared on the historical cost convention except for certain financial assets and liabilities, which  
are measured at fair value.t he preparation of financial statements in conformity with iFRS requires the use of certain critical accounting 
estimates. it also requires management to exercise its judgement in the process of applying the group’s accounting policies. the areas  
involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial 
statements are disclosed in note 4. 
GoinG conceRn CeneS pharmaceuticals plc group does not have sufficient cash resources to fund its current level of activities for the next twelve months. 
this represents a material uncertainty which may cast significant doubt on the group’s ability to continue as a going concern. 
on 10 April 2008, it was announced by p aion Ag that it proposes to acquire all of the issued and to be issued share capital of CeneS by 
a court sanctioned scheme of arrangement under part 26 of the Companies Act 2006. if the proposed acquisition is completed, Cen eS will 
have a considerably strengthened financial position by being part of the paion group, which will assist with partnering and clinical 
development decisions. 
if the acquisition is completed, Cen eS, as part of the enlarged g roup, will continue to maintain its focus on advancing each of its programmes, 
with a number of key milestones and deliverables expected in 2008. the results of the first of two planned phase ii studies for CnS 5161 will 
report results mid‑2008. An ind (“investigational new drug”) filing in the uS and proof of concept phase i study for CnS 7056 in sedation 
is planned for H2 2008. t he Board believe that a successful outcome from this trial will transform the value of this asset. Cen eS partner o no 
is planning a phase i study in anaesthesia in Japan in H2 2008. 
Based on the structure of the enlarged Group and the broadened pipeline the Directors of CeNeS believe the enlarged Group will be able 
to achieve significant pre‑clinical, clinical and commercial milestones.
in the event that the acquisition is not completed, the Company will need to raise additional funding through one or a combination of equity 
fund raising, partnering or collaboration opportunities activity in order to continue as a going concern. t he directors have a reasonable 
expectation that the Company can raise such additional cash resources. therefore, the directors consider that it is appropriate to prepare the 
financial statements on a going concern basis. if the Company was unable to continue in operational existence in the foreseeable future, 
adjustments would have to be made to revise the balance sheet values of assets to their recoverable amounts, to provide for further 
liabilities that might arise and to reclassify fixed assets as current assets.
(A) FiRSt tiME Adoption
these financial statements are the first to be prepared under iFRS.
iFRS 1 “First Time Adoption of international Financial Reporting Standards” sets out the approach to be followed when iFRS are applied 
for the first time. As a general principle, iFRS 1 requires that accounting policies are to be applied retrospectively although iFRS 1 provides 
a number of optional exceptions including where the cost of compliance is deemed to exceed the benefits to users of the financial 
statements. Where applicable, the options selected by management under iFRS 1 are set out in note 21).
(B) St And ARdS, AMEndMEnt And intERpREt AtionS EFFECtivE in 2007
iFRS 7, ‘Financial instruments: disclosures’, and the complementary amendment to iAS 1, ‘presentation of financial statements – Capital 
disclosures’, introduces new disclosures relating to financial instruments and does not have any impact on the classification and valuation 
of the group financial instruments, or the disclosures relating to taxation and trade and other payables. 
iFRiC 8, ‘Scope of iFRS 2’, requires consideration of transactions involving the issuance of equity instruments, where the identifiable consideration 
received is less than the fair value of the equity instruments issued in order to establish whether or not they fall within the scope of iFRS 2. 
this standard does not have any impact on the group’s financial statements.
iFRiC 10, ‘interim financial reporting and impairment’, prohibits the impairment losses recognised in an interim period on goodwill and 
investments in equity instruments and in financial assets carried at cost to be reversed at a subsequent balance sheet date. this standard 
does not have any impact on the group financial statements. 
_0_CEN_ar07_back.indd   33 06/05/2008   11:17:30 34 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
2. PriNCiP al aCCouNtiNg PoliCieS CoNtiNued
(C) intERpREt AtionS EARly AdoptEd B y tHE gRoup And CoMp Any 
iFRiC 11, ‘iFRS 2 – g roup and treasury share transactions’, was early adopted in 2007. iFRiC 11 provides guidance on whether share‑based 
transactions involving treasury shares or involving g roup entities (for example, options over a parent’s shares) should be accounted for 
as equity‑settled or cash‑settled share‑based payment transactions in the stand‑alone accounts of the parent and Group companies. 
this interpretation does not have an impact on the group financial statements.
(d) St And ARdS, AMEndMEntS And intERpREt AtionS EFFECtivE in 2007 But not RElEv Ant 
t he following standards, amendments and interpretations to published standards are mandatory for accounting periods beginning on or after 
1 January 2007 but they are not relevant to the Group operations: 
iFRS 4, ‘insurance contracts’; 
iFRiC 7, ‘Applying the restatement approach under iAS 29, Financial reporting in hyper‑inflationary economies’; and 
iFRiC 9, ‘Re‑assessment of embedded derivatives’. 
(E) St And ARdS, AMEndMEntS And intERpREt AtionS to EXiSting St And ARdS tHA t ARE not yEt EFFECtivE And HA vE not 
BEEn EARly AdoptEd B y tHE gRoup 
the following standards, amendments and interpretations to existing standards have been published and are mandatory for the group’s 
accounting periods beginning on or after 1 January 2008 or later periods, but the group have not adopted them early:
iAS 23 (Amendment), ‘Borrowing costs’ (effective from 1 January 2009). the amendment to the standard is still subject to endorsement 
by the European union. the group will apply iAS 23 (Amended) from 1 January 2009, subject to endorsement by the Eu but is currently 
not applicable to the Group as there are no qualifying assets. 
iFRS 8 ‘operating segments’ (effective from 1 January 2009). iFRS 8 replaces iAS 14 and aligns segment reporting with the requirements 
of the uS standard SFAS 131 ‘disclosures about segments of an enterprise and related information’. Management do not expect a material 
change to the current presentation.
iFRS 3 (revised) ‘Business Combinations’ (effective for business combinations after 1 July 2009). the revision to this standard continues to 
apply the acquisition method to business combinations, with some significant changes. the standard is applicable to business combinations 
occurring in accounting periods beginning on or after 1 July 2009, with earlier application permitted. this standard may have a significant 
impact on the accounting for any future business combinations the Group may enter into.
iAS 27 (revised) ‘Consolidated and separate financial statements’ (effective from 1 January 2008). iAS 27 (revised) requires the effects of all 
transactions with non‑controlling interests to be recorded in equity if there is no change in control. They will no longer result in goodwill or gains 
and losses. the standard also specifies the accounting when control is lost. Any remaining interest in the entity is re‑measured to fair value and  
a gain or loss is recognised in profit or loss. this standard is not expected to have any impact on the results of the group.
iAS 1 (as revised in 2007) ‘presentation of financial statements’. iAS 1 (revised) amended the terminology used throughout iFRS. 
These amendments apply for annual periods beginning on or after 1 January 2009.
(F) int ERpREt Ation S to  EXiSting  St And ARdS t HAt  ARE not  yEt  EFFECtiv E And  not  REl EvAnt  Fo R t HE gR oup’ S op ERAtion S 
the following interpretations to existing standards have been published and are mandatory for the group’s accounting periods beginning 
on or after 1 January 2008 or later periods but are not relevant for the group’s operations:
iFRiC 14 ‘iAS 19 – the limit on a defined benefit asset, minimum funding requirements and their interaction’ (effective from 1 January 2008). 
iFRiC 14 provides guidance on assessing the limit in iAS 19 on the amount of the surplus that can be recognised as an asset. it also explains 
how the pension asset or liability may be affected by a statutory or contractual minimum funding requirement. iFRiC 14 is not relevant as the 
group does not operate any defined benefit pension schemes.
BaSiS of CoNSolidatioN
the consolidated financial statements include the financial information of the Company and all of its subsidiary undertakings. 
Subsidiaries are all entities over which the group has the power to govern the financial and operating policies generally accompanying 
a shareholding of more than one half of the voting rights. the existence and effect of potential voting rights that are currently exercisable 
or convertible are considered when assessing whether the Group controls another entity. Subsidiaries are fully consolidated from the date 
on which control is transferred to the Group. They are de‑consolidated from the date that control ceases.
the acquisition of CeneS drug delivery limited has been consolidated using the principles of ‘merger accounting’. the principles of merger 
accounting are that the assets and liabilities of the acquired company are not restated to fair value, no goodwill arises and the consolidated 
financial information incorporates the combined companies’ results as if the companies had always been combined.
_0_CEN_ar07_back.indd   34 06/05/2008   11:17:30 35 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
2. PriNCiP al aCCouNtiNg PoliCieS CoNtiNued
basis of consolidation continued All other subsidiaries have been consolidated using the principles of acquisition accounting under iFRS 3. u nder iFRS 3, the results of acquired 
subsidiaries are included in the consolidated income statement from the date that they are acquired. The cost of an acquisition is the fair value 
of consideration, including costs directly attributable to the acquisition. All of the subsidiary’s assets and liabilities that exist at the date of acquisition 
are recorded at their fair values. the excess of the cost of acquisition over the fair value of the Company’s share of the identifiable net assets  
acquired is recorded as goodwill.
intra‑group transactions, profits and balances are eliminated in full on consolidation.
intanGible fixed assets (A) good Will
goodwill arising on the acquisition of subsidiary undertakings and businesses, representing the excess of the fair value of the consideration 
given over the fair value of the identifiable assets and liabilities acquired, is capitalised as an asset on the balance sheet. goodwill is tested 
annually for impairment or when events or changes in circumstances indicate the carrying value may be impaired and is carried at cost less 
accumulated impairment losses.
goodwill arising on acquisitions before the date of transition to iFRS has been retained at the previous uK gAAp amount. 
(B) pAtEnt RigHtS And liCEnSES
Purchased patents and licenses are recognised at cost on acquisition and are subject to amortisation over their useful life from the point at 
which the asset is available for use. The amortisation charge is calculated on a straight‑line basis over their estimated useful lives (15 years).
financial assets the group classifies its financial assets in the following categories: at fair value through profit and loss and loans and receivables. 
Management determines the classification of its financial assets at initial recognition.
(A) FinAnCiAl ASSEtS A t FAiR v AluE tHRougH pRoFit And loSS
Financial assets at fair value through profit and loss are financial assets held for trading. A financial asset is classified in this category 
if acquired principally for the purpose of selling in the short term. Assets in this category are classified as current assets.
(B) l oAnS And RECEiv ABlES
l oans and receivables are non‑derivative financial assets with fixed or determinable payments that are not quoted in an active market. t hey are 
included in current assets, except for those assets with maturities greater than twelve months after the balance sheet date, which are classified as 
non‑current assets. the group’s loans and receivables comprise ‘trade and other receivables’ and cash and cash equivalents in the balance sheet.
deRivative financial instRuments and hedGinG
the group does not currently have any derivative financial instruments or hedging activities.
ReseaRch and development expendituRe the group considers that the regulatory, technical and market uncertainties inherent in the development of new products mean that internal 
development costs should not be capitalised as intangible fixed assets until, inter alia, commercial viability of a product is demonstrable and 
appropriate resource is in place to launch the product. Except in those circumstances, research and development expenditure is expensed 
as incurred.
pRopeRty , plant and equipment
property, plant and equipment is stated at cost, net of depreciation and any provision for impairment. depreciation is provided on all property, 
plant and equipment at rates calculated to write off the cost, less estimated residual value, of each asset on a straight‑line basis over its 
expected useful life as follows:
leasehold improvements   over the shorter of the lease term or ten years 
Fixtures, fittings and computers    over two – seven years 
plant and machinery      over five – ten years 
laboratory equipment      over three – five years 
office equipment        over two – seven years
tRade Receivables 
t rade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, 
less provision for impairment. A provision for impairment of trade receivables is established when there is objective evidence that the 
Group will not be able to collect all amounts due according to the original terms of the receivables. 
the amount of the provision is the difference between the asset’s carrying amount and the present value of estimated future cash flows, 
discounted at the original effective interest rate. The carrying amount of the asset is reduced through the use of an allowance account and 
the amount of the loss is recognised in the income statement. When a trade receivable is uncollectible, it is written off against the allowance 
account for trade receivables. Subsequent recoveries of amounts previously written off are credited against ‘selling and marketing costs’ 
in the income statement.
_0_CEN_ar07_back.indd   35 06/05/2008   11:17:30 36 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
2. PriNCiP al aCCouNtiNg PoliCieS CoNtiNued
cash and cash equivalents Cash and cash equivalents comprise cash in hand and deposits with banks that have a maturity of three months or less from the date of inception.
The Group does not currently have any deposits that have a maturity of greater than three months.
foReiGn cuRRencies (A) FunCtionAl And pRESEnt Ation CuRREnCy
items included in the financial statements of each of the g roup’s entities are measured using the currency of the primary economic 
environment in which the entity operates (‘the functional currency’). the consolidated financial statements are presented in ‘sterling’ (£), 
which is the Company’s functional and presentation currency.
(B) tRAnSACtionS And BAlAnCES
t ransactions in foreign currencies are recorded at the rate of exchange prevailing at the date of the transactions. Monetary assets 
and liabilities denominated in foreign currencies at the balance sheet date are reported at the rate of exchange prevailing at that date. 
All exchange gains arising on the retranslation of assets and liabilities are dealt with in the income statement.
leases Rentals under operating leases are charged on a straight‑line basis over the lease term, even if the payments are not made on such a basis. 
provisions are made in respect of onerous leases to the extent that the directors believe that costs will be incurred under the terms of the 
lease with no benefit to the group.
t axation Current tax, including uK corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using the tax rates and 
laws that have been enacted or substantively enacted by the balance sheet date.
deferred tax is provided in full using the liability method in respect of temporary timing differences arising from differences between the 
carrying amount of assets and liabilities in the financial statements and the corresponding tax bases. deferred tax assets are recognised 
to the extent that it is probable that future taxable profit will be available against which the temporary difference can be utilised. their carrying 
amount is reviewed at each balance sheet date on the same basis.
deferred tax is measured on an undiscounted basis and at the tax rates that are expected to apply in the period in which the asset is realised or 
liability is settled. it is recognised in the income statement except when it relates to items credited or charged directly to equity, in which case the 
deferred tax is also dealt with in equity.
ReseaRch and development tax cRedits t he g roup makes claims each year for Research and development tax Credits. t he amount of expected cash benefit for each year is accrued 
into that year’s financial statements. 
Revenue RecoGnition Revenue consists of income received, in the normal course of business, from licence and development agreements and is stated net of any 
vAt and other sales related taxes. income from these agreements is typically in the form of fees on signature, milestone receipts on achievement  
of predetermined events and royalties on the sale of the product once marketed.
Revenue is recognised when licence rights are granted to the extent that the group has performed its contractual obligations, based on the 
fair value of the right to consideration for each component of the agreement.
intERESt inCoME 
interest income is recognised on a time‑proportion basis using the effective interest method.
shaRe capital ordinary shares are classified as equity. incremental costs directly attributable to the issue of new shares or options are shown in equity  
as a deduction, net of tax, from the proceeds.
tRade payables Trade payables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.
employee benefits 
(A) poSt ‑REtiREMEnt BEnEFitS
the group makes defined contributions to personal pension arrangements of its executive directors and employees. the amount charged 
to the income statement in respect of pension costs is the contribution payable in the period.
Differences between contributions payable in the period and contributions actually paid are shown either as accruals or prepayments in the 
balance sheet. termination benefits payable are charged to the income statement in the period in which they are payable.
_0_CEN_ar07_back.indd   36 06/05/2008   11:17:30 37 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
2. PriNCiP al aCCouNtiNg PoliCieS CoNtiNued
employee benefits continued (B) SHARE‑BASEd pAyMEntS
the group operates a number of executive and employee share schemes. For all grants of share options and awards, the fair value as at the 
date of grant is calculated using an appropriate option pricing model and the corresponding expense is recognised over the vesting period.
The Group has taken advantage of the transitional provisions of iFRS 2 in respect of equity‑settled awards and has applied iFRS 2 only 
to equity‑settled awards granted after 7 november 2002 that had not vested by 1 January 2005. national insurance payable on the exercise 
of share‑based payments is treated as a cash‑settled share‑based payment under iFRS 2 and the Group makes charges to the income 
statement based on an estimate of the National insurance liability in respect of the outstanding awards at each period end. Where the 
National insurance liability is virtually certain to be recovered from the relevant employees a corresponding receivable amount is also 
recognised in the income statement. 
3. fiNaNCial riSK maNagemeNt
financial Risk factoRs the group’s activities expose it to a variety of financial risks: market risk, credit risk, interest rate and liquidity risk. the group’s risk management  
programme seeks to minimise where possible, potential adverse effects of the group’s financial performance. Currently the group does not use  
derivative financial instruments to hedge certain risk exposures because they are not considered to be material. Risk is assessed on an ongoing 
basis by the Board of Directors and the Audit Committee who have put in place certain controls and policies to manage the risks.
(A) MARKEt RiSK
(i) Foreign exchange risk
the group is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the euro and the uS dollar. 
Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
Management reviews foreign exchange risk on a regular basis and currently it is not considered to be significant. Where possible expenditure in 
foreign currency is matched to income in the same currency. The Group does not currently have an active policy to hedge its foreign currency 
risks because it is not considered significant. 
The Group has no investments in foreign operations.
The Group has $1 million held in a treasury deposit as at 31 December 2007 (2006: $nil). it is anticipated that this will be used to meet 
uS dollar expenditure for the remainder of the year, including the phase i study for CnS 7056 scheduled to commence in Q3 2008.
At 31 december 2007, if the uS dollar had weakened/strengthened by 10% against the British pound with all other variables held constant, 
post tax losses would have been c.£45,000 higher/lower as a result of losses/gains on treasury deposits held in uS dollars. 
The Group does not have any trade receivables denominated in a foreign currency.
(ii) Price risk
the group  is exposed to equity securities price risk because of investments held by the group. the group is not  exposed to commodity price 
risk. the group does not actively manage the equity security price risk as it is not considered to be significant to the group.
the group’s equity investment is not publicly traded and it has been fully written down in the financial statements. As a result there would be 
no impact on the income statement from a decrease in the value of the investment.
(iii) Cash flow and fair value interest rate risk
the group has no significant interest bearing assets and therefore the group’s operating cash flows are substantially independent 
of changes in market interest rates. The Group has no long term borrowings.
(B) CREdit RiSK
Credit risk arises from cash and cash equivalents, and deposits with banks and financial institutions. the group does not have any trade 
receivables. For banks and financial institutions, only independently rated parties with a minimum rating of ‘A’ are accepted.
Apart from the loan receivable explained in note 15, the fair value of other receivables and trade and other payables is equal to the carrying value. 
_0_CEN_ar07_back.indd   37 06/05/2008   11:17:30 38 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
3. fiNaNCial riSK maNagemeNt CoNtiNued
financial Risk factoRs continued (B) CREdit RiSK ContinuEd
the table below shows the credit limit and balance of the group’s two major banks at the balance sheet date.
     at At 
     31 december 31 December 
     2007 2006 
Counterparty    Rating £’000  £’000
lloyds TSB    AAA 499 63
Bank of Scotland    AA 3,757  6,204
(C) liQuidity RiSK
prudent liquidity risk management implies maintaining sufficient cash and cash equivalents to meet the liabilities of the group as they  fall due. 
Management monitors rolling forecasts on a regular basis to assess the group’s liquidity.
the table below shows the group’s financial liabilities which are not discounted and which are all due within one year.
     at At 
     31 december 31 December 
     2007 2006
Trade and other payables     1,756  2,993
the group does not currently have any derivative financial instruments.
capital Risk manaGement the group’s objectives when managing capital are to safeguard the group’s ability to continue as a going concern in order to provide returns 
for shareholders and benefits for stakeholders and to maintain an optimal capital structure to reduce the cost of capital. 
the Company is not subject to externally imposed capital requirements
The Group does not currently have any gearing.
f aiR value estimation the group does not currently have any financial instruments traded in active markets.
the fair value of financial instruments that are not traded in active markets is determined using valuation techniques.
4. CritiCal aCCouNtiNg eStimateS aNd JudgemeNtS
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future 
events that are believed to be reasonable under the circumstances.
cRitical accountinG estimates and assumptions the group makes estimates and assumptions concerning the future. the resulting accounting estimates will, by definition, seldom equal the 
related actual results. the estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts 
of assets and liabilities within the next financial year are discussed below.
(A) EStiMA tEd iMp AiRMEnt oF good Will
t he g roup tests annually whether goodwill has suffered any impairment, in accordance with the accounting policy stated in note 2. t he g roup 
uses risk adjusted net present v alue (“rnpv ”) calculations based on expected future cash flows and industry standard assumptions to measure 
the value of these programmes. These calculations require the use of estimates (note 13).
(B) FAiR vAluE oF FinAnCiAl inStRuMEntS
the fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. the group uses its 
judgement to select the method and make assumptions that are mainly based on conditions existing at each balance sheet date. the group 
has used discounted cash flow analysis for fair valuation of non‑current loan receivables.
_0_CEN_ar07_back.indd   38 06/05/2008   11:17:30 39 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
5. SegmeNtal iNformatioN
the directors are of the opinion that under iAS 14 ‘Segmental information’ the group has only one business segment, being drug development.  
in addition the directors are of the opinion that there is only one geographical segment, the uK.
6. l oSS oN ordiNary aCtivitieS Before taxatioN
the following items have been included in arriving at the loss on ordinary activities before taxation:
     2007 2006 
     £’000  £’000
Depreciation of owned assets     12 11
Amortisation of licences     5 3
operating lease rentals: land and buildings          474  447
operating lease rentals: other          17 25
     2007 2006 
     £’000  £’000
Auditors’ remuneration:
Fees payable to Company’s auditors for the audit of parent company and consolidated financial statements    22 16
Fees payable to the Company’s auditors and its associates for other services:
  – the audit of Company’s subsidiaries pursuant to legislation          14 10
 – other services pursuant to legislation – interim review work     11 7
  – tax services          11 7
7. other oPeratiNg iNCome
     2007 2006 
     £’000  £’000
Rental income     — 26
8. fiNaNCe iNCome 
     2007 2006 
     £’000  £’000
interest receivable on short term bank deposits     188 267
_0_CEN_ar07_back.indd   39 06/05/2008   11:17:30 40 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
9. Staff CoStS
the average monthly number of employees during the year (including Executive directors) was: 
     2007 2006 
     Number Number
Administration     8 9
Research and development     8  8
     16 17
Their aggregate remuneration comprised:
     2007 2006 
     £’000  £’000
Wages and salaries     1,614  1,551
Social security costs     168 177
other pension costs (see note 23)          107 100
Termination payments     87 —
Share‑based payments     93 167
     2,069  1,995
the Board of directors consider the key management to currently comprise the three senior managers on page 15 and the three executive 
Directors on page 15 and Dr Smith who left CeNeS in 2007. Compensation for key management was:
     2007 2006 
     £’000  £’000
Wages and salaries     1,058  899
Social security costs     119 110
other pension costs           78 67
Termination payments     87 —
Share‑based payments     72 75
     1,414  1,151
the termination payment of £87,000 was made to dr t erry Smith, who was development director, and who left in May 2007.
10. direCtorS’ remuNeratioN
     2007 2006 
     £’000  £’000
Aggregate emoluments     548  482
Pension costs     34 30
     582 512
Highest paid Director
Aggregate emoluments     256  248
Pension costs     19  18
     275 266
the disclosure of individual directors’ remuneration, share options, pension contributions and pension entitlements are shown in the 
Remuneration Report on pages 22 to 26.
Retirement benefits are accruing to three directors (2006: two) under defined contribution pension schemes.
_0_CEN_ar07_back.indd   40 06/05/2008   11:17:30 41 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
11. t ax Credit oN loSS oN ordiNary aCtivitieS
     2007 2006 
     £’000  £’000
uK corporation tax – research and development tax credits          (836) (650)
Adjustment in respect of prior periods     (1) (165)
     (837)  (815)
the tax result for the period is different from the standard rate of corporation tax in the uK (16%) (2006: 16%).
the differences are explained below:
     2007 2006 
     £’000  £’000
loss on ordinary activities before tax          (7,394)  (9,456)
loss on ordinary activities multiplied by the rate at which uK R&d tax credits may be claimed of 16% (2006: 16%)    (1,183)  (1,513)
Effects of:
Expenses not deductible for tax purposes          36  64
Accelerated capital allowances and other timing differences     (3) 1
tax losses unutilised in the year          314  798
Adjustment in respect of prior periods     (1) (165)
Current tax credit for the period          (837)  (815)
12. l oSS Per ordiNary Share
the basic and diluted loss per ordinary share is based on a group loss for the financial year of £6.6 million (2006: £8.6 million) on 18,208,800 
(2006: 13,821,312) ordinary shares (after share consolidation per note 20), the weighted average number of shares in issue during the year. 
13. iNtaNgiBle aSSetS
    licences Goodwill t otal 
        £’000  £’000  £’000
Cost
As at 1 January 2006        1,939  50,746  52,685
Additions    77 — 77
Adjustment     — (212) (212)
as at 31 december 2006 and at 31 december 2007    2,016 50,534 52,550
amortisation and impairment
As at 1 January 2006        1,939  44,233  46,172
Amortisation for the year    3 — 3
as at 31 december 2006 and at 1 January 2007    1,942 44,233 46,175
Amortisation for the year    5 — 5
as at 31 december 2007    1,947  44,233 46,180
Net book value as at 31 december 2007    69 6,301 6,370
net book value as at 31 december 2006        74  6,301  6,375
net book value as at 31 december 2005        —  6,513  6,513
The adjustment of goodwill in 2006 arose from the reduction in the original assessment of the fair value of contingent consideration payable.
licences relate to patent rights acquired for £77,000 from Alza Corporation in July 2006. this amount has been capitalised in the balance 
sheet and is being amortised on a straight‑line basis over the life of the licence (15 years).
_0_CEN_ar07_back.indd   41 06/05/2008   11:17:31 42 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
13. iNtaNgiBle aSSetS CoNtiNued
impaiRment tests foR Goodwill the group tests goodwill annually for impairment, or more frequently if there are indications that goodwill may be impaired, in accordance 
with iAS 36. the group uses a risk adjusted net present v alue (“rnpv ”) model which incorporates future cash inflows, including milestones 
and royalties, and cash outflows, including clinical development costs, marketing and sales costs. goodwill is allocated to the group’s value 
generating research and development programmes, categorised by the initial company acquisition. t hus, the rnpv  of M6g , which was 
acquired with the acquisition of CeneS limited in december 1999, is used to test the goodwill arising on the acquisition of CeneS limited 
for impairment. Similarly CNS 7056 is used to test the goodwill arising on the acquisition of TheraSci limited for impairment.
the following key assumptions are used in the rnpv model:
 Discount rate of 20% – the management consider this to be suitable for biotechnology companies.
  term of cash flows used to calculate rnpv – the expected patent life or market exclusivity period.
 No growth in market sizes has been assumed.
  Peak sales forecasts used are based on publicly known and paid for market research information. Management has reduced the peak 
sales forecast by half in these calculations to provide an extra level of comfort.
the resultant rnpv values for both M6g and CnS 7056 were in excess of the carrying values of goodwill for CeneS limited and theraSci 
limited respectively as at 31 December 2007 and therefore no impairment has been made.
14. ProPerty , PlaNt aNd equiPmeNt
        Computers,    
      plant,  office      
      machinery  equipment,    
   and leasehold laboratory Furniture  
     improvements  equipment  and fittings  t otal 
      £’000  £’000  £’000  £’000
Cost
As at 1 January 2007      1,908  56  333  2,297
Additions   — — 6 6
as at 31 december 2007   1,908 56 339 2,303
depreciation
As at 1 January 2007      1,908  56  307  2,271
Charge for the year   — — 12 12
as at 31 december 2007   1,908 56 319 2,283
Net book value as at 31 december 2007   — — 20 20
Net book value as at 31 December 2006   — —  26 26
there are no items held under existing finance lease or hire purchase agreements included within property, plant and equipment.
        Computers,    
      plant,  office      
      machinery  equipment,    
   and leasehold laboratory Furniture  
     improvements  equipment  and fittings  t otal 
      £’000  £’000  £’000  £’000
Cost
As at 1 January 2006      1,908  56  332  2,296
Additions   — — 1 1
as at 31 december 2006   1,908 56 333 2,297
depreciation
As at 1 January 2006      1,908  56  296  2,260
Charge for the year   — — 11 11
as at 31 december 2006       1,908  56  307  2,271
Net book value as at 31 december 2006   — — 26 26
Net book value as at 31 December 2005   — —  36 36
_0_CEN_ar07_back.indd   42 06/05/2008   11:17:31 43 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
15. trade aNd other reCeivaBleS – NoN‑CurreNt aSSetS
     2007 2006 
     £’000  £’000
Xention ltd loan note           375 375
less: provision for impairment      (227) (227)
     148  148
the loan note was issued by Xention limited to CeneS limited in 2002 as part of its consideration for the acquisition of the Channelwork 
division from CeneS limited. the norminal value of the loan note is £375,000 and is receivable on 31 december 2009.
the fair value assigned to the loan notes is £148,000 to reflect the risk that the full value of the loan note may not be recoverable given the 
inherent high risk of small unquoted biotechnology companies.
16. trade aNd other reCeivaBleS
     2007 2006 
     £’000  £’000
other receivables          84  246
Prepayments and accrued income     188 120
     272 366
17. trade aNd other P ayaBleS
     2007 2006 
     £’000  £’000
Trade payables     1,239  1,541
other taxation and social security          48  45
other payables          16 3
Accruals     453  1,404
     1,756  2,993
18. deferred iNCome tax 
deferred tax assets have not been recognised as the directors consider that this would be inappropriate as the group is not expected to 
realise sufficient profits in the foreseeable future. this will be reassessed at such time as the group makes a profit. the amount unprovided/
unrecognised of the total potential liability/(asset) is as follows:
 2007  2006
   amount amount Amount Amount 
    recognised  unrecognised recognised unrecognised 
   £’000  £’000  £’000  £’000
tax effect of timing differences:
Excess of capital allowances over depreciation       — (129)   —  (134)
Short term timing differences    —  (112)  —  (90)
tax effect of losses carried forward       —  (15,947)   —   (16,045)
other provision       —  (6)  —  (13)
    —  (16,194)   —   (16,282)
t he rate of u K corporation tax will be reduced from 30% to 28% with effect from 1 April 2008. t he change in tax rate has been applied to timing 
differences at 31 December 2007 where applicable. 
_0_CEN_ar07_back.indd   43 06/05/2008   11:17:31 44 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
19. ProviSioNS for liaBilitieS aNd ChargeS 
     2007 2006 
     £’000  £’000
At 1 January      959 959
utilised in year          (354)  (354)
Amortisation of discount     32 32
Additions to provision     322 322
At 31 December      959 959
The maturity of the provision at the year end was as follows:
     2007 2006 
     £’000  £’000
Amounts falling due:
Within one year     321 321
After more than one year     638  638
     959 959
the group has reviewed and recalculated the onerous lease provision of £1.0 million (31 december 2006: £1.0 million) which reflects the 
expected liability relating to the leases of premises in Scotland that are no longer required by the group. the provision balance is based 
on the directors’ current expectations for the time it will take to sublet the properties. o f this provision, £0.7 million (2006: £0.7 million) 
is due after more than one year and £0.3 million (2006: £0.3 million) is due within one year.
the fair values of future lease payments are based on cash flows discounted using a rate based on the market interest rate and the risk 
premium (2007: 10%; 2006: 10%).
20. Share CaPital
The share capital of the Company is shown below:
     Restated*  
   2007 2007 2006 2006 
   Number £’000  number  £’000
authorised
ordinary shares of 30 pence each     33,776,318 10,133  33,776,318  10,133
    Number issued Share capital 
    of ordinary share capital to be issued 
        30p shares  £’000  £’000
allotted, issued and fully paid
At 1 January 2007 (restated*)       16,131,055  4,839  3,687
issues of new shares – placing        5,789,137  1,737  —
at 31 december 2007    21,920,192 6,576 3,687
*on 22 August 2007, the Company consolidated its ordinary shares of 1 pence each into ordinary shares of 30 pence each. 
Also, on 22 August 2007 the Company raised £5,747,000 net of £332,000 issue costs, by a placing of 5,789,137 new ordinary shares 
of 30 pence each at 105 pence per share. the issue resulted to £1,737,000 additional share capital and £4,010,000 share premium.
shaRes to be issued Following the reverse takeover of Core group plc by CeneS limited in december 1999 there are 250,725 ordinary 30pence shares to be 
issued as deferred consideration to holders of options over ordinary shares in CeneS limited. these were valued at approxiamtely £13 per 
share at the date of the reverse takeover of Core group plc by CeneS limited giving a value of £3,003,000 after deducting £371,000 
receivable by CeneS limited on exercise of the options. 
t here are also 28,948 (2006: 28,948) ordinary 30 pence shares to be issued as deferred consideration to holders of options over shares in 
Cambridge n euroScience inc. t hese were valued at approximately £19.85 per share at the date of the takeover of Cambridge n euroScience inc 
in december 2000 giving them a value of £390,000 after deducting £185,000 receivable by CeneS on exercise of the options.
o n 21 n ovember 2003, the Company acquired the entire share capital of t heraSci l imited (“t heraSci”). A further allotment of 120,752 ordinary 
30 pence shares, valued at £294,000, is due to glaxoSmithKline plc subject to the achievement of a project milestone.
 
_0_CEN_ar07_back.indd   44 06/05/2008   11:17:31 45 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
20. Share CaPital CoNtiNued
schedule of options outstandinG as at 31 decembeR 2007
  As at    
  31 December   Contracted  
  notes  2007  Exercise price  date of grant  remaining life
Approved share option scheme  1  12  £15.45  9 november 1998  1.8 years
Approved share option scheme  1  508  £24.60  11 May 2000  2.3 years
unapproved share option scheme  1  12,500  £16.05  18 december 2000  3 years
unapproved share option scheme  1  19,082  £2.40  1 January 2002  1 year
Approved share option scheme  1  10,832  £2.40  1 January 2002  4 years
unapproved share option scheme  1  58,333  £1.20  1 August 2003  2.6 years
unapproved share option scheme  1  33,333  £2.14  21 november 2003  2.9 years
unapproved share option scheme  1  152,330  £3.11  20 April 2004  3.3 years
unapproved share option scheme  1  164,884  £2.33  22 december 2004  4 years
unapproved share option scheme  1  10,000  £2.70  5 May 2005  4.3 years
unapproved share option scheme  1  25,000  £2.33  1 november 2005  4.8 years
unapproved share option scheme  1  296,662  £2.06  2 February 2006  5.1 years
unapproved share option scheme  1  283,326  £1.84  30 March 2007  6.2 years
Executive Share option plan  2  4,230  £1 in aggregate  30 June 2000  2.5 years
Executive Share option plan  2  3,365  £1 in aggregate  3 July 2000  2.5 years
Executive Share option plan  2  70,155  £1 in aggregate  31 december 2001  4 years
Executive Share option plan  2  98,228  £1 in aggregate  1 August 2003  5.6 years
Executive Share option plan  2  76,666  £1 in aggregate  20 April 2004  6.3 years
t otal   1,319,446   
Notes:
1)   Subject to the satisfaction of any applicable condition of exercise, options may be exercised in whole or in part at any time and from time to time after the 
earliest of the third anniversary of grant, the death of the option holder, or the option holder ceasing to be a director or employee of the Company by reason 
of injury, disability or redundancy, or retirement, or at the discretion of the Remuneration Committee, for any reason. no options were exercised (2006: nil) and 
273,385 (2006: 25,469) options lapsed during the year.
2)   the CeneS Executive Share option plan (the “plan”) provides for the grant of rights to acquire shares by way of purchase to eligible employees of CeneS. 
under the plan options are granted at an aggregate exercise price of £1 and will normally only vest after the third anniversary of the date of grant and if the 
Company’s share price has exceeded the growth in total shareholder return for the FtSE All‑Share 900 Companies over that period. Further information about  
the performance targets is shown in the Remuneration Report on pages 22 to 26.
_0_CEN_ar07_back.indd   45 06/05/2008   11:17:31 46 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
20. Share CaPital CoNtiNued
schedule of options outstandinG as at 31 decembeR 2006
   As at   Contracted  
    notes  31 december 2006  Exercise price  date of grant  remaining life
Approved share option scheme  1  400  £0.52  9 november 1998  1.8 years
unapproved share option scheme  1  103,658  £0.82  11 May 2000  0.3 years
Approved share option scheme  1  15,243  £0.82  11 May 2000  3.3 years
Approved share option scheme  1  9,422  £0.82  26 September 2000  3.7 years
unapproved share option scheme  1  24,540  £0.82  3 october 2000  0.7 years
unapproved share option scheme  1  375,000  £0.54  18 december 2000  4 years
unapproved share option scheme  1  2,198,125  £0.08  1 January 2002  2 years
Approved share option scheme  1  569,750  £0.08  1 January 2002  5 years
unapproved share option scheme  1  3,360,000  £0.04  1 August 2003  3.6 years
unapproved share option scheme  1  1,000,000  £0.07  21 november 2003  3.9 years
unapproved share option scheme  1  5,870,000  £0.10  20 April 2004  4.3 years
unapproved share option scheme  1  5,840,470  £0.08  22 december 2004  5 years
unapproved share option scheme  1  300,000  £0.09  5 May 2005  5.3 years
unapproved share option scheme  1  750,000  £0.08  1 november 2005  5.8 years
unapproved share option scheme  1  100,000  £0.07  30 november 2005  5.9 years
unapproved share option scheme  1  10,090,000  £0.07  2 February 2006  6.1 years
Executive Share option plan  2  126,923  £1 in aggregate  30 June 2000  3.5 years
Executive Share option plan  2  100,961  £1 in aggregate  3 July 2000  3.5 years
Executive Share option plan  2  2,104,688  £1 in aggregate  31 december 2001  5 years
Executive Share option plan  2  2,946,875  £1 in aggregate  1 August 2003  6.6 years
Executive Share option plan  2  2,300,000  £1 in aggregate  20 April 2004  7.3 years
t otal   38,186,055   
Notes:
1)   Subject to the satisfaction of any applicable condition of exercise, options may be exercised in whole or in part at any time and from time to time after the earliest 
of the third anniversary of grant, the death of the option holder, or the option holder ceasing to be a director or employee of the Company by reason of injury, 
disability or redundancy, or retirement, or at the discretion of the Remuneration Committee, for any reason. no options were exercised (2005: nil) and 727,490 
(2005: 120,951) options lapsed during the year.
2)   the CeneS Executive Share option plan (the “plan”) provides for the grant of rights to acquire shares by way of purchase to eligible employees of CeneS. 
under the plan options are granted at an aggregate exercise price of £1 and will normally only vest after the third anniversary of the date of grant and if the 
Company’s share price has exceeded the growth in total shareholder return for the Ft SE All‑Share 900 Companies over that period. Further information 
about the performance targets is shown in the Remuneration Report on pages 22 to 26.
_0_CEN_ar07_back.indd   46 06/05/2008   11:17:31 47 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
21. Share ‑BaSed P aymeNtS
All employees of the group are awarded share options. Recently option grants to uK employees have been made under the CeneS 
unapproved Share option Scheme share option scheme (“unapproved”). previously options have also been granted under the CeneS 
Approved Share o ption Scheme and the Executive Share o ption plan (“ESop ”). o ptions granted under the u napproved scheme have a fixed 
exercise price based on the market price at the date of grant. the contractual life of the options is seven years. options cannot normally be 
exercised before the third anniversary of the date of grant. For options granted to all directors and employees, the options are exercisable 
only if at the time of exercise, a performance condition has been met. the performance conditions for each scheme are set out in the 
Remuneration Report on pages 22 to 26. 
options were valued using the Black‑Scholes option pricing model. the group has taken the exemption provided in iFRS 2 which allows 
the charge for share‑based payment to be calculated only in respect of options granted to employees after 7 November 2002 which had 
not vested by 1 January 2005. 
The fair value per award granted and the assumptions used in the calculations are as follows:
       
    Share   
    price at Discount  
      Exercise  grant  factor r.e.  
  option  number   price  date   performance  Fair value 
Date of grant scheme of awards (£) (£) conditions per option
01 August 2003  unapproved  128,000  1.20  1.20  25%  £0.265
21 november 2003  unapproved  33,333  2.14  2.14  25%  £0.472
20 April 2004  unapproved  200,000  3.11  3.11  25%  £0.688
22 december 2004  unapproved  202,242  2.32  2.32  25%  £0.514
05 May 2005  unapproved  10,000  2.70  2.70  25%  £0.597
01 november 2005  unapproved  25,000  2.32  2.32  25%  £0.514
30 november 2005  unapproved  3,333  2.06  2.06  25%  £0.456
02 February 2006  unapproved  100,000  2.10  2.10  25%  £0.452
02 February 2006  unapproved  236,333  2.06  2.06  25%  £0.456
30 March 2007  unapproved  319,992  1.84  1.84  25%  £0.412
01 August 2003  ESop  98,229  £1 in aggregate  1.20  38%  £0.384
20 April 2004  ESop  76,667  £1 in aggregate  3.11  38%  £1.058
The key assumptions used are as follows:
1) the expected future volatility is calculated at 60%. this is based on historical volatility for the period since January 2002.
2)   the risk‑free rate of return of 5.35% is the yield on zero‑coupon uK government bonds of a term consistent with the expected option life. the expected 
dividend yield is nil.
3) the charge is spread over the expected vesting period.
4)   discount factors of 25% for the unapproved scheme and 38% for the ESop have been applied to take account of the performance conditions which must 
be met before the options can be exercised. 
5) the expected life of options has been estimated at five years after the grant date.
A reconciliation of movements in all options over the year to 31 December 2007 is shown below:
 2007  2006
    w eighted  Weighted 
    average  average 
   Number exercise  number  exercise 
   (‘000) price  (‘000)  price
outstanding at 1 January      1,273 204p 962 207p
Granted   320 184p 336 207p
Forfeited   (273) 290p  (25)  240p
outstanding at 31 december      1,320 189p  1,273  204p
Exercisable at 31 december      210 120p 210 120p
t he total charge for the year relating to employee share‑based payment plans was £93,000 (2006: £167,000) all of which related to 
equity‑settled share‑based payment transactions. t he fair value of options granted during the year was £117,000 (2006: £138,000). 
_0_CEN_ar07_back.indd   47 06/05/2008   11:17:31 48 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
22. CoNtiNgeNt liaBilitieS aNd guaraNteeS
the Company has a guarantee in relation to the lease arrangements for 3 Riverside Way, irvine, entered into by CeneS drug delivery limited. 
t he lease has a 25 year term, commencing 12 February 1998, with a break point at year 20. t he annual amount payable is £168,000. 
This property is no longer required and the Company is actively seeking to sublet the property.
in September 1999, Core t echnologies limited concluded an agreement to take a lease of new, additional premises adjacent to the main site at  
Riverside Way, irvine. the lease term is until March 2010 and the annual rental is £186,500. the Company is actively seeking to sublet the property.
t he Company has reviewed and recalculated the onerous lease provision of £1.0 million (31 december 2006: £1.0 million) which reflects 
the expected liability relating to the leases of premises in Scotland that are no longer required by the g roup. o f this provision, £0.7 million 
(2006: £0.7 million) is due after more than one year and £0.3 million (2006: £0.3 million) is due within one year. 
The Company has entered into cross guarantees within the Group as part of its banking arrangements. 
23. PeNSioN CommitmeNtS
CeneS has a stakeholder pension scheme which is available to all uK based employees. the pension charge for the year was £107,000 
(2006: £100,000). At 31 december 2007 contributions totalling £22,000 (2006: £45,000) were payable to these pension arrangements. 
24. fiNaNCial CommitmeNtS
obligations under non‑cancellable operating leases are as follows:
   land and  land and  
   buildings other  buildings  other 
   2007 2007 2006 2006 
   £’000 £’000   £’000  £’000
Due no later than one year   442 15  442  17
due later than one year but no later than five years       1,152  2  1,426   17
due later than five years       860 —  1,028  —
   2,454 17  2,896  34
25. SuBSidiary ComP aNieS 
The Group has included the following subsidiaries in its consolidation:
       % holding 
    Nature of Country of (all classes 
Summary of subsidiary undertakings    business incorporation of shares)
Subsidiary undertakings held directly
CeNeS Drug Delivery limited     Non‑trading  Scotland 100%
CeneS limited        drug development  England  100%
CeneS pharmaceuticals inc.        dormant  uSA  100%
CeNeS (Bermuda) limited    Dormant Bermuda 100%
theraSci limited        dormant  England  100%
_0_CEN_ar07_back.indd   48 06/05/2008   11:17:31 49 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
26. related P arty diSCloSureS
During the year ended 31 December 2007 the Directors of the Company subscribed for new ordinary shares of 30 pence each as follows:
    Number  
    of shares Price  
Director    subscribed per share Date
Alan goodman        9,523  105p  22/08/07
neil Clark        9,523  105p  22/08/07
Ron irwin        4,760  105p  22/08/07
Alan Smith        4,760  105p  22/08/07
the following fees and expenses were incurred during the period from the associated companies of the non‑executive directors of the group 
as follows:
     2007 2006 
     £’000  £’000
irwin Associates international (Mr T Ronald irwin)     33 31
Johnson Partners (Dr Peter Johnson)     33 31
The balances due at the year end and included in creditors and accruals were as follows:
     2007 2006 
     £’000  £’000
irwin Associates international (Mr T Ronald irwin)     13 16
Alan goodman, the Chairman of CeneS, and Alan Smith, a non‑executive director of CeneS are also directors of Avlar Bioventures limited. 
one of the funds managed by Avlar Bioventures limited holds 2,436,449 CeneS ordinary shares. 
Refer to note 9 for details of key management compensation. 
Directors consider that there is no ultimate controlling party to the Company.
27. rePortiNg uNder iNterNatioNal fiNaNCial rePortiNg StaNdardS (“ifrS”)
CeneS pharmaceuticals plc has produced its consolidated financial statements in accordance with iFRS.
the commentary below highlights the key changes that have arisen due to the transition from reporting under uK gAAp to reporting under 
iFRS. the group’s date of transition to iFRS is 1 January 2006, which is the beginning of the comparative period for the 2007 financial year. 
Therefore the opening balance sheet for iFRS purposes is that reported at 1 January 2006 as amended for changes due to iFRS.
these financial statements are the first to be prepared under iFRS. the comparative figures have been prepared on the same basis and are 
therefore restated from those previously reported under uK gAAp. to help understand the impact of the transition, reconciliations have been 
produced below to show the changes made to statements previously reported under uK gAAp in arriving at the equivalent statements under 
iFRS. The following reconciliations are provided:
1. Consolidated balance sheet at 1 January 2006.
2. Consolidated income statement for the year to 31 December 2006.
3. Consolidated balance sheet at 31 December 2006.
The income statement for the year ended 31 December 2007 and the balance sheet at that date are reported under iFRS. As they have not 
previously been reported under uK gAAp no reconciliation to iFRS is required.
the net effect of presenting the 2006 full year financial statements under iFRS rather than uK gAAp is to decrease the loss after tax reported 
from £9.7 million to £8.6 million and to increase net assets by £1.1 million. 
income tax credits of £1,065,000 received during the year ended 2006 are classified as a part of operating cash flows under iFRS, but were 
included in a separate category of tax cash flows under uK gAAp. there are no other material differences between the cash flow statement 
presented under iFRS and the cash flow statement presented under uK gAAp .
_0_CEN_ar07_back.indd   49 06/05/2008   11:17:31 50 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
27. rePortiNg uNder iNterNatioNal fiNaNCial rePortiNg StaNdardS (“ifrS”) CoNtiNued
Where applicable, the options selected by management under iFRS 1 are set out in the explanatory notes below:
Reconciliation of equity
uk Gaap to ifRs as at 1 JanuaRy 2006
        As reported  Effects of  Restated 
    under  transition to under 
        uK gAAp  iFRS  iFRS 
        £’000  £’000   £’000
Non‑current assets
intangible assets        6,513  —  6,513
property, plant and equipment        36  —  36
t rade and other receivables        148  —  148
        6,697    6,697
Current assets
t rade and other receivables        487  —  487
income tax asset        900  —  900
Cash and cash equivalents         8,464  —  8,464
        9,851  —  9,851
Current liabilities
t rade and other payables        (1,471)  —  (1,471)
provisions for liabilities and charges        —  (491)  (491)
Net current assets        8,380  (491)  7,889
t otal assets less current liabilities        15,077  (491)  14,586
Non‑current liabilities
provisions for liabilities and charges        (1,009)  491  (518)
Net assets        14,068  —  14,068
Capital and reserves
Share capital        4,098  —  4,098
Share capital to be issued        3,899  —  3,899
Share premium        113,080  —  113,080
Capital redemption reserve        15,697  —  15,697
other reserves        10,396  —  10,396
profit and loss account        (133,102)  —  (133,102)
t otal equity     14,068  —  14,068
g oodwill is not amortised under iFRS but is measured at cost less impairment losses. u nder u K g AAp , goodwill was amortised on 
a straight‑line basis over an estimate time that the group was to benefit from it. this change does not affect equity as at 1 January 2006 
because as permitted under iFRS 1, goodwill arising on acquisition before January 2006 (date of transition to iFRS) has been frozen 
at the uK gAAp amounts subject to being tested for impairment at that date, the results of which indicated no such impairment. 
provisions for liabilities and charges have been split between current liabilities and non‑current liabilities in accordance with iAS 1, 
“presentation of financial statements”. 
_0_CEN_ar07_back.indd   50 06/05/2008   11:17:31 51 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
27. rePortiNg uNder iNterNatioNal fiNaNCial rePortiNg StaNdardS (“ifrS”) CoNtiNued
Reconciliation of equity
uk Gaap to ifRs foR the yeaR ended 31 decembeR 2006
        As reported  Effects of  Restated 
    under  transition to under 
        uK gAAp  iFRS  iFRS 
      notes  £’000  £’000   £’000
revenue    53 — 53
Research and development costs      (i)  (7,277)  77  (7,200)
Administrative expenses      (ii)  (3,552)  950  (2,602)
other operating income        26  —  26
operating loss         (10,750)  1,027  (9,723)
Finance income    267 — 267
loss before tax         (10,483)  1,027  (9,456)
income tax credit        815  —  815
loss for the period, being retained loss for the year        (9,668)  1,027  (8,641)
Notes:
(i)   licence acquired for £77,000 from Alza Corporation in July 2006 has been capitalised in the balance sheet, in accordance with iAS38. the amount is being 
amortised over the licence period (15 years). the amortisation charge for 2006 was £3,000.
(ii)   goodwill is not amortised under iFRS but is reviewed annually for impairment. goodwill amortisation under uK gAAp was £953,000. this amount is netted 
off against the licence amortisation of £3,000. 
_0_CEN_ar07_back.indd   51 06/05/2008   11:17:31 52 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe FinAnciAL st AteMents continueD
for the year ended 31 december 2007
27. rePortiNg uNder iNterNatioNal fiNaNCial rePortiNg StaNdardS (“ifrS”) CoNtiNued
Reconciliation of the equity
uk Gaap to ifRs as at 31 decembeR 2006
        As reported  Effects of  Restated 
    under  transition to under 
        uK gAAp  iFRS  iFRS 
      notes  £’000  £’000   £’000
Non‑current assets
intangible assets       (i)  5,348  1,027  6,375
property, plant and equipment        26  —  26
t rade and other receivables        148  —  148
        5,522  1,027  6,549
Current assets
Trade and other receivables    366 — 366
income tax asset        650  —  650
Cash and cash equivalents        6,296  —  6,296
        7,312  —  7,312
Current liabilities
t rade and other payables        (2,993)  —  (2,993)
Provisions for liabilities and charges    (321) — (321)
Net current assets        3,998  —  3,998
t otal assets less current liabilities        9,520  1,027  10,547
Non‑current liabilities
provisions for liabilities and charges        (638)  —  (638)
Net assets        8,882  1,027  9,909
Capital and reserves
Share capital        4,839  —  4,839
Share capital to be issued        3,687  —  3,687
Share premium        116,866  —  116,866
Capital redemption reserve        15,697  —  15,697
other reserves        10,396  —  10,396
profit and loss account        (142,603)  1,027  (141,576)
t otal equity        8,882  1,027  9,909
Notes:
(i)   g oodwill amortisation of £953,000 under u K g AAp is not required under iFRS. t he licence acquired for £77,000 in July 2006 has been capitalised, and is amortised 
over the life of the licence. 
_0_CEN_ar07_back.indd   52 06/05/2008   11:17:31 53 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
inDepenDent AuDitors’ report to tHe MeMBers oF cenes pHArMAceuticALs pLc We have audited the parent company financial statements of CeneS pharmaceuticals plc for the year ended 31 december 2007 which 
comprise the Company Balance Sheet and the related notes. these parent company financial statements have been prepared under the 
accounting policies set out therein.
We have reported separately on the g roup financial statements of Cen eS pharmaceuticals plc for the year ended 31 december 2007. 
that report is modified by the inclusion of an emphasis of matter.
reSPeCtive reSPoNSiBilitieS of direCtorS aNd auditorS
the directors’ responsibilities for preparing the Annual Report and the parent company financial statements in accordance with applicable 
law and united Kingdom Accounting Standards (united Kingdom generally Accepted Accounting practice) are set out in the Statement of 
directors’ Responsibilities.
our responsibility is to audit the parent company financial statements in accordance with relevant legal and regulatory requirements and 
international Standards on Auditing (uK and ireland). this report, including the opinion, has been prepared for and only for the Company’s 
members as a body in accordance with Section 235 of the Companies Act 1985 and for no other purpose. We do not, in giving this opinion, 
accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come 
save where expressly agreed by our prior consent in writing.
We report to you our opinion as to whether the parent company financial statements give a true and fair view and whether the parent 
company financial statements have been properly prepared in accordance with the Companies Act 1985. We also report to you whether 
in our opinion the information given in the directors’ Report is consistent with the parent company financial statements. the information given 
in the directors’ Report includes that specific information presented in the Chief Executive’s Review and the Financial Review that is cross 
referred from the Business Review section of the directors’ Report. 
in addition we report to you if, in our opinion, the Company has not kept proper accounting records, if we have not received all the information and 
explanations we require for our audit, or if information specified by law regarding directors’ remuneration and other transactions is not disclosed.
We read the other information contained in the Annual Report and consider whether it is consistent with the audited parent company financial 
statements. the other information comprises only: key events since January 2007, the Chairman’s Statement, the Chief Executive’s Review, 
the Financial Review, Board of directors, Senior Management, Scientific Advisory Board, the directors’ Report, the directors’ Remuneration 
report and the directors, advisors and contacts. We consider the implications for our report if we become aware of any apparent misstatements 
or material inconsistencies with the parent company financial statements. our responsibilities do not extend to any other information.
BaSiS of audit oPiNioN 
We conducted our audit in accordance with international Standards on Auditing (uK and ireland) issued by the Auditing practices Board. 
An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the parent company financial statements. 
it also includes an assessment of the significant estimates and judgments made by the directors in the preparation of the parent company 
financial statements, and of whether the accounting policies are appropriate to the Company’s circumstances, consistently applied and 
adequately disclosed.
We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide 
us with sufficient evidence to give reasonable assurance that the parent company financial statements are free from material misstatement, 
whether caused by fraud or other irregularity or error. in forming our opinion we also evaluated the overall adequacy of the presentation 
of information in the parent company financial statements.
_0_CEN_ar07_back.indd   53 06/05/2008   11:17:31 54 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
inDepenDent AuDitors’ report to tHe MeMBers oF cenes pHArMAceuticALs pLc continueD
oPiNioN
in our opinion:
    the parent company financial statements give a true and fair view, in accordance with united Kingdom generally Accepted Accounting 
practice, of the state of the Company’s affairs as at 31 december 2007;
  the parent company financial statements have been properly prepared in accordance with the Companies Act 1985; and
  the information given in the directors’ Report is consistent with the parent company financial statements.
emPhaSiS of matter – goiNg CoNCerN
in forming our opinion on the financial statements, which is not qualified, we have considered the adequacy of the disclosures made in the 
financial statements concerning the basis of preparation described in note 1. the financial statements have been prepared on a going concern  
basis and the validity of this depends on the Company successfully obtaining future funding. t his indicates the existence of a material 
uncertainty which may cast significant doubt on the Company’s ability to continue as a going concern. t he financial statements do not include 
any adjustments that would result from a failure to obtain such funds.
PriCewaterhouSeCooPerS llP
chaRteRed accountants and ReGisteRed a uditoRs cambRidGe 10 apRil 2008
Notes:
  The maintenance and integrity of the CeNeS Pharmaceuticals plc website is the responsibility of the Directors; the work carried out by the 
auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may 
have occurred to the financial statements since they were initially presented on the website.
   legislation in the united Kingdom governing the preparation and dissemination of financial statements may differ from legislation in 
other jurisdictions.
 
_0_CEN_ar07_back.indd   54 06/05/2008   11:17:31 55 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
coMp AnY BALAnce sHeet aS at 31 december 2007
     2007 2006 
    Notes £’000  £’000
fixed assets
investments    3 11,477  11,384
Current assets
debtors        4  24 51
Cash at bank and in hand     1 17
     25  68
Creditors: amounts falling due within one year    5 (148) (356)
Net current liabilities     (123)  (288)
t otal assets less current liabilities     11,354  11,096
Net assets     11,354  11,096
Capital and reserves
Share capital    6 6,576  4,839
Share capital to be issued    6 3,687  3,687
Share premium    7 4,010  116,866
Capital redemption reserve    7 15,697  15,697
other reserves        7  26 26
profit and loss account        7  (18,642)  (130,019)
Shareholders’ funds        8  11,354  11,096
the financial statements were approved by the Board of directors on 10 April 2008 and signed on its behalf by:
Neil ClarK
chief executive _0_CEN_ar07_back.indd   55 06/05/2008   11:17:31 56 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe coMp AnY FinAnciAL st AteMents aS at 31 december 2007
1. SigNifiCaNt aCCouNtiNg PoliCieS
basis of accountinG
these separate financial statements of the Company are prepared on the going concern basis, under the historical cost convention, and in 
accordance with the Companies Act 1985 and applicable accounting standards in the united Kingdom (uK gAAp). the principal accounting 
policies, which have been applied consistently throughout the year, are set out below.
GoinG conceRn CeneS pharmaceuticals plc does not have sufficient cash resources to fund its current level of activities for the next twelve months. 
this represents a material uncertainty which may cast significant doubt on the Company’s ability to continue as a going concern. 
o n 10 April 2008, it was announced by paion Ag  that it proposes to acquire all of the issued and to be issued share capital of Cen eS 
by a court sanctioned scheme of arrangement under part 26 of the Companies Act 2006. if the proposed acquisition is completed, CeneS 
will have a considerably strengthened financial position by being part of the paion group, which will assist with partnering and clinical 
development decisions. 
if the acquisition is completed, Cen eS, as part of the enlarged group, will continue to maintain its focus on advancing each of its programmes, 
with a number of key milestones and deliverables expected in 2008. the results of the first of two planned phase ii studies for CnS 5161 will 
report results mid‑2008. An ind (investigational new drug) filing in the uS and proof of concept phase i study for CnS 7056 in sedation  
is planned for H2 2008. t he Board believe that a successful outcome from this trial will transform the value of this asset. Cen eS partner o no 
is planning a phase i study in anaesthesia in Japan in H2 2008. 
Based on the structure of the enlarged group and the broadened pipeline the Directors of CeNeS believe the enlarged group will be able 
to achieve significant pre‑clinical, clinical and commercial milestones.
in the event that the acquisition is not completed, the Company will need to raise additional funding through one or a combination of equity 
fund raising, partnering or collaboration opportunities activity in order to continue as a going concern. t he directors have a reasonable 
expectation that the Company can raise such additional cash resources. t herefore, the directors consider that it is appropriate to prepare the 
financial statements on a going concern basis. if the Company was unable to continue in operational existence in the foreseeable future, 
adjustments would have to be made to revise the balance sheet values of assets to their recoverable amounts, to provide for further liabilities 
that might arise and to reclassify fixed assets as current assets.
cash flow statement the Company has taken advantage of the exemptions available in FRS 1 ‘Cash flow statements’ from presenting a cash flow statement on 
the basis that the cash flows of the Company are consolidated in the cash flows in the CeneS pharmaceuticals plc consolidated financial 
statements for the year ended 31 December 2007. 
tuRnoveR
turnover represents amounts receivable for goods and services provided in the normal course of business, net of trade discounts, vAt and 
other sales related taxes.
t axation Current tax is provided at amounts expected to be paid or recovered using the tax rates and laws that have been enacted or substantially 
enacted by the balance sheet date.
provision is made for deferred taxation, in accordance with FRS 19, ‘deferred tax’, on all material timing differences. deferred tax assets are 
recognised to the extent that they are regarded as recoverable. deferred tax assets and liabilities are not discounted.
investments investments in subsidiary companies which are accounted for under merger accounting principles are shown at the nominal value of shares 
issued in accordance with the provisions of the Companies Act 1985.
investments in subsidiary companies which are accounted for under acquisition accounting principles are shown at cost less any provision 
for impairment.
foReiGn cuRRency t ransactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities 
denominated in foreign currencies at the balance sheet date are reported at the rates of exchange prevailing at this date.
ReseaRch and development Research and development expenditure is charged to the profit and loss Account as incurred and includes relevant staff costs as well 
as an apportionment of occupancy costs, general overheads and depreciation.
financial instRuments 
the Company has taken advantage of the exemptions available in FRS 25 ‘Financial instruments: disclosure and presentation’ from 
disclosing information on financial instruments on the basis that these disclosures are set out in the consolidated financial statements 
of CeNeS Pharmaceuticals plc for the year ended 31 December 2007.
_0_CEN_ar07_back.indd   56 06/05/2008   11:17:32 57 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
1. SigNifiCaNt aCCouNtiNg PoliCieS CoNtiNued
shaRe options
the cost of share options awarded to employees under the group’s share option schemes is measured by reference to their fair value at the 
date of grant. t his cost is recognised over the vesting period of the options based on the number of options, which in the opinion of the 
directors will, ultimately vest.
the Company does not have any employees with the options. Following the adoption of uitF 44, ‘FRS 20 – group and treasury share  
transactions’ in the year, all share‑based compensation has been recharged to subsidiary undertaking by way of a capital contribution to the 
subsidiary. this capital contribution for both current and the prior year has increased investment value by £392,000 (2006: £299,000) with the 
corresponding credit posted to equity. the prior year numbers have been restated to reflect this adjustment. 
2. l oSS for the year
As permitted by Section 230 of the Companies Act 1985 the Company has elected not to present its own profit and loss account for the year. 
the Company’s loss for the year to 31 december 2007 was £5,582,000 (2006: £4,829,000).
The Company has no employees (2006: nil).
3. iNveStmeNtS 
The Company has investments in the following subsidiaries:
      % holding 
     Country of (all classes  
Summary of subsidiary undertakings:     incorporation of shares)
Subsidiary undertakings held directly
CeNeS Drug Delivery limited      Scotland 100%
CeneS limited          England  100%
CeneS pharmaceuticals inc.          uSA  100%
CeNeS (Bermuda) limited     Bermuda 100%
theraSci limited          England  100%
The principal activity of CeNeS limited is the development of pharmaceutical products for the treatment of pain and disorders of the central 
nervous system. the activities of CeneS drug delivery limited have been discontinued. CeneS pharmaceuticals inc., CeneS (Bermuda) 
limited and TheraSci limited are dormant companies. 
subsidiaRies     2007 2006 
     £’000  £’000
Cost
As at 1 January      22,426  22,127
prior year adjustment – uitF 44          — 132
as restated     22,426  22,259
Capital contribution arising from FRS 20 charge     93 167
As at 31 December      22,519  22,426
Provisions for impairment
As at 1 January and 31 December     (11,042)  (11,042)
Net book value at 31 december      11,477  11,384
Where options over the Company’s shares have been issued to the employees of subsidiary undertaking, the fair value of the employee 
service performed (equal to the FRS 20 charge) has been recorded as a capital contribution.
_0_CEN_ar07_back.indd   57 06/05/2008   11:17:32 58 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe coMp AnY FinAnciAL st AteMents continueD
aS at 31 december 2007
4. deBtorS
     2007 2006 
Amounts falling due within one year     £’000  £’000
other debtors          8 35
Prepayments and accrued income     16 16
     24 51
5. trade aNd other CreditorS
     2007 2006 
Amounts falling due within one year     £’000  £’000
Trade creditors     60 70
Accruals     88  286
     148 356
6. deferred taxatioN
deferred tax assets have not been recognised as the directors consider that this would be inappropriate as the Company is not expected to 
realise sufficient profits in the foreseeable future. this will be reassessed at such time as the Company expects to make a profit. the amount 
unprovided of the total potential asset is as follows:
 2007  2006
      Restated 
   amount  amount Amount Amount 
   provided unprovided provided unprovided 
   £’000 £’000  £’000  £’000
tax effect of timing differences:
Short term timing differences   — (2) — (2)
tax effect of losses carried forward      — (2,117)  —  (1,983)
   — (2,119)  —  (1,985)
t he rate of u K corporation tax will be reduced from 30% to 28% with effect from 1 April 2008. t he change in tax rate has been applied 
to timing differences at 31 December 2007 where applicable. 
7. Called‑uP Share CaPital
The share capital of the Company is shown below:
  2007  2006
     Restated* 
   Number £’000  number  £’000
authorised    
ordinary shares of 30 pence each    33,776,318 10,133  33,776,318  10,133
    Number issued Share capital 
    of ordinary share capital to be issued 
        30p shares  £’000  £’000
Allotted, issued and fully paid
At 1 January 2007 (restated*)       16,131,055  4,839  3,687
issues of new shares – placing        5,789,137  1,737  —
at 31 december 2007    21,920,192 6,576 3,687
*on 22 August 2007, the Company consolidated its ordinary shares of 1 pence each into ordinary shares of 30 pence each. 
Also, on 22 August 2007 the Company raised £5,747,000 net of £332,000 issue costs, by a placing of 5,789,137 new ordinary shares 
of 30 pence each at 105 pence per share. the issue resulted to £1,737,000 additional share capital and £4,010,000 share premium.
_0_CEN_ar07_back.indd   58 06/05/2008   11:17:32 59 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
8. reServeS
        Capital    profit 
      other  redemption  Share  and loss 
   reserves  reserve premium account 
      £’000  £’000   £’000  £’000
As at 1 January 2007      26  15,697  116,866  (130,318)
prior year adjustment – uitF 44      —  —  —  299
As restated       26  15,697  116,866  (130,019)
Capital restructuring      —  —  (116,866)  116,866
issue of new shares
– placing      —  —  4,010  —
Share‑based payments      93
loss for the year to 31 december 2007      —  —  —  (5,582)
as at 31 december 2007   26 15,697 4,010 (18,642)
other reserves as at 31 december 2007 relate to share option reserve of £26,000 (2006: £26,000). 
The capital redemption reserve of £15.7 million arose as a result of a sub‑division of shares in August 2003.
Capital restructuring relates to a write off of share premium balance £116,866,000, against the brought forward losses following a court order 
issued by Scottish Court on 10 July 2007. The capital restructuring was approved by shareholders at the Annual General Meeting held on 
5 July 2005.
9. reCoNCiliatioN of movemeNt iN ShareholderS’ fuNdS
     2007 2006 
     £’000  £’000
As at 1 January      11,096  11,144
prior year adjustment – uitF 44          — 132
As restated      11,096  11,276
issue of shares (net of issue expenses of £0.3 million (2006: £0.3 million)          5,747  4,527
Movement in share capital to be issued     — (212)
Share‑based payments     93 167
loss for the year      (5,582)  (4,662)
As at 31 December      11,354  11,096
10. CoNtiNgeNt liaBilitieS aNd guaraNteeS
The Company has entered into cross guarantees within the Group as part of its banking arrangements. 
_0_CEN_ar07_back.indd   59 06/05/2008   11:17:32 60 CeNeS PharmaCeutiCalS PlC Annual Report and Accounts 2007
notes to tHe coMp AnY FinAnciAL st AteMents continueD
aS at 31 december 2007
11. related P arty diSCloSureS
During the year ended 31 December 2007 the Directors of the Company subscribed for new ordinary shares of 30 pence each as follows:
    Number of  
    shares Price  
Director    subscribed per share Date
Alan goodman        9,523  105p  22/08/07
neil Clark        9,523  105p  22/08/07
Ron irwin        4,760  105p  22/08/07
Alan Smith        4,760  105p  22/08/07
the following fees and expenses were incurred during the period from the associated companies of the non‑executive directors of the group 
as follows:
     2007 2006 
     £’000  £’000
irwin Associates international (Mr T Ronald irwin)     33 31
Johnson Partners (Dr Peter Johnson)     33 31
The balances due at the year end and included in creditors and accruals were as follows:
     2007 2006 
     £’000  £’000
irwin Associates international (Mr T Ronald irwin)     13  16
Alan goodman, the Chairman of CeneS, and Alan Smith, a non‑executive director of CeneS are also directors of Avlar Bioventures limited. 
one of the funds managed by Avlar Bioventures limited holds 2,436,449 CeneS ordinary shares. 
Directors consider that there is no ultimate controlling party to the Company.
_0_CEN_ar07_back.indd   60 06/05/2008   11:17:32 DireCtorS
AlAn GoodmAn Chairman
neil ClArk Chief exeCutive
Tony osborne finanCe DireCtor
ronAld irwin non‑exeCutive DireCtor
dr PeTer Johnson
non‑exeCutive DireCtor
AlAn smiTh non‑exeCutive DireCtor 
ComP aNy SeCretary Tony osborne regiStereD offiCe riverside Way  
riverside Business Park  
irvine  
Ka11 5DJ  
Scotland
regiStereD No: SC 166791
WeBSite www.Cenes.Com StoCk ex ChaNge CoDe Cen.l Share regiStrarS
equiniti 
the Causeway 
Worthing 
West Sussex 
Bn99 6D a 
england
Shareholder helpline:  
tel: +44 (0) 871 384 2477
NomiNateD aD viSor (NomaD) aND  
fiNaNCial aD viSor a uDitorS
Jm Finn CAPiTAl mArkeTs limiTed 4 Coleman Street 
London 
eC2r 5ta 
england
tel: +44 (0) 20 7600 1658
a uDitorS
PriCew ATerhouseCooPers llP
abacus house 
Castle Park 
Cambridge 
CB3 0an 
england
la WyerS
morrison & FoersTer one ropemaker Street 
London  
eC2Y 9a W  
england
PuBliC relatioNS
FinAnCiAl dynAmiC s lTd holborn Gate 
26 Southampton Buildings 
London 
WC2a 1PB 
england
tel:  +44 (0) 20 7831 3113  
f ax:  +44 (0) 20 7242 8695
Directors, ADvisors AnD cont Acts index_CEN_ar07_cover.indd   4 06/05/2008   11:10:45 CeNeS Pharmaceuticals plc 
Compass House 
Vision Park 
Chivers Way 
Histon 
Cambridge CB24 9ZR 
Tel:  01223 266466 
Fax:  01223 266467 
Website: www.cenes.com 
CeNeS PharmaCeutiCalS PlC
Annual Report and Accounts 2007
index_CEN_ar07_cover.indd   1 06/05/2008   11:10:45
